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Abstract 
Angiotensin-I (Ang-I) converting enzyme (ACE) is a zinc metalloprotease that plays a vital role in the 
Renin Angiotensin Aldosterone System (RAAS) and is a key antihypertensive drug target. In addition 
to Ang-I, ACE cleaves many other physiological substrates, thus extending its function beyond the 
regulation of blood pressure. Somatic ACE (sACE) consists of two structurally homologous yet distinct 
catalytic sites termed the N- and C-domains. The two catalytic domains of ACE have distinct substrate 
affinities and play different regulatory roles. The antifibrotic tetrapeptide Ac-SDKP is hydrolysed solely 
by the N-domain and thus is a potential target for interactions between the ligand and unique residues 
within the active site of the N- and C-domains, which need to be exploited to effect either N- or C-
domain selectivity. 
N-domain selective ACE inhibition has been demonstrated with peptides while crystallographic studies 
have shown that the N-domain to C-domain substitution of Arg381 with Glu403 within the S2 subsite 
is integral to N-domain selective ACE inhibition. Three computer aided drug discovery (CADD) 
approaches were pursued to design N-domain selective drug-like ACE inhibitors (ACEi) with an acidic 
P2 functional group that would confer N-domain selectivity via an interaction with Arg381 in the S2 
subsite. 
Firstly, a fragment-based screening protocol was performed by running a set of chemical filters on 
16000 drug fragment compounds (MW < 350), all of which contained a metal chelating group. 60 
Ligands capable of binding to both the zinc metal and Arg381 in the S2 subsite of the N-domain were 
tested for ACE inhibition against the two domains of ACE. Two of the fragments identified in this screen 
showed a modest ACE inhibition (IC50 +/- 200 μM), but no domain selectivity.  
Secondly, a combinatorial library was created to explore the P2 structure activity relationship (SAR) of 
a scaffold based on the core structure of the clinical ACEi, Enalaprilat. Over 400 variants were created 
to generate a combinatorial library. These compounds were docked against the two domains of ACE 
and a synthetic scheme was developed to synthesise compounds from this library. Using this scheme, 
one Enalaprilat analogue, SF07 was synthesised as a mixture of diastereomers. SF07 exhibited low 
micromolar N-domain inhibition with no C-domain inhibition observable below 100 μM.  
For the third approach, 25 000 compounds containing biological data pertaining to ACE were extracted 
from the GVK BIO GOSTAR database. These compounds were filtered for drug-like properties and 
manually inspected for promising P2 functionality. The N-domain selectivity of these compounds was 
then assessed via molecular docking against the two domains of ACE. This screen identified a series of 
diprolyl compounds with varied groups in the P2 position.  These compounds were subsequently 
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synthesised and tested in vitro for inhibition against both domains. The most N-domain selective 
compound from the series proved to be SG6, a diprolyl compound with an Asp group in the P2 position. 
SG6 displayed potent inhibition (Ki = 12 nM) and was 83-fold more selective towards the N-domain 
than the C-domain. 
This study has demonstrated the N-domain selective inhibition of ACE by drug-like peptidomimetics. 
Two promising leads on drug-like N-domain selective ACE inhibitors, SG6 and SF07, have been 
identified.  These two compounds have the potential to pave the way for clinical N-domain selective 
ACEis and a novel treatment for cardiac and pulmonary fibrosis.  
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Chapter 1 – Literature Review 
1.1 Introduction 
The Angiotensin-I converting enzyme (ACE) is a zinc metalloprotease best known as an 
antihypertensive drug target.1 ACE inhibitors (ACEi) have proven to be a popular treatment for chronic 
hypertension with at least 19 clinically approved drugs. 
Since the elucidation of the structure of ACE, there has been renewed interest in the study of its 
inhibitors2. ACE was shown to contain two distinct homologous catalytic sites with a more diverse set 
of substrates than the principle vasoconstrictive Angiotensin-I substrate.3 These two catalytic sites 
show different kinetic profiles towards a range of different substrates. While it has been shown that 
the inhibition of just one active site is sufficient for antihypertensive vasodilation,4 the other active 
site is solely responsible for the hydrolysis of Ac-SDKP in vivo, a peptide responsible for collagen 
deposition and cardiac remodelling5.  
Previous studies suggest site-selective ACE inhibition could either reduce the side-effects of anti-
hypertensive drugs or treat cardiac fibrosis, thus greatly expanding the original therapeutic scope of 
ACE inhibition.5 Modern computer aided drug discovery (CADD) software and high resolution crystal 
structures lend themselves to a structure based approach for the optimisation of current ACEis into a 
site-specific inhibitor with either reduced anti-hypertensive effects or a novel anti-fibrotic drug.  
Given its potential as a novel anti-fibrotic drug target, the full potential for site-selective ACE inhibition 
is yet to be explored. The extensive collection of ACEis and high resolution crystal structures provided 
a unique opportunity to derive site-specific ACEis from existing ACEis with no preference for either 
catalytic site. Modern CADD software is ideally suited to the task with the ability to accurately model 
and guide small chemical changes to these ACEis. The application of CADD software to the ACE target 
provides a unique opportunity to apply a structure based-approach to optimise the established set of 
ACEis into domain selective inhibitors. 
1.2 Historical Aspects of ACE 
1.2.1 The Discovery of ACE 
ACE was first discovered by Skeggs et al6 in 1956. The discovery began with the identification of two 
peptides responsible for elevated blood pressure.7 These peptides were named hypertensin 1 and 
hypertensin 2 after the discovery of their vasoconstrictive properties8. Of the two peptides, only 
hypertensin 2 was shown to be capable of effecting a vasoconstrictive response on isolated aortic 
tissue strips. The peptides were then sequenced with hypertensin 2 observed to contain the same 
Chapter 1   – Literature Review 
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sequence as hypertensin 1 minus the two C-terminal residues. Following this observation, Skeggs 
managed to isolate the enzyme responsible for this action from horse serum. This enzyme was shown 
to belong to the Zinc metalloprotease class of enzymes.1 Today these peptides are known as 
angiotensin (Ang) I and II (Figure 1.1) while the enzyme is called angiotensin converting enzyme (ACE). 
This work followed on from studies performed by Goldblatt et al9 a few years prior where the kidneys 
were linked to hypertension via the a renal enzyme named renin and an unknown substrate. The 
substrate of renin is now known to be angiotensinogen, a large peptide precursor to Angiotensin-I. 
The discovery of Ang I and Ang II completed the picture of the blood pressure control mechanism first 
elucidated by Goldblatt. This pathway is known as the Renin Angiotensin Aldosterone System (RAAS). 
Lowered sodium levels and loss of blood volume triggers the release of angiotensinogen from the 
liver. The angiotensinogen is then cleaved in the kidneys by renin into Ang-I before returning to the 
bloodstream. While circulating, Ang-I is hydrolysed by ACE into Ang-II. From here Ang-II interacts with 
the G-protein coupled receptor (GPCR) angiotensin type 1 receptor (AT1) to effect a cellular response 
leading to vasoconstriction, salt reabsorption and water retention. Figure 1.2 provides a simplistic 
overview of this pathway. Many decades of research have added several new axes and enzyme 
substrates to this pathway. Figure 1.2 summarises the best known axis of the RAAS.10 
Ang I:  Asp-Arg-Val-Tyr-Ile-His-Pro–Phe|His-Leu 
Ang II: Asp-Arg-Val-Tyr-Ile-His-Pro–Phe 
Figure 1.1: The peptide sequences of Ang-I and Ang-II. The site of cleavage is indicated with a |. 
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Figure 1.2: A Schematic outline of the major axis of the RAAS 
1.2.2 Bradykinin Potentiating Peptides 
Bradykinin (BK) Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg, a well-known vasodilating nonapeptide is a 
crucial component of the kallikrein kinin system (KKS). BK was first discovered by Silva et al11 in 1949 
when studying the anticoagulating properties of the snake venom from the Brazilian pit viper Bothrops 
jararaca. B. jararaca venom was observed to be capable of lowering blood pressure by stimulating the 
release of a hypotensive nonapeptide which would later become known as BK. In reality, B. jararaca 
venom prevented the degradation of this native peptide as shown subsequently by Ferreira et al.12 
The BK preserving component of the venom was termed the Bradykinin potentiating factor (BPF). In 
1968 Bakhle et al13 demonstrated BPF to be capable of inhibiting the conversion of Ang-I to Ang-II. 
This was not just the first evidence of ACE inhibition, but also the first evidence of a link between ACE, 
BK and the KKS. Today the complete scope of the KKS is still not fully understood, but blood pressure 
regulation appears to be one of its primary functions. The KKS regulates blood pressure via the release 
of BK from kininogen allowing it to interact with the B2 receptor, a GPCR which effects a vasodilatory 
cellular response in smooth endothelial muscle tissue. 
To investigate the ACE inhibition mechanism of the BK potentiating factor, Ondetti et al separated the 
B. jararaca  venom into its base components14. Using chromatographic techniques, six distinct 
peptides were isolated ( 
Kidney 
Adrenal Gland 
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), all showing some degree of ACE inhibition. Following on, Collier et al15 synthesised the similar 
artificial SQ 20881 nonapeptide, with a potent ACE IC50 of 0.56 µM, an order of magnitude stronger 
than the BPPs. Despite reasonable in vivo inhibition of ACE when administered parenterally, this large 
bulky nonapeptide has poor oral bioavailability due to its digestion by tryptic enzymes and a lack of 
permeability. A successful orally administered ACEi would therefore need to be small molecule 
resistant to tryptic enzyme degradation while mimicking some structural features of SQ20881.  
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Table 1.1: A list of the different peptides separated by Ondetti et al14 and their associated ACE IC50 values. 
To consolidate these findings, Dorer et al16 investigated the ACE-catalysed hydrolysis of BK. It was 
found that there are two successive dipeptidase cleavages converting BK into BK(1-7) and then into BK(1-
5). Unexpectedly, the optimal chloride concentration for ACE-mediated BK hydrolysis was shown to be 
a tenth of the optimal concentration for Ang-I hydrolysis. This anomaly would later be attributed to 
the dual domain nature of ACE. The vastly different sequences of Ang-I and BK as well as the three 
different products of dipeptide hydrolysis (His-Leu, Phe-Arg and Ser-Pro) suggested a broader 
substrate specificity of ACE than previously thought. This raised some doubts regarding its suitability 
as a therapeutic target. Such fears were later allayed during in vivo evaluation. 
1.2.3 First Generation ACE Inhibitors 
Captopril was the first orally administered ACE inhibitor to receive clinical approval. It was developed 
by Cushman and Ondetti in the mid 1970s17 using an inspired piece of insight to guide structure activity 
relationship (SAR) studies in the absence of crystal structures. They started by examining the work of 
Shechter and Berger18 where a variety of proteases were studied crystallographically. They 
categorised 3 classes of proteases and found them all to contain a central binding cleft with a catalytic 
site. Residue specific binding pockets were discovered to reside on either side of the central catalytic 
site. All subsites in the N-terminal direction along the peptide sequence from the catalytic site were 
named S1, S2 ... Sn while all the subsites in the C-terminal direction along the cleft were named S1’, S2’ 
… Sn’. Peptide residues termed Pn bind to the subsite Sn (Figure 1.3). With this formalism recently 
established, Cushman and Ondetti began to focus their attention on carboxypeptidase A (CPA), the 
only crystallised metalloprotease at the time. 







Glp-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro-Gln-Ile-Pro-Pro (SQ20881) 0.56 
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Figure 1.3 The Schechter and Berger representation of a protease active site. 18 
Byers and Wolfendonden19 identified that the S1’ site of CPA had a preference for Phe residues and 
experimented with attaching a variety of carboxylic acid groups to Phe finding 2(S)-phenyl-succinic 
acid (Figure 1.4) to be a potent inhibitor. Cushman and Ondetti correctly assumed the carboxylic acid 
of 2(S)-phenyl-succinic acid to coordinate with the catalytic Zn atom thus blocking the enzyme binding 
site. The C-terminal carboxylic acid was also observed to be important in binding to CPA.  Positively 
charged residues were therefore hypothesised to interact with this acid. The positioning of this 
positively charged residue helps define the end of the prime-side in the binding cleft, thus determining 
the number of C-terminal residues to be cleaved from the peptide substrate.  
Since ACE is a dipeptidase rather than a carboxypeptidase, two subsites were assumed to exist 
between the Zn atom and the positively charged carboxylic acid binding site. To fit this model, 
Cushman and Ondetti began coupling succinic acid to a variety of amino acids. The chelating carboxylic 
acid was then substituted with a thiol, a much stronger Zn chelator. This substitution increased ACE 
inhibition by over 1000-fold in many cases, thus confirming the succinyl carboxylic acid was indeed 
coordinating with the Zn. The strongest succinyl amino acid inhibitor was succinyl-Pro while a thiol 














Succinic Acid Analogue 
Carboxypeptidase A Active Site 
IC50 = 450 nM 
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substitution of the succinyl acid yielded a 2000-fold increase in potency. This observation was 
consistent with the B. jararaca venom peptide sequences as they contain a C-terminal Pro. The next 
step in the SAR exploration was P1’ methyl substitution. Methyl groups were added to both succinyl 
and thiol Pro with a variety of different stereochemical configurations in both the 2 and 3 positions. 
Variations in chain length were also tested. The best inhibitor proved to be thiol-2-methyl-Pro. This 
small molecule mimics an Ala-Pro fragment binding in the S1’ and S2’ subsites and has a strong metal 
coordinating thiol. This compound became known as Captopril (Figure 1.5) and was a pioneering 
example of the peptidomimetic class of small molecule drugs.17  
Captopril was clinically approved as an effective antihypertensive agent in 1981. It was, however, 
plagued by side-effects such as skin-rash, angioedema and loss of taste. This prompted Patchett et al20 
to improve on Captopril and develop a new line of ACE inhibitors. It was suggested that most of the 
Captopril side-effects were caused by the thiol group. A weaker Zn coordinating carboxylic acid group 
Figure 1.5: The SAR evolution of Captopril from the C-terminal Pro-Pro to Captopril.  
Zn2+ 
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was consequently revisited. With a weaker Zn coordination, more interactions within the ACE binding 
pocket would need to be exploited. The two interactions targeted were a H-bond between the amide 
of the scissile peptide bond and an additional peptidomimetic side-chain moiety to interact with the 
S1 subsite. After replacing the thiol moiety with a carboxylic acid, a secondary amino group was added 
to a position β to the carboxylic acid, mimicking the H-bond donor characteristic of the native amide. 
As expected, this compound displayed reduced ACE inhibition with an IC50 of 2.4 µM compared to the 
IC50 of 23 nM of Captopril.  
In an attempt to improve inhibition, SAR in the P1 position was explored. Examining the sequence of 
Ang-I and the BPPs reveals the S1 subsite to be highly specific towards hydrophobic side-chain moieties 
such as Phe and Ile. Hydrophobic side-chain mimics were attached to the P1 position with the best 
moiety proving to be a phenyl group attached to a two carbon alkyl chain. Since a new stereocentre 
was created during this substitution, the two different diastereomers originating from this 
substitution were separated and tested individually. The S stereoisomer at this centre proved to be 
more potent (IC50 = 1.2 nM) than the diastereomeric mixture (IC50 = 3.8 nM). In this molecule with 
three chiral centres, the SSS stereochemical configuration mimics the stereochemistry of a natural 
Phe-Ala-Pro peptide emphasising the importance of stereochemistry in peptidomimetics. Since 
previous studies had shown the S1’ subsite of ACE to bind to a wide variety of side-chains, Patchett et 
al also explored the P1’ SAR by switching methyl side-chains of Ala with a variety of both natural and 
synthetic side-chain moieties. The introduction of a Lys side-chain into this molecule gave rise to a 
potent inhibitor with an IC50 of 1.2 nM. Both these new ACEis achieved improved potencies over 
Captopril.  
The Phe-Ala-Pro like compound suffered from poor oral bioavailability due to its net charge in solution 
of -1 which compromised cell permeability. This problem was rectified by esterifying the one 
carboxylic acid and delivering it in the prodrug form. These two compounds went on to pass clinical 
trials and are now known as Lisinopril and Enalaprilat. Figure 1.6 illustrates the SAR evolution of these 
compounds. 
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Enalaprilat and Lisinopril proved to be hugely successful drugs and laid out a useful guideline for 
designing small molecule metallo-protease inhibitors. The Zn coordinating carboxylic acid mimics the 
tetrahedral oxyanionic transition state of the hydrolysis reaction involved in the cleavage of a peptide 
bond (Figure 1.7). The C-terminal end of the drug then requires a carboxylic acid to interact with an 
electropositive pocket, which is important for ensuring peptides bind in the correct orientation. A 
good ACEi also needs good side-chain mimicking groups, natural or unnatural, while a secondary 
amine helps to improve the pharmacokinetic properties of the compound by raising its net charge to 
counter the negatively charged carboxylic acids while providing a H-bond donor. Unlike Lisinopril, 
Zn2+ 

















Figure 1.6: The SAR evolution of Enalaprilat and Lisinopril. The thiol of Captopril was substituted for a carboxylic acid and a secondary amine was added to create an H-bond donor analogue. An h-Phe group was then introduced onto the carbonadjacent to the new carboxylic acid to create Enalaprilat which was esterified to make the Enalapril prodrug. Lisinopril came about by substituting the Ala mimicking methyl group with a Lys mimicking amino-butyl group.  
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Figure 1.7: Mechanism of metalloprotease catalysed peptide hydrolysis. A carboxylic ZBG mimics the tetrahedral intermediate of peptide hydrolysis. 
Since Lisonopril and Enalapril entered the market, at least 17 additional ACEis have been approved 
(Table 1.2). All of them follow the same design pricinciples with a core Zinc binding group (ZBG), a 
terminal P2’ carboxylic acid, 2-3 side-chain mimicking groups and/or a secondary amine H-bond donor. 
Only Captopril, Zofenopril, Alacepril and Rentiapril utilise a thiol ZBG. Attempts to minimise thiol 
toxicity were made with Zofenopril and Alacepril by capping this group to make a thioester prodrug.  
 
Almost all of the remaining ACEis have a carboxylic acid ZBG,  a P1’ Ala/methyl and a P1 Phenyl group. 
For reasons described earlier, substituting the thiol ZBG with a carboxylic acid neccesitates the 
introduction of a H-bond donor amine in a position adjacent to the acid. In a similar manner to 
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Enalaprilat, the introduction of both a second carboxylic acid and an amine to an ACEi in most cases 
gave the molecule a net charge of -1, making the compound too polar for optimal bioavailability. These 
drugs have therefore, had their bioavailabilty optimised with an ethyl ester capping a carboxylic acid 
for the oral formulation of the drug. Most of the carboxylic acid class of ACEis differ in the P2’ position. 
The original ACEis had a Pro in this position while the later examples often have much larger ring 
systems. These ring systems include a wide variety of hydrophobic cycloalkyl, aromatic, 
heteroaromatic and heterocyclic moieties. 
  
Fosinopril and Ceranopril are notable exceptions as they contain a phosphinic acid ZBG. Phosphinic 
acids are not popular in oral drugs as their high polarity often compromise permeability and 
bioavailibility. Fosinopril is therefore delivered with a large and bulky lipophillic phosphoester to 
improve its permeability. Ceranopril lacks this prodrug phosphoesterification as its P1’ Lys moiety is 
positively charged in solution countering the acidity of the phosphinic acid. These two drugs are 
analagous to the esterified Enalapril and the non-esterified Lisinopril. Since the market is saturated 
with potent ACEis, further research on this target might have seemed pointless. That was until the 
structure of the target was investigated.  
 















Carboxylic Acid ZBG 
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1.3 The Two Catalytic Domains of ACE 
1.3.1 The Discovery of the Two Domains of ACE 
The first detailed enzymatic characterisation of ACE was performed by Das and Soffer in 1975.37 This 
study established ACE as a glycosylated protein with a MW of 129 kDa. Furthermore, kinetic studies 
revealed ACE activity to be chloride-dependent. A few years later El-Dorry et al38 isolated what 
appeared to be a very similar enzyme from rabbit testis tissue using Lisinopril-Sepharose affinity 
chromatography. This enzyme was shown to be significantly smaller than ACE at 94 kDa, but showed 
a remarkably similar kinetic profile with respect to the cleavage of Hip-His-Leu and Ang-I substrates. 
In addition, both enzymes could be successfully immunoprecipitated using the same antibodies. 
mRNA comparisons of the two enzymes proved that this testicular enzyme was not a post translational 
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product of ACE but rather that the two proteins originate from different promoters within the same 
gene. The role of this ACE-like enzyme was not understood at the time since Ang-II had no known 
targets in the testicular tissue while its expression appeared to be hormonally controlled.  
 
The 1980s saw massive advances in the field of genetics and molecular biology with the advent of 
polymerase chain reaction (PCR) and DNA sequencing technology. This new technology helped to fast-
track the structural studies on ACE. Soubrier et al2 sequenced somatic ACE for the first time. From this 
sequence, a C-terminal lipophilic region for the membrane anchor was identified. The sequence of 
ACE was then overlaid with that of thermolysin and neutral endopeptidase (NEP), two Zn 
metallopeptidases whose structures were known. Surprisingly, ACE was shown to possess not one but 
two catalytic sites. In a protein of 1277 residues, two homologous regions of 357 residues (termed N- 
and C-domains) were identified with an overall sequence homology of 67.7%. 
 
Sequencing also solved the mystery of the similar ACE-like enzyme found in testicular tissue. This 
enzyme was shown to be an exact copy of the C-domain region from the full enzyme. ACE was 
therefore shown to be expressed in two different isoforms depending on its location within the body. 
The testicular isoform of this enzyme is designated testis ACE (tACE) while the isoform expressed 
throughout the rest of the body is designated somatic ACE (sACE) (Figure 1.8). This structural 
breakthrough regarding the domain structure of the protein paved the way for studies investigating 
the two active sites of the enzyme.  
 
Figure 1.8: A schematic representation of two different isoforms of ACE; sACE and tACE. sACE is the ubiquitously expressed isoform with both the N- and C-domains present along with a transmembrane and linker region. tACE is a form of ACE expressed only in testicular tissue with just the C-domain and the transmembrane anchor present. 
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1.3.2 Kinetic Properties of the Two Domains of ACE 
The first line of research into the different catalytic domains was directed towards comparing the 
differential rates of substrate hydrolysis between the two domains. Wei et al3a expressed truncated 
forms of ACE containing either just the C-domain or the N-domain active site mutants with zinc-
binding sites disrupted. Under assay conditions, both the N- and C-domains showed almost identical 
Km values towards Ang-I. However, N-domain knockout mutants showed a 3-fold increase in the kcat 
values as opposed to the C-domain knock out mutants. The kcats of the individual domains add up to 
the kcat of sACE suggesting no synergistic effect between the two domains is present. The rates of 
hydrolysis were also compared between the two domains using the Hip-His-Leu (HHL) substrate. It 
was found that the C-domain was responsible for 90% of the HHL hydrolysis of sACE. The implication 
here is that Ang-I and HHL hydrolysis is primarily controlled by the C-domain hence all inhibitors were 
developed against C-domain inhibition without much information regarding their N-domain binding.  
 
The chloride dependence of the different domains was also investigated3b. sACE was known to be 
highly chloride dependent with an optimal chloride concentration of 800 mM. The optimum chloride 
concentration for the individual domains was determined to be 10 mM and 800 mM for the N- and C-
domains respectively with only the C-domain activity proving to be chloride dependent. In vivo 
chloride concentration is related to water volume, a kidney regulated function thus suggesting C-
domain chloride dependence to be another link between renal function and the RAAS. Conversely, 
the N-domain appears to operate independently of in vivo chloride concentrations. These findings 
further emphasise that the majority of the known ACE characteristics at that time were a result of the 
C-domain function while the precise role of the N-domain remained unclear. 
 
As the differences between the two domains were elucidated, a more comprehensive study of the 
domains and their substrates was performed. Jaspard et al39 expanded on the previous two studies to 
investigate the activity of ACE using three additional peptides, BK, substance P, (Arg-Pro-Lys-Pro-Gln-
Gln-Phe-Phe-Gly-Leu-Met-NH2) and luteinising hormone releasing hormone (LH-RH), Glp-His-Trp-Ser–
Tyr-Gly-Leu-Arg-Pro-Gly-NH2. Both domains showed similar Km and kcat values for the hydrolysis of BK. 
In wild type sACE, the total BK kcat proved to be roughly equivalent to the sum of the individual kcats 
implying that both domains hydrolyse BK with similar efficiencies. 
 
In the case of substance P, sACE was able to cleave both the C-terminal dipeptide and tripeptide, a 
rare observation for an enzyme, which had been assumed to be an exclusive dipeptidase. In this 
instance, sACE cleaved the terminal tripeptide of Substance P at three times the rate of its terminal 
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dipeptide. This is presumably because Phe-Gly-Leu is a better fit for the S1, S1’ and S2’ subsites. The N-
domain catalysed this peptide at 1.5 times the rate of the C-domain. In the case of LH-RH, ACE was 
able to cleave both the C- and N-terminal tripeptides. Here the reaction was catalysed by the N-
domain at 10 times the rate of the C-domain. While this study showed that some substrates are 
selective towards the N-domain, sACE showed very high Km values of 265 µM and 6 mM towards LH-
RH and substance P respectively. Such high dissociation constants are unlikely to translate into any 
observable activity towards these substrates in vivo.  Another point to note is the C-terminal amidation 
of these two peptides. It was originally postulated that a C-terminal acid was essential for a peptide 
to bind to sACE yet substance P and LH-RH are clear exceptions. Despite this exception it is possible 
that the C-terminal amidation of these peptides is responsible for their high dissociation constants. 
1.3.3 AcSDKP – An N-Domain Selective Substrate  
The new discovery of the two homologous active sites of ACE posed almost as many new questions as 
it answered. While it had been shown that the C-domain is responsible for the majority of Ang-I 
hydrolysis and more than half of the BK degradation, no distinct role for the N-domain had been 
identified until the discovery of AcSDKP. AcSDKP is a small tetrapeptide first isolated by Lenfant et al40 
from foetal calf marrow. It was identified as a signalling molecule responsible for the inhibition of 
pluripotent haematopoietic stem cell proliferation after irradiation. It acts by arresting the cell’s entry 
into the S-phase of the cell cycle. Further investigation by Robinson et al41 showed the role played by 
AcSDKP in the cell cycle arrest to be indirect, suggesting it to inhibit the release of a S-phase stimulator. 
This new pathway was implicated in the prevention of tumour growth and cell death in irradiated cell 
lines hence it showed the potential as a novel cancer therapeutic.  
 
AcSDKP was subsequently shown to be rapidly hydrolysed by ACE,42 providing further evidence that 
its role extends beyond blood pressure regulation. Examining the hydrolysis by the individual domains, 
it was found that the N and C-domains have similar binding affinities towards AcSDKP with Kms of 31 
and 39 µM respectively.43 The N-domain, however, catalyses AcSDKP at about 40 times the rate of the 
C-domain (N-domain kcat = 16s-1; C-domain kcat = 0.40 s-1) suggesting the in vivo ACE hydrolysis of 
AcSDKP occurs exclusively at the N-domain. This was the first pathway identified where the N-domain 
of ACE plays a primary role. Later studies showed that ACE inhibition was a viable in vivo treatment 
for maintaining AcSDKP levels and arresting the cell cycle of irradiated haemopoietic stem cells.44   
 
At the same time a link between ACE and cardiac remodelling/fibrosis was being established. Sun et 
al45 showed ACE to play a crucial role in the deposition of collagen in cardiac tissue, the lead cause of 
cardiac fibrosis. Brooks et al46 then showed that captopril was capable of treating fibrosis induced 
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myocardial infarction. AcSDKP was subsequently shown to mitigate the fibrotic effects of increased 
collagen deposition in cardiac tissue.47 Furthermore, Peng et al48 linked the antifibrotic effect of ACEis 
to raised AcSDKP concentrations in vivo. Thus, ACE was suggested to be a viable antifibrotic 
therapeutic target in addition to an antihypertensive one. 
1.4 Selective Inhibition of the Two Domains 
1.4.1 ACEis and the Two Domains of ACE 
To complement the recent kinetic studies on the individual domains of ACE, Wei et al3b completed an 
inhibitor study on these individual domains. The Kis of four ACEis were reassessed against the 
individual domains using Hip-His-Leu as a substrate (Table 1.3). 
Table 1.3: The Ki values of 4 inhibitors against the N- and C-domains of ACE.3b 
Ki (nM) 
ACE Form Captopril Enalaprilat Lisinopril Trandolaprilat 
Wild type 1.3 0.65 0.39 0.045 
N-domain 0.89 2.6 4.4 0.31 
C-domain 1.4 0.63 0.24 0.029 
 
Since the C-domain is predominantly responsible for the cleavage of Hip-His-Leu, it is not surprising 
that each ACEi displayed similar Kis towards both sACE and its C-domain. In contrast, the N-domain Kis 
were different to that of sACE in each case. Of the four ACEis, Lisinopril and Trandolaprilat were the 
most C-domain selective, showing 18 and 10-fold selectivities towards the C-domain over the N-
domain respectively. Surprisingly, Captopril proved to be marginally N-domain selective. While the 
inhibition profiles of the two domains appear distinct, all four inhibitors are potent against both 
domains suggesting a high degree of structural similarity despite their functional differences. 
1.4.2 Selective Inhibition of the Two Domains 
With the success of ACEis as a treatment for hypertension, there have been several side-effect 
drawbacks. The most notable of these side-effects are persistent cough and angioedema which, 
despite being uncommon, is potentially life threatening.49 When the cause of angioedema and cough 
was identified as excess BK accumulation,50 the idea of developing domain specific ACEis became an 
attractive one. The rationale being that a C-domain selective ACEi could sufficiently reduce Ang-I 
hydrolysis to treat hypertension but would leave the N-domain free to degrade BK, thus mitigating the 
cause of angioedema and cough. Conversely N-domain selective ACE inhibition has therapeutic 
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potential in the treatment of cardiac and pulmonary fibrosis/remodelling without affecting blood 
pressure.  
 
While the first generation of ACEis were shown to potently inhibit both domains, the different kinetic 
profiles of the two domains suggested domain selective inhibition was possible. Michaud et al51 
examined the differences in inhibition by Captopril, Lisinopril and Fosinoprilat against the two domains 
using the two native substrates, Ang-I and AcSDKP. Captopril was the only one of the three inhibitors 
to display a slight selectivity towards the inhibition of AcSDKP hydrolysis as opposed to Ang-I 
hydrolysis. Since AcSDKP hydrolysis is entirely controlled by the N-domain, the N-domain selectivity 
of Captopril was assumed to be responsible. Deddish et al52 went on to examine the differential 
activity of ACE on many different peptides and found Ang1-7 to be of particular interest. The N-domain 
hydrolysed Ang1-7 much faster than the C-domain with a kcat of 27 min-1 as opposed to 0.36 min-1. The 
second observation was that Ang1-7 is a 10 to 15-fold stronger inhibitor of C-domain Ang-I hydrolysis 
than the N-domain. These measurements were later contradicted by Thomas et al53 measuring these  
kcats for the N- and C-domain at 3.0 and 1.4 s-1 respectively. Despite the disagreement over these 
kinetic parameters, the sequence of Ang1-7 played an integral role in the design of the first C-domain 
selective ACEi. 
 
Ang1-7 has the sequence Asp-Arg-Val-Tyr-Ile-His-Pro. Since all ACEis at the time had mimicked the 
terminal two or three residues on the C-terminal of a peptide, the search for a small molecule inhibitor 
mimicking this sequence was conducted. An ACEi published in 1981 by Weare et al54 called Keto-ACE 
(Figure 1.9) stood out with its peptide mimicking  pseudo Phe-Phe-Gly-Pro sequence sharing some 
chemical similarity with the sequence of the four C-terminal residues of Ang1-7. When tested in vitro, 
keto-ACE showed a remarkable 50-fold C-domain selectivity when tested against the BK substrate 
while a 30-fold selectivity was observed when tested against the Ang-I substrate. Thus the first small 
molecule C-domain selective inhibitor was confirmed. 
  
Figure 1.9: Chemical structure of keto-ACE 
This techinique of studying the inhibition and kinetics of native peptides to customise a 
peptidomimetic inhibitor also proved useful for designing an N-domain selective inhibitor. In the mid 
1990s, Jiracek et al55 discovered several metalloprotease inhibitors based on a central phosphinate 
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ZBG with two amino acid residues on either side. N-terminal acetylation and C-terminal amidation was 
also tested on these peptides. A high throughput solid-phase peptide synthesis protocol was used to 
synthesise various permutations of this phosphinic acid tetrapeptide template. Using the sequence of 
AcSDKP as a guideline, Dive et al found Ac-Asp-Phe-(PO2CH2)-Ala-Ala-NH2 to be a potent N-domain 
selective ACE inhibitor with a 2000-fold selectivity towards the N-domain.56 This compound was 
named RXP407 (Figure 1.10).  
 
Figure 1.10: Chemical structure of RXP407 
Table 1.4: Inhibition of the two ACE catalytic domains by RXP407 and its analogues 
Name Sequence ACE-N Ki (nM) ACE-C Ki (nM) 
RXP407 Ac-Asp-PheΨ(PO2CH2)-Ala-Ala-NH2 12 25000 
Compound II Ac-Asp-PheΨ (PO2CH2)-Ala-Ala-OH 2 7 
Compound III NH2-Asp-PheΨ (PO2CH2)-Ala-Ala- NH2 5 800 
Compound IV Ac-Ala-PheΨ (PO2CH2)-Ala-Ala- NH2 15 200 
 
Table 1.4 details the inhibition of RXP407 and its derivative compounds against the two domains of 
ACE. Substituting the C-terminal amide for a carboxylic acid in Compound II abrogates the N-domain 
selectivity of RXP407. A 3600-fold decrease in N-domain Ki caused by substituting the C-terminal 
carboxylic acid with an amide is extremely surprising as both domains are dipeptidases with assumed 
positively charged regions in the S2’ prime subsite. A non-uniform change in binding affinity between 
the two domains over this carboxylic acid to amide substitution was inconsistent with the existing 
model for the two domains of ACE. Compound III is the N-terminal deacetylated form of Compound 
I. This deacetylation produces a 30-fold reduction in N-domain selectivity. Lastly in Compound IV, the 
P2 Asp is replaced with an Ala. This substitution effects a 100-fold reduction in N-domain selectivity. 
The SAR conclusions drawn from this study showed that all four of these phosphinic peptides are 
potent ACE N-domain inhibitors. The selectivity towards the N-domain over the C-domain hinged on 
a carboxy terminal amide, a terminal amine acetylation and a P2 carboxylic acid, all of which appear 
to be crucial to the disruption of C-domain binding.  
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Georgiadis et al57 followed a similar approach to develop a C-domain selective phosphinic acid 
tripeptide. The most potent ACE C-domain selective inhibitor derived from this study was Cbz-Phe-
(PO2CH2)-Pro-Trp which was later named RXPA380 (Figure 1.11) 
 
Figure 1.11: Chemical structure of RXPA380 
In a Mca-Ala-Ser-Asp-Lys-DPa-OH competitive inhibition assay, the Ki of RXPA380 towards the ACE C-
domain was 3 nM while no inhibition of the ACE N-domain was observed for inhibitor concentrations 
up to 10 µM. The C-domain selectivity of RXPA380 was suggested to stem from either the entropic 
constraints brought about by the P1’ pseudo-Pro or the large hydrophobic indole group of the Trp in 
the S2’ pocket.  
Table 1.5: An SAR series probing for C-domain selectivity at the P1’ and P2 positions. 





RXPA380 Cbz-Phe-(PO2)-Pro-Trp-OH 3 > 10000 > 3300 
7 Cbz-Phe-(PO2)-Ala-Trp-OH 0.5 45 90 
8 Cbz-Phe-(PO2)-Pro-Ala-OH 20 450 22.5 
9 Cbz-Phe-(PO2)-Ala-Ala-OH 0.8 0.8 1 
10 Cbz-Phe-(PO2)-Pro-Pro-OH 4 60 15 
11 Cbz-Phe-(PO2)-Pro-Arg-OH 9 200 22.2 
12 Cbz-Ala-(PO2)-Pro-Trp-OH 60 8000 133 
13 Cbz-(h)Phe-(PO2)-Pro-Trp-OH 65 9000 138 
 
Georgiadis et al58 examined the chemical basis for the C-domain selectivity of RXPA380 and 
synthesised a series of RXPA380 analogues to probe the contribution made by each amino acid side-
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chain towards this domain-selectivity. Compounds 7-13 from Table 1.5 each have one or two side-
chain substitutions. From this SAR study, it emerged that both the P1’ pseudo-Pro and the P2’ Trp are 
essential for C-domain selectivity. Substituting either moiety for an Ala came at a significant cost but 
not a complete loss in C-domain selectivity. This would seem to suggest that both the P1’ Pro and P2’ 
Trp are deleterious to N-domain binding with the P1’ Pro more so than the P2’ Trp. Considering all the 
BPPs contain a P1’ Pro, this moiety alone cannot be responsible for a deleterious N-domain interaction. 
The P2’ Trp would seem to be a much better candidate for the deleterious N-domain interaction. 
Intriguingly, the Pro-Trp combination appear to be crucial for C-domain selectivity. This suggests that 
the Pro locks the Trp in a conformation forcing an unfavourable interaction with the S2’ pocket of the 
N-domain.  
The development of RXP407 and RXPA380 was a major breakthrough in designing domain-specific 
ACEis. Both compounds display poor drug-like properties due to their large molecular weights, their 
highly polar phosphinic acid groups and the presence of several peptide bonds. These molecules, 
however, do serve as useful templates for further SAR studies and the development of small molecule 
drug-like domain-selective ACE inhibitors.  
 
1.4.3 In vivo Domain Specific Inhibition 
In vivo domain specific ACE inhibition has been investigated to determine the pharmacological and 
therapeutic efficacy of inhibiting catalytic domains of ACE individually. Since RXPA380 and RXP407 
have poor oral bioavailability, Georgiadis et al57 tested their effects intravenously by injecting each 
inhibitor into mice and then infusing them with radiolabelled Ang-I, BK or AcSDKP substrate. The ratio 
of radiolabelled hydrolysed substrate was then measured at regular intervals. RXPA380 and RXP407 
behaved as expected when inhibiting the hydrolysis of these three radiolabelled substrates. The 
RXPA380 inhibition curve of Ang-I hydrolysis showed two inflection points. It was capable of inhibiting 
75% of the Ang-I hydrolysis at low concentrations and was only able to inhibit it completely at very 
high concentrations. Almost the reverse was observed with the dual inflection inhibition profile of 
RXP407.  RXP407 was shown to be capable of inhibiting about 30% of Ang-I hydrolysis at low 
concentrations with full inhibition achieved again at very high concentrations. In the case of BK, only 
partial inhibition of BK hydrolysis was achieved with each inhibitor when administered individually yet 
full inhibition was achieved in the presence of both inhibitors when administered in combination. In 
the case of AcSDKP, RXPA380 had no effect on its degradation while RXP407 was capable of inhibiting 
AcSDKP hydrolysis completely. 
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The above findings were entirely consistent with previous observations relating to the role of the two 
domains of ACE and the three substrates. However, since exogenous substrates were used, the mouse 
model did not show the effect of domain selective inhibition on the endogenous levels of these three 
substrates and the associated physiological responses. To study the effect of domain selective ACE 
inhibition on endogenous Ang-I, BK and AcSDKP, Fuchs et al developed transgenic mice where either 
the N- or C-domain was inactivated.5  
 
In their first study, Fuchs et al bred ACE mutant mice with their N-domain disabled. The serum from 
these mice displayed about 75% of the Ang-I cleavage ability of wild type mice without the ability to 
hydrolyse Ac-SDKP. However, in vivo, the N-domain inactivated mice showed identical Ang-II/Ang-I 
ratios as wild type mice. Even more surprising was the response of the mice to an Ang-I infusion. The 
N-domain knockout mice again showed an identical response to an Ang-I infusion as the wild type 
mice. N-domain knockout mice on the other hand displayed negligible AcSDKP hydrolysis in 
comparison to the wild type. These findings suggest that N-domain inactivated mice can compensate 
for the lower Ang-I hydrolysis further upstream in the RAAS via increased hydrolysis of 
angiotensinogen. It also infers that N-domain selective ACE inhibition will have no effect on blood 
pressure.  
 
In the corollary study, Fuchs et al4 bred ACE mutant mice with inactivated C-domains. As expected, 
serum from these mutant mice could only hydrolyse the substrate HHL at a small fraction of the wild 
type while its AcSDKP hydrolysis was identical to wild type serum. In vivo, the mutant mice displayed 
a 4.2-fold reduction in the Ang-II/Ang-I ratio compared with wild type while BK(1-7)/BK ratios were 
similar to wild type mice. Furthermore, when injected with Ang-I, the hypertensive response was half 
the magnitude in the C-domain mutant mice than the wild type while a similar blood pressure 
reduction was observed in response to a BK infusion in both the wild type and C-domain knockout 
mice. 
 
These experiments indicate that selective inhibition of the C-domain is more than sufficient to achieve 
the desired anti-hypertensive response from inhibiting both catalytic sites of ACE. Furthermore, 
selective C-domain inhibition leaves the N-domain free to hydrolyse some BK which can negate some 
of the side-effects like angioedema and persistent cough caused by dual domain inhibition. This study, 
therefore, successfully demonstrated the benefits of individually inhibiting both domains of ACE while 
showing them to be promising drug targets in their own rights. 
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1.5 ACE Structural Determination 
1.5.1 Crystal Structures of ACE 
During the second half of the 20th century, protein crystallography developed into an important tool 
for drug discovery and proved invaluable for studying small molecule-protein interactions. The first 
crystal structure of ACE was solved by Natesh et al59 in 2003, nearly 30 years after the discovery of 
Captopril, making the achievement of Cushman and Ondetti even more remarkable. Many 
unsuccessful attempts were made over the decades to crystallise ACE until the advent of recombinant 
expression and DNA sequencing revealed the reason for these failures to some extent. Sequencing 
showed ACE to contain a lipophilic membrane anchor and a highly flexible linker region connecting 
the two domains. Both the membrane anchor and the linker region are highly disordered in solution.  
In addition to these disordered regions, ACE is highly glycosylated posing a hindrance to crystal 
packing. These physical features meant ACE could not be crystallised without a few manipulations.  
Natesh et al59 crystallised a truncated variant of the tACE isoform lacking the N-terminal 36 residues, 
the TM and the cytoplasmic region. Since tACE consists of a single globular domain with an exact 
replica of the ACE C-domain, there was no disordered linker region or N-domain to contend with. This 
truncated construct still appeared to retain all of the original enzymatic activity of tACE and was co-
crystallised with Lisinopril (PDB code: 1O86, resolution: 2.0 Å) and in the apo form (PDB code: 1O8A, 
resolution: 2.0 Å).  
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Figure 1.12: The first crystal structure of tACE (PDB entry 1O86). A. A representation of the entire tACE crystal structure with the binding cleft visible. Inside the binding cleft the catalytic Zn metal is clearly coordinated to Lisinopril. B. A close-up of Lisinopril inside this C-domain binding site. Here it can be seen that Zn coordinates with 3 residue side-chains (His384, His387 and Glu411). The central carboxylic acid of Lisinopril also coordinates with the Zn while its terminal carboxylic acid fits into an electropositive hole created by the adjacent Lys511 and Gln281 residues. Its Lys and Phe side-chains appear to be firmly fixed within distinct subsites. C. A 2D ligand interaction map summarising all the residue side-chain interactions experienced by Lisinopril within this binding site. 
The crystal structure 1O86 confirmed and contextualised many of the features of the ACE C-domain 
(Figure 1.12). The chloride dependency was explained by the presence of two chloride binding sites 
within electropositive pockets. These chloride ions appear to be essential for correct protein folding. 
The structure was largely globular with a central binding cleft. The C-domain could be further split into 
two sub-domains on either side of the binding cleft. As expected, the Zn was centrally located within 
the binding cleft coordinated to two His and one Glu residues (His383, His387 and Glu411). The 
terminal carboxylic acid of Lisinopril was anchored in an electropositive hole in the S2’ pocket created 
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pockets are deep and lined with several hydrophobic residues while the amine of Lisinopril acts as a 
donor in an H-bond with a backbone carbonyl. 
Crystallising the N-domain proved to be more of a challenge, most likely due to the increased number 
of glycans on the surface of the N-domain. Nevertheless, a truncated N-domain construct was 
crystallised after some of the N-glycan networks were enzymatically trimmed.60 Unfortunately, 
crystallisation was still compromised by a few highly disordered loops, which restricted the resolution 
of the structure to 3.0 Å. At this resolution, the two ACE domains were easily superimposed with a Cα 
RMSD of 0.45 Å between 82 active site residues. The Lisinopril poses were virtually identical in these 
two structures (Figure 1.13). 
  
Figure 1.13: An overlay of the crystal structures of the two domains of ACE. The N-domain (cyan) and the C-domain (blue) are derived from the PDB entries 2C6N and 1O86 respectively. A shows the entire crystal structure overlays of both domains. All the α-helices are clearly present in both structures while there is some deviation in the disordered loop regions. B shows a close-up of the Lisinopril ligand from both crystals which clearly bind with identical poses in both domains. 
The N-glycosylation of the N-domain was examined in more detail by Anthony et al61 with a series of 
glycosylation site mutants to establish the sites essential for maintaining enzyme activity. Figure 1.14 
shows a map of the N-glycosylation sites of the two domains. It was found that the N-domain with 
only the 3, 8 and 9 N-glycosylation sites intact (Ndom389G) was the minimally glycosylated form of 
the enzyme necessary to preserve both its stability and enzymatic activity. This glycosylation mutant 
was crystallised in a stable complex with RXP407 and its structure was solved to a resolution of 1.99 
Å (PDB code: 3NXQ). 
A B 
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Figure 1.14: An N-glycosylation map of the two active site domains of ACE. The 7 sites in the C-domain and the 10 sites in the N-domain are indicated. The black boxes indicate conserved sites, the grey boxes indicate the glycosylation sites unique to that domain and the white boxes are unglycosylated sites. 
To date (Dec 2016), there are 35 entries in the PDB for H. sapien ACE using either the tACE (tACEΔ36NJ) 
construct or the G13 mutant for the C-domain and the Ndom389G construct for the N-domain. Of 
these 29 entries, 14 are from the N-domain and the remaining 21 are from the C-domain. (Table 1.6). 
Table 1.6: A table cataloguing all the published ACE crystal structures. The fields provided are the construct used, resolution and the ligand cocrystal. 
PDB Code Construct Resolution (Å) Ligand 
C-domain 
1O8A tACEΔ36NJ 2.00 Apo 
108659 tACEΔ36NJ 2.00 Lisinopril 
1UZE tACEΔ36NJ 1.82 Enalaprilat 
1UZF62 tACEΔ36NJ 2.00 Captopril 
2OC260 tACEΔ36NJ G13 2.25 RXPA380 
2IUL tACEΔ36NJ G13  2.01 Apo 
2IUX63 tACEΔ36NJ G1234  2.80 Apo 
2XY964 tACEΔ36NJ G13 1.97 FII 
2YDM65 tACEΔ36NJ G13 2.44 Se-Captopril 
3BKK tACEΔ36NJ G13 2.17 kAF 
3BKL66 tACEΔ36NJ G13 2.18 kAW 
3L3N67 tACEΔ36NJ G13 2.30 lisW 
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4APH tACEΔ36NJ G13  1.99 Ang-II 
4APJ68 tACEΔ36NJ G13 2.6 BPPb 
4CA569 tACEΔ36NJ G13 1.85 FI 
4C2R tACE G13 R522Q 2.30 Apo 
4C2Q tACE G13 R522K 2.40 Apo 
4C2P tACE G13 R522K 1.99 Captopril 
4C2O tACE G13 D465T 1.80 Apo 
4C2N70 tACE G13 E403R 2.59 Apo 
4BZR71 tACEΔ36NJ G13  1.84 K-26 
N-domain 
2C6F Ndom wt 3.01 Apo 
2C6N60 Ndom wt 3.00 Lisinopril 
2XYD64 Ndom389 2.15 FII 
3NXQ61 Ndom389 1.99 RXP407 
4BXK72 Ndom389 2.20 33RE 
4BZS71 Ndom389 2.10 K-26 
4CA669 Ndom389 1.91 FI 
4UFB Ndom389 1.80 Lys-Pro 
4UFA73 Ndom389 1.80 Ac-SD 
5AM8 Ndom389 1.90 Amyloid-β 4-10 
5AM9 Ndom389 1.80 Amyloid-β 10-16 
5AMA Ndom389 1.80 Amyloid-β 1-16 
5AMB Ndom389 1.55 Amyloid-β 35-42 
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5AMC Ndom389 1.65 Amyloid-β 4-10 
 
1.5.2 Structural Determinants of C-Domain Selectivity  
As already discussed, Georgiadis et al investigated the effect of each side-chain moiety on the C-
domain selectivity of RXPA38058. In this study, some molecular modelling experiments were 
performed to determine the most important interactions to explain the C-domain selectivity of 
RXPA380. Molecular Mechanics (MM) simulations were performed on RXPA380 in the binding pocket 
of the crystal structure 1O86 to predict bioactive conformations of RXPA380. These simulations 
suggested that the indole moiety of RXPA380 sits deeper in the S2’ pocket of ACE than the Pro group 
of Lisinopril. Here the indole is brought into contact with the residues Val379 and Val380 of the 1O86 
crystal structure. These two hydrophobic residues serve to create a hydrophobic region in the vicinity 
of the indole moiety of RXPA380. These interactions were confirmed in the crystal structure 2OC2.74 
Superimposing the N-domain and C-domain structures showed that Val379 and Val380 of the C-
domain are replaced with a Ser357 and Thr356 respectively (Figure 1.15). These polar residues create 
a hydrophilic region in the vicinity of the hydrophobic indole moiety of RXPA380. This leads to an 
unfavourable interaction in the S2’ subsite of the N-domain of ACE. It therefore explains the lack of 
binding to the N-domain, hence the C-domain selectivity observed with RXPA380.  
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Figure 1.15: Structural determinants of the C-domain selectivity experienced by ACE. A. RXPA380 (green) bound to the C-domain and overlaid with Lisinopril (yellow) from 1O86. The indole moiety of RXPA380 sits much deeper in the S2’ subsite where it can interact with Val379 and Val380. It must also be noted that the Cbz moiety of RXPA380 sits in the S2 subsite which Lisinopril cannot access. B. RXPA380 is placed within the active site of the N-domain (2C6N). In the N-domain, Val379 and Val 380 have been replaced with a Ser and Thr residue respectively. These polar side-chains interact unfavourably with the Indole moiety.  
The SAR of a bulky P2’ hydrophobic group was also explored in two other series; a series based on 
keto-ACE which has a P2’ Pro and a series based on Lisinopril (Table 1.7). In the case of the Keto-ACE 
series,60 replacing the P2’ Pro with a Trp and Phe destroyed any remaining N-domain inhibition. This 
trend was also observed with the Lisinopril derivative. Substituting the C-terminal Pro moiety of 
Lisinopril for a Trp to create Lis-W greatly reduced its N-domain inhibition (400-fold) but maintained 
its C-domain inhibition. LisW67 seemed like a promising drug lead owing to its similarity to Lisinopril;75 
however, it displayed poor oral bioavailability.76 Despite the failure of LisW, Lisinopril P2’ analogues 
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Table 1.7: A table of two chemical series exploring P2' SAR in ACEis. The two series shown are derivatives of either Keto-ACE (kAP) or Lisinopril 
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1.5.3 Structural Determinants of N-Domain Selectivity 
N-domain selectivity has already been discussed within the context of the discovery of RXP407. Based 
on the sequence of five phosphinic acid tetrapeptides, it was concluded that N-domain selectivity was 
caused by both the presence of a C-terminal amide and an N-terminal Asp. The successful 
cocrystallisation of RXP407 in the N-domain by Anthony et al61 challenged the findings of Dive et al 
with respect to the importance of the C-terminal amide. Modelling RXP407 within the active site of 
the original N-domain crystal60 (PDB code: 2C6N) did not provide any direct evidence to support the 
theory that a C-terminal amidation was in part responsible for the selective N-domain binding. Both 
domains have clearly defined positively charged cavities at the edge of the S2’ pocket facilitating the 
binding of the anionic C-terminal carboxylic acid. The positively charged hole is lined with the side-
chains of a Lys and Gln, which occupy identical positions in both domains. The notion of a C-terminal 
amidation being responsible for a massive deleterious C-domain interaction (three orders of 
magnitude loss in binding affinity) would therefore seem improbable. It is rare to find such a large 
change in binding energy during SAR studies, which can be solely attributed to such a small change.  
The interaction between the acidic P2 group and the Arg381 residue in the S2, pocket is more likely to 
be responsible for conferring N-domain selectivity.77 In the crystal structure of the N-domain in 
complex with Lisinopril (2C6N), Arg381 is pointing away from the active site. Kroger et al77 correctly 
predicted Arg381 to reposition itself to form a salt bridge with the aspartate of RXP407 as was 
observed in the PDB structure 3NXQ.61 The Arg to Glu substitution in the C-domain would result in a 
clash between two negatively charged groups. The proposed relationship between C-terminal 
amidation and a deleterious C-domain interaction is presumably related to the mechanism of RXP407 
entering the active site cleft rather than its final resting position.  
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Figure 1.16:The crystal structure of RXP407 in complex with the N-domain. A. The RXP407 ligand bound to the ACE N-domain from the crystal 3NXQ. Here a salt bridge is clearly visible between RXP407’s P2 carboxylic acid and Arg381. B. When overlaid with the N-domain structure from 2C6N (cyan), a huge difference in the position of Arg381 is observed. In the absence of a P2 carboxylic acid, Arg381 is capable of swinging out and reorientating itself away from the binding cleft. C. RXP407 in the 3NXQ crystal structure (yellow) overlaid with the C-domain of 1O86 (green). Here it is shown that Arg381 is substituted for Glu403 in the C-domain. An acid-acid clash in the S2 subsite can explain the deleterious effect this moiety has on the binding of RXP407 to the C-domain. 
The contribution of an acidic P2 moiety towards disrupting the ligand binding with the C-domain and 
conferring C-domain selectivity has been reaffirmed with a recent scaffold hopping exercise by 
Douglas et al.72 Using the SHOP78 methodology, the substitution of the P2 Asp moiety of RXP407 with 
a tetrazole was predicted to preserve N-domain selective ACE inhibition. This substituted RXP407 
analogue was synthesised and named 33RE (Figure 1.16) and the Ki of this compound towards the N- 
and C-domains of ACE were measured at 11.2 nM and 10.4 µM respectively. These Ki values translate 
to an N-domain selectivity factor of 927, comparable to that of RXP407. While 33RE reaffirms the 
contribution towards N-domain selectivity made by a P2 acidic moiety, it is still a phosphinic 
tetratpeptide like ACE. To date no drug-like N-domain selective ACEis have been reported but RXP407 
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Figure 1.17: 33RE 
1.6 Summary and Research Objectives 
Despite the wide ranging therapeutic success of ACE inhibitors, new evidence has come to light 
regarding ACE and its role within the RAAS. As previously mentioned, there are clear advantages to 
targeting both catalytic domains of ACE individually with domain specific inhibitors. There is now an 
extensive collection of crystal structures available for both domains. Modern CADD software and high 
performance computers make it possible to precisely target the structural differences between these 
two domains as opposed to the more traditional methods of designing peptidomimetics based on 
peptide substrates.  
The research objective of this project was therefore to use a variety of CADD tools and crystal data to 
guide the design of novel drug-like N-domain selective ACE inhibitors. Several techniques were 
employed to develop such N-domain selective inhibitors. These include: 
 Fragment screening 
 Combinatorial libraries 
 Database mining 
 Protein-ligand docking 
 Molecular Dynamics 
Once the most promising hits were decided on, they were purchased or synthesised and then 
subjected to competitive inhibition assays in vitro against both domains to test for ACE domain 
selectivity. Subsequent chapters will describe this approach and the results thereof.  
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Chapter 2 – Fragment-Based Screening 
2.1 Introduction 
2.1.1 Docking Background 
The primary objective of this study was to discover N-domain selective ACE inhibitors using computer 
aided drug discovery (CADD) methods. CADD or in silico drug discovery is the use of computer software 
to predict the behaviour of potential drug compounds before synthesis or in vitro testing. Using 
modern computer hardware, CADD software has the ability to predict drug behaviour on a massive 
set of compounds before undertaking any synthesis or in vitro testing. Depending on the methodology, 
CADD has the ability to save time and resources over traditional screening methods like high 
throughput screening (HTS). In the last two decades, CADD has developed into an essential tool to 
complement traditional drug discovery techniques. There are two major streams of CADD, structure 
based (SB) or ligand based (LB). SB techniques study and predict interactions between drugs and the 
target using crystal structures, homology models or NMR-derived models of the target. LB drug 
discovery makes predictions based on the known behaviour of a set of ligands in the absence of a 
reliable model of the target.  
One of the most widely used and versatile drug discovery techniques is molecular docking.79 In the 
context of drug discovery, docking entails the fitting of a small molecule into a designated binding site 
of a modelled target protein.80 A model of the target can be derived from a crystal structure, a 
homology model or an NMR-derived structure. Crystal structures are the most accurate depictions of 
protein structure. Fortunately, the improvement of crystallisation techniques and the advent of high 
performance computers has dramatically reduced the time and cost required to grow and solve high 
resolution crystal structures. Protein crystallography is now the preferred method to study and 
visualise protein–small molecule interactions.  
A docking algorithm operates by fitting a small molecule or ligand into a predefined space containing 
the binding site of the protein target. These algorithms consist of two main components, a search 
algorithm and a scoring function. The search algorithm explores the 6 degrees of freedom (3 degrees 
of translational and 3 degrees of rotational freedom) of the ligand to find an appropriate orientation. 
Once a satisfactory orientation has been found, the rotatable bonds are manipulated to determine 
the optimal ligand conformation. The simplest search algorithm would entail scanning all the possible 
conformations evaluating each conformation or pose after sequentially rotating each rotational bond 
by a small and finite increment. This approach becomes highly problematic as the molecules grow 
larger. The addition of each rotational bond adds an additional degree of freedom, thus exponentially 
increasing the conformational space available to the ligand. Such a calculation quickly becomes 
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prohibitively expensive due to combinatorial explosion as explained by equation 2.1. To work around 
this problem, many ingenious solutions have been devised to search a representative portion of the 
available conformational space.   
 N =  360θ ,  (2. 1) 
Docking was initially developed as a tool for virtual screening (VS). VS is the screening of a database 
of drug-like compounds for a novel chemical class of inhibitors against a target. The utility of docking 
protocols has since been expanded to many additional CADD applications such as de novo design, 
determining the starting geometry of ligands for molecular dynamics (MD) and binding energy 
calculations. This is thanks to the ability of docking algorithms to rapidly predict the bioactive 
conformation of a ligand within a protein binding site from a newly rendered 3D structure. 
2.1.2 Search Algorithms 
The role of a search algorithm is to explore the available conformational space while the scoring 
function evaluates the energetics of each suggested pose. The search algorithm and scoring function 
works synergistically to enable the docking programme to rapidly converge on a realistic prediction of 
the bioactive pose of small molecules within a protein binding site. 
Docking simulations are usually performed in a predefined space inside the active site of the target in 
which the potential field is calculated. This predefined space in which docking simulations are 
performed is called a docking grid. A docking grid is typically defined as a rectangular box centred on 
a bound ligand in the respective binding site. While the grid may be defined with flat surfaces, the 
topology of the docking site is dictated by the surface of the protein. The atoms of the protein are 
modelled as hard spheres of a radius less than the van der Waals radii (Table 2.1)81.  Sub van der Waal 
radii gives the ligand some space to move within the binding site. van der Waal radii violations do, 
however, lead to steric clashes and large energy penalties in the final pose. A compromise is usually 
found between allowing the ligand conformational freedom and applying energy penalties to favour 
accurate poses. This compromise is found by softening the potential and setting the atomic radii in 
this model to a fixed factor of the van der Waal radii. This topological consideration reduces the 
conformational space of the search. 
 
 
Chapter 2   – Fragment-Based Screening 
37  Stephen Fienberg – PhD Thesis 
 
Table 2.1: The van der Waals radii81(rw) of the common atoms found in biological systems 






The vast majority of search algorithms fall into one of two classes, Monte Carlo82 (MC) and Genetic 
Algorithms83 (GA). MC algorithms apply a stochastic approach to generate random poses and quickly 
populate the conformational space with a representative set of poses. GAs apply a penalty-reward 
system mimicking the process of natural selection. Both methods have their advantages and 
disadvantages but the key to applying them effectively lies in their parameterisation and the 
refinement of the algorithm. 
2.1.3 Scoring Functions 
All good docking algorithms need a good scoring function to complement the search algorithm. The 
purpose of a scoring function is to cheaply evaluate or score the favourability of a generated pose. It 
is by no means an attempt to accurately quantify the binding energy between the ligand and protein 
but rather a tool to drive the search algorithm and rank the poses. There are three major classes of 
scoring functions employed in docking algorithms; force-field, empirical or knowledge-based. Force-
field based functions evaluate the energetics of the pose arising from the placement of a ligand in the 
electrostatic potential field generated by the surrounding protein. Protein force-fields can be created 
using one of the major protein force-field generating algorithms such as CHARMM84, AMBER85 or 
OPLS86. Empirical scoring functions are based on the sum of uncorrelated terms to describe the 
interaction between a ligand and a binding site together with the change in solvent accessible surface 
area. The coefficients of these terms are weighted via a regression analysis of experimentally 
determined binding energies and X-ray crystal structure derived parameters such as dihedral 
potentials. Knowledge-based scoring functions are derived statistically by collecting data from large 
3D databases of crystal interactions and creating an appropriate potential function to favour these 
observed contacts and poses.  
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Scoring functions can only rank poses relative to each other as docking scores correlate poorly with 
experimentally observed binding energies. The reason is that binding affinity is dependent on certain 
variables which cannot be accurately evaluated from an end point pose. Binding affinity is dependent 
on the change in energy (ΔG) of the protein-ligand-solvent system upon the ligand binding to the 
protein. Initially, the binding site of the unbound Apo protein will be solvated under biological 
conditions as will the ligand. Both the ligand and the binding site need to be desolvated before the 
ligand can bind. The binding of the ligand can therefore be described by equation 2.2. The two most 
popular algorithms for estimating ligand binding energy are the Molecular Mechanics Generalised 
Born Surface Area (MM-GBSA)87 and Molecular Mechanics Poisson Boltzmann Surface Area (MM-
PBSA)88 methods. These methods will be discussed in more detail at a later stage. Both the MM-GBSA 
and MM-PBSA methods are computationally exhaustive and performing these calculations on 
imprecise predicted ligand poses would be frivolous. Scoring functions are better suited to cheaply 
evaluate ligand poses. 
 ∆G = ∆G − ∆G − ∆G  (2.2) 
Scoring functions are typically a sum of the interaction energies of a given pose. An example of a 
simple scoring function is ChemScore developed by Elridge et al89 (equation 2.3). As shown, this 
function sums the energy terms of the different types of interactions. It has terms to describe the 
strength of the lipophilic interactions (lipo), the hydrogen bond interaction (hbond), the metal 
interactions (metal) and the enthalpy of a rotational bond (rotb). Each energy term carries a coefficient 
C which has been empirically determined to weight its corresponding interaction term accordingly. 
 ∆G =  C + C f(r ) + C g (∆r)h(∆α) + C f(r )
+ C H  
(2. 3) 
 
Weighting the lipophilic interaction term to reflect the realistic contributions made by lipophilic 
groups is a big challenge in endpoint scoring functions. (Table 2.2) shows the relative energies of each 
interaction type. Lipophilic interactions or dispersion forces are a full order of magnitude weaker than 
dipole-dipole interactions, which in turn are another order of magnitude weaker than hydrogen bond 
or ionic interactions. Nevertheless, it is well established that non-polar interactions can influence 
ligand binding to a similar extent as H-bonds. This observation is explained by the displacement of 
unfavourable water molecules trapped in hydrophobic pockets of the binding site. Displacing such 
molecules returns them into the bulk solvent system with a large binding energy reward. This 
desolvation of the binding cavity step depends on several variables which cannot be evaluated from 
the final pose. To estimate this multivariable binding energy, scoring functions have both weighted 
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coefficients and a lipophilic term incorporated into the function. This term takes the volumes of 
lipophilic cavities into account while considering the volume occupied by the hydrophobic groups. 
Table 2.2: Relative interaction energies of the different types of intermolecular interactions 
Interaction type Energy (kcal/mol) 
Hydrogen 1–12 
Dipole – Dipole 0.5–2 
Lipophillic < 1 
 
2.1.4 Rigid Receptor 
Arguably the biggest drawback of docking algorithms is the rigid receptor model. When a ligand binds 
to a receptor, small changes occur within the protein to accommodate the ligand. Most of these 
changes involve side-chain movements although backbone adjustments are also possible.90 
Accounting for full protein flexibility would render most docking exercises computationally unviable. 
Hence almost all docking is performed against a rigid receptor. The few exceptions impart flexibility 
on one or two side-chains. Wei et al91 had some success in improving the predictions by docking 
against an ensemble of conformational variants of a single protein. However, fully flexible systems can 
only be modelled using MD simulations. There are a few examples of hybrid MD-docking protocols, 
which are attempts at a fully flexible docking system.92  Most hybrid MD-docking protocols are still 
under development as only the latest computational hardware is capable of handling such simulations. 
2.1.5 Docking Software 
Having been first developed in the 1980s, docking algorithms have been steadily refined and 
diversified into the vast selection of docking algorithms available today. There are too many docking 
protocols available to list but some of the most popular examples today are Glide93, Gold94, ICM95, 
AutoDock96, MOE-Dock97 and FlexX98. For this study, all docking simulations were performed using 
Glide for a few reasons. The first is that it is widely used in the field. The second is that there have 
been several studies comparing the different protocols on a variety of test cases.99 In these studies, 
the metrics used for the comparison are the RMSD when reproducing the poses of ligands and the 
enrichment factor for identifying known active compounds from databases. Glide consistently 
performs favourably when measured using both metrics. It is not uncommon to perform docking 
studies on the same protein-ligand systems across multiple docking platforms and rank the docking 
scores via consensus scoring. While such methodologies have their merits, they also have the potential 
to be time consuming and computationally expensive without adding much value to the study.  
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Glide is one of the newer docking algorithms having been released in 2003. Its search algorithm is a 
hybrid of spatial analysis hierarchical filters and MC conformational sampling. The hierarchical filters 
help to quickly find the correct orientation and position within the docking grid, thus greatly reducing 
the conformational space to be scanned by the MC sampler. The result is a rapid convergence on the 
correct pose.  
The Glide scoring function (GlideScore) is a derivative of the ChemScore scoring function (equation 
2.4). The key modification is the splitting of the H-bond terms into three classes of H-bond interactions. 
These classes are H-bonds between charged-charged, charged-neutral and neutral-neutral H-bonding 
atom pairs. This sub classification of H-bond types provides an improved approximation of H-bonding 
energies. Another addition is the van der Waals and solvation terms, which help to better evaluate 
the effects of cavity desolvation in an end-point evaluation. This scoring function evaluates interaction 
energies using an OPLS force field, which was specially developed to handle side-chains and almost all 
the chemical species found in drug-like molecules.86 The van der Waals terms are evaluated using the 
12-6 Lennard-Jones potential (equation 2.5, figure 2.1). Potential softening by a factor of 0.8 is applied 
to the van der Waals radii. This enables ligands to access blocked pockets and better approximate the 
H-bonds, which are always shorter than the sum of two van der Waals radii. The Glide algorithm has 
three different precision settings, high throughput virtual screening (HTVS), standard precision (SP) 
and extra precision (XP). These levels of precision utilise progressively more integration points to 
evaluate their functions for more precise predictions. A greater number of integration points improves 
precision but at great computational cost. 
 
∆G =  C + C f(r ) + C g (∆r)h(∆α)
+ C g (∆r)h(∆α) + C g (∆r)h(∆α)
+ C f(r ) + C H + C V + C E
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 E = 4ε σr −
σ
r  (2.5) 
2.1.6 Metalloprotein Docking 
A big challenge associated with accurately modelling ACE is the central Zn atom. Zn is a transition 
metal with a preference for the 2+ oxidation state. It has a propensity to coordinate with many lone 
pairs, all of which can affect its affinity for further coordination and the energy associated with such a 
coordination.  
Accurately quantifying the interaction between the Zn and a chelating group requires very expensive 
quantum mechanical (QM) calculations. Such calculations are much too time consuming to 
incorporate into docking scoring functions. Glide has opted for an interaction pair approach to 
approximate metal coordination energies. Each metal-chelator pair has its interaction approximated 
from a template of pre-calculated values. These values are then applied to the output pose. This 
solution provides a rough approximation of an interaction, which is comparably inexpensive to 
calculate. This metal interaction term has improved the accuracy of GlideScore but it is still left with a 
few caveats. The first being that only ligands with the same metal chelators can be directly compared. 
The second is that ligands with more than one of the same chelating group are prone to having the 
incorrect group assigned to the metal for chelation. Glide is nevertheless sufficiently customisable to 
ensure the correct chelator-metal pair is always assigned. 
There have been several previous attempts at applying docking techniques to find novel domain 
selective ACEis. A notable example is the one carried out by Cresset (unpublished) in 2010. In this 
study, 200 promising compounds from a database were docked into ACE using the LigandFit100 docking 
algorithm. 38 Of the most promising compounds were selected for in vitro assays. None of the tested 
compounds showed more than 50% inhibition of the total ACE activity when tested against either 
Figure 2.1:The Lennard-Jones 6-12 potential as a function of a finite distance from an atom σ where a zero potential is experienced with an experimentally predetermined energy minima ε between each atom pair. 
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domain at a concentration of 500 µM. This poor enrichment factor was attributed to many weaknesses 
in their binding protocol. 
LigandFit is a shape-based docking algorithm, which fits ligands to binding site cavities based on their 
shape complementarity. According to the developers, no special allowances or weightings are made 
to incorporate a metal binding term like those used in Glide. Another consideration is that the error 
associated with poor metal binding prediction propagates in larger ligands. The consequence is that 
errors caused by poor metal binding predictions will propagate in the overall binding prediction. 
Considering the above-mentioned factors, it was important to develop a clear and focused docking 
strategy to address all the challenges presented by ACE. Glide is a better docking algorithm for drug 
targets containing metals. It also allows the user to set particular docking constraints forcing an 
interaction between a specific chelator and the metal. Another option to minimise the propagation of 
error is to dock smaller ligands with fewer rotatable bonds and therefore fewer degrees of freedom. 
Fragment docking is an attractive solution for the prevention of propagation of error in larger 
molecules. 
2.1.7 Database Preparation 
As previously mentioned, VS is the most commonly used application of docking algorithms. Screening 
exercises usually follow a strict protocol. This protocol typically starts with a selection of drug-like 
compounds from a database. There are many such freely available databases online. Some have been 
developed in-house by pharmaceutical companies and are derived from their own archives. Others 
are subscription based with access requiring costly subscriptions. Other databases are intended mainly 
for academic research and are widely available to academic institutions. These databases are a 
collection of decades of drug discovery research across academia and industry globally. As a result, 
these databases are of the order of a few million to tens of millions of compounds spanning a diverse 
range of chemical space, much of which will be irrelevant to any given target of interest. Most 
databases include some data relating to each hit such as biological assay information, physicochemical 
properties and publication references. The GVK101 database is an example of a subscription database 
while ZINC102 is freely available.  
ZINC is the largest free to use database of drug-like compounds, containing contributions from the 
entire drug discovery community. The database is pre-divided into many subsets and the website 
contains many useful filtering tools to customise a set of compounds tailor-made for the target before 
downloading. 
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Handling and analysing these high-volume databases present their own challenges and has given rise 
to the field of Chemoinformatics. To analyse compounds in the databases, chemical structures for 
each molecule need to be entered in a format with low memory requirements that can easily be read. 
For this purpose the simplified molecular input line entry system (SMILES)103 language was invented. 
SMILES was devised to describe molecules in their entirety with a string of standard input characters. 
For example, all the atoms are represented by their letter, but bonds are specified with numbers and 
stereochemistry is specified with the @ symbol. The advantage being that each molecule can be 
described with a one-line string which can easily fit on spreadsheets while certain motifs can be quickly 
identified from a string within the SMILES. This enables a wide variety of filtering and manipulation 
programs to be applied to the database reducing it to a more manageable size and streamlining it 
towards the relevant chemical space.  
2.1.8 Database Filtering 
Filtering often begins with the Lipinski ‘Rule of 5,’ a set of physicochemical parameters under which 
compounds are likely to make a good oral drug.104 These parameters are a MW ≤ 500 Da, at most 10 
H-bond acceptors, 5 H-bond donors and ClogP (measure of hydrophobicity) ≤ 5. While these are not 
strict rules to follow, they do serve as useful guidelines to filter databases for molecules with good 
drug-like properties. 
Studying the target and its known ligands can help establish a set of secondary parameters. These may 
include the inclusion or exclusion of specific chemical groups, the size of a fused aromatic region or 
the number of rotatable bonds. Once filtered down to a manageable size, the database is docked 
against the target. The top poses are analysed and a cut-off docking score is decided upon based on 
the point at which the predicted poses become improbable. The next step is to further reduce the size 
of the hit compound set by visual inspections; removing ligands with an unfavourable docking score 
due to an improbable pose or conformation. Once the final set has been sufficiently reduced, a 
representative set is usually chosen for purchase and tested in vitro against the target.  
2.1.9 Fragment Screening 
A fragment screen is an adaptation of a traditional virtual screening protocol based on a few simple 
assumptions. Smaller molecules have fewer rotational degrees of freedom and therefore less 
conformational space to explore. The predicted poses from smaller molecules are therefore 
theoretically more accurate. A smaller molecule also leaves more room for synthetic optimisation at 
a later stage. Lastly, fragment screening exercises are computationally cheaper and therefore quicker 
to run. Instead of using the Lipinski ‘rule of five’ parameters, fragment screens use Congreve’s rule of 
3105 as a guideline. These parameters are MW ≤ 300, CLogP ≤ 3 and at most 3 H-bond donors or 
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acceptors. Since the fragments are small, fragment screening sets will usually be selected based on a 
few defining chemical features. Once a set of fragments is selected for purchase, they are usually 
tested at higher concentrations with in vitro inhibition assays (500-1000 µM).  
A fragment screening method would be well suited to finding a domain selective ACE inhibitor. The 
metal binding introduces a degree of uncertainty, which can be mitigated by smaller ligands. Absolute 
domain selectivity could be hard to come by with smaller ligands. A fragment may nevertheless 
provide useful information for selective drug design. 
2.2 Aims and Objectives 
2.2.1 Aim 
The aim of this chapter was to screen a set of fragment compounds for potential leads on N-domain 
selective ACE inhibition. 
2.2.2 Objectives 
 Build a set of metal chelating drug fragments from the ZINC database. 
 Perform constrained docking on this set against the N- and C-domains of ACE. 
 Analyse and visually inspect the docking outputs for this fragment set against both domains. 
 Screen a representative set of compounds for ACE inhibition in vitro. 
2.3 Methods 
2.3.1 Database Filtering 
A chelating fragment database was created using the chelating fragment library (CFL) (Figure 2.2) 
devised by Agrawal et al106 from the study of matrix metalloproteinase (MMP) inhibitors and the ZINC 
database. A substructure search was performed on a ZINC database subset of 1.2 million fragments 
titled “Fragment Leads Now” which by and large fall within the Congreve’s ‘rule of 3’ parameters. 
Using the ZINC substructure search function, substructure searches were performed using all 96 
chelating fragments from the CFL against the Fragment Leads Now subset to find molecules containing 
these motifs. 
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Figure 2.2: The metal binding functional groups of the CFL. 
2.3.2 Protein Preparation 
A high-resolution crystal structure for both the N- and C-domains of ACE was selected for docking 
simulations. The PDB crystal structures 3NXQ and 1O86 were selected to model the respective N- and 
C-domains. Each structure was prepared for docking according to the following protein preparation 
protocol using Maestro’s protein preparation tool, PrepWizard (Schrödinger Suite 14.0) with the 
following settings applied. PyMOL 1.8 was used to generate all images containing protein ribbons from 
crystal and docked structures. 
C-domain Steps: 
1. Under PrepWizard’s import and process tab, the Preprocess protocol was run on the 1O86 
PDB file with the following boxes ticked; assign bond orders, add hydrogens, create zero order 
bonds to metals, fill in missing side-chains using prime and delete waters beyond 5 Å from a 
het group. 
2. In the Review and modify tab, the Analyze Workspace button was selected and the structure 
was manually inspected. The structure of Lisinopril was manually corrected and the generate 
states function was run to generate the correct metal binding and ionisation state of the 
ligand.  
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3. Under the refine tab, H-bond assignment was run with just the sample water orientations box 
ticked. The remove waters option was run for waters with less than 3 H-bonds to non-waters. 
Lastly a restrained minimisation was run with the heavy atoms set to converge on the default 
0.30 Å using the OPLS_2005 force field. 
N-domain Steps: 
1. The PDB file 3NXQ was imported and the Preprocess protocol was run in a manner identical 
to the C-domain. 
2. The 3NXQ file contains two repeats of the N-domain structure in its asymmetric unit. Chain B, 
the less complete copy of the protein was deleted. As before the metal binding states were 
then generated. 
3. As before the H-bonds were assigned, the waters removed and the structure minimised. 
From these two prepared structures, docking grids were created. The docking grid was centred on the 
Zn. The size of the docking grid was adjusted to accommodate ligands of a maximum length of 12 Å, a 
length estimated to be the maximum theoretical length of a fragment. Lastly a docking constraint for 
a metal chelating interaction was set. 
2.3.2 Ligand Preparations 
The next step was to prepare ligands in the fragment database. The substructure filtered database 
was downloaded in the 2D sdf format. The Maestro LigPrep protocol (Schrödinger Suite 14.0) was run 
on this ligand set rendering the 3D structures for each ligand in the most likely ionisation and 
tautomerisation state under biological conditions. To achieve this, the pH was set at 7.0 ± 2.0 allowing 
for multiple tautomers. This step created a few duplicate entries but the acids were mostly 
deprotonated while the bases were mostly protonated.  
2.3.3 Validation and Execution of Docking Protocol 
Before docking the fragment set, the protocol was validated against a set of fragments derived from 
known ACEis to demonstrate a correlation between the known ligand-enzyme interactions and the 
docking score. After an examination of the set of ACEis, a few fragments were created through the 
deconstruction of the Enalaprilat (E1, E2 and E3) and RXP407 (R1) into fragments (Table 2.3). The 
dummy fragment (D1) was introduced to investigate the impact of the Zn binding disruption. These 
fragments were docked using the Glide (Schrödinger Suite 14.0) standard precision (SP) settings with 
default settings. After validation, the prepared set of compounds were docked against both targets 
with the settings unchanged. 
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The docking results were then analysed. Due to the fragment nature of these ligands, ligand efficiency 
(LE), the docking score of the ligand divided by its heavy atom count (HAC), was chosen as the metric 
for ranking docking poses. A LE cut-off where the poses were deemed nonsensical was chosen. All 
ligands with a LE above the cut-off were discarded. 
2.3.4 Visual Inspection  
During the visual inspection, the set of remaining ligands was overlaid with the space known to be 
occupied by cocrystalised inhibitors of ACE. All compounds displaying unlikely poses or occupying a 
space within the active site where ligands are not known to bind were eliminated.  
The second round of visual inspection entailed closer scrutiny of the space occupied by each fragment. 
All ligands found to occupy space outside the confines of the known binding site were eliminated. 
Special priority was given to ligands interacting favourably with Arg381 from the N-domain.  
The remaining compounds were investigated for commercial availability. Often compounds are listed 
in these databases without regularly updating its availability status. This achieved another reduction 
in the set of remaining compounds. In order to reduce cost and maximise the chemical space of the 
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remaining set, the remaining compounds were clustered using an extended connectivity fingerprint 
(ECFP4) algorithm.107 A chemically representative set of compounds spanning all the clusters was 
chosen and purchased for in vitro screening. 
2.3.5 Inhibition Assays 
The 60 compounds (Appendix 2.1) were tested in vitro in a fluorogenic competitive inhibition assay. 
For the C-domain the tACE Δ36NJ construct was used while the Ndom389 construct was used for the 
N-domain. The N- and C-domain samples were stored frozen in stock solutions of 14.0 µM and 7.3 µM 
respectively. The N- and C-domain stock solutions were diluted to 10 nM and 5 nM respectively, 
double the previously determined assay optimised enzyme concentrations. The 60 compounds were 
each dissolved in DMSO to make stock solutions of 50 mM. Aliquots of stock solutions were diluted to 
10 mM with deionised H2O followed by dilution into a phosphate buffer (100 mM KHPO4, pH 8.3, 300 
mM NaCl, 10 µM ZnSO4, 1mg/ml albumin). All inhibitor-buffer solutions were calculated to have a 
DMSO concentration of no more than 0.5% when incubated with the prepared enzyme-buffer 
solutions. 
To begin with, a broad inhibition screen at 500 µM for each of the compounds was performed. Each 
10 mM stock solution was diluted down to 1 mM in buffer. 40 µL of the diluted compound was mixed 
with 40 µL of the enzyme in buffer halving the concentration of both solutions. This mixture was 
incubated at room temperature for 30 minutes then triplicate 20 µL aliquots were added into 3 
individual wells of a 96 well plate. 30 µL of 1 mM Z-FHL substrate (Bachem Ltd., Bubenhof, Switzerland) 
was then added to each well. Each 96-well plate experiment contained a negative control with the 
inhibitor solution substituted for buffer only, a positive control with 10 µM of Lisinopril and a blank 
zero time (bzt) to measure the background using just buffer. The plate was then incubated at 40 ˚C for 
15 minutes in a shaker. The reactions were then stopped and the product was derivatised with the 
addition of 190 µL of a base and O-pthaldehyde solution (0.28 M NaOH and 7 mM O-pthaldehyde) to 
each well. The plate was then incubated on a shaker at room temperature for 10 minutes. The wells 
were quenched with 25 µL of 3 M HCl and the plate was read in the fluorimeter (Varian Inc., Mulgrave, 
Victoria, Australia) with an excitation wavelength at 360 nm and an emission wavelength at 485 nm. 
Change in fluorescence correlated to nmol HL using linear regression analysis and activity expressed 
as nmol/ml/min or nmol/mg/min. Compounds displaying more than 50% inhibition at 500 µM were 
selected for a second round of inhibition assays at lower concentrations to approximate their IC50 
values. 
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2.4 Results 
2.4.1 Fragment Substructure Search 
Substructure searches were run on each chelating fragment from the CFL against the Fragments Now 
subset of the ZINC database using the substructure tool on the ZINC website. Approximately 16 000 
unique fragments were returned from these cumulative searches. The Initial inspection of this set 
showed a wide chemical diversity and a fair representation across the entire range of chelating groups 
listed in the CFL. Since 16 000 compounds is a manageable size for docking, no additional steps were 
necessary to filter this set before any further docking. 
2.4.2 Fragment Docking Protocol Validation 
All four ligands assigned the correct ZBG to the Zn metal (Figure 2.3) when docked with just a metal 
binding constraint. Fragments E1 and E2 were placed in the respective S1’ and S2’ subsites in an almost 
identical position to the pose of their parent crystal structure. The phenyl ring of E3 was placed in the 
correct S1 pocket of the C-domain but was flipped around and placed in the S1’ pocket of the N-domain. 
Fragment R1 assigned the correct ZBG in both domains. The important salt bridge between its acid 
and Arg381 of the N-domain was also predicted. The fragment did, however, flip around in the C-
domain when it encountered the Glu403. The dummy compound D1, which is E3 with methyl ester 
caps on the two acids managed to reproduce the poses observed for E1 in both domains despite the 
disruption of the Zn binding.    
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Figure 2.3: Docked poses of the benchmark fragments. 3A and 3B show the respective crystal poses of RXP407 and Enalaprilat, the parent compounds from which the benchmark fragments were derived in the respective N- and C-domains. 3C shows the fragment E1 docked in the N-domain. Here this Enalaprilat Ala-Pro scaffold coordinates with the Zn using its C-terminal carboxylic acid to facilitate a salt bridge with Arg381. In 3D this fragment returns to the more familiar prime side of the active site occupying a similar position to its parent Enalaprilat molecule. 3E shows fragment E3 docked into the N-domain with its phenyl group occupying the incorrect S1’ subsite unlike the C-domain (3F) where the fragment has swung around into correct S1’ subsite. 3E shows R1 docked into the N- domain with its phenyl group binding to the correct S1’ subsite to allow for the formation of a salt bridge with Arg381. In the C-domain (3H), the entire molecule swings around to keep its acid away from Glu403. Fragment D1 docked in almost an identical conformation in both the N- and C-domain (I and J respectively) despite the capping of its two acid groups with a methyl ester. 
The LE of these benchmark fragments is shown in Table 2.4. Fragments E1 and E2 fit snugly within the 
2’ side subsite poses similar to Enalapril and most ACEis. These poses are coupled with excellent LEs 
(<-0.5), thus validating the docking protocol against these fragments, which would be expected to 
these binding sites with a strong inhibtion given their small sizes. In the case of E3, the phenyl group 
finds the incorrect S1’ subsite of the N-domain while binding to the correct S1 subsite of the C-domain. 
The failure of this fragment to find the correct binding pose in the absence of the Ala-Pro group 
emphasises its importance for ACE binding. The RXP407 fragment made an important salt bridge 
interaction with Arg381 in the N-domain while flipping around in the C-domain to avoid Glu403. This 
pose correlated with a superior LE towards the N-domain. The effect of interrupting the Zn binding 
through an esterification of the carboxylic acid group was quantified with fragment D1. This fragment 
returned the correct ACE binding pose with LEs above -0.3 for both domains suggesting -0.3 to be a 
reasonable LE cut-off for this system.  
  
I J 
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Table 2.4: LE of the benchmark ligands 
Ligand N-domain LE C-Domain LE 
E1 -0.570 - 0. 611 
E2 -0.504 -0.569 
E3 -0.560 -0.634 
R1 -0. 458 -0.350 
D1 -0.221 -0.275 
With all the predicted poses reproduced using these ACEi derived fragments, this fragment docking 
protocol was successfully validated. With the protocol validated and the domain selective fragment 
binding patterns illustrated, the entire fragment set was docked.   
2.4.3 Fragment Set Docking 
The metal binding moieties from the CFL were all represented in this set. These moieties were all easily 
recognised by Glide as a metal binding group. A set of 16 000 ligands can be docked using the Glide SP 
level of precision in a reasonable timeframe but a set this size is too large for Glide XP. Another point 
for consideration is that the improved accuracy of Glide XP on small ligands would be negligible.   
While inspecting the docking output, the LE cut-off of -0.30 was chosen as an arbitrary point where 
the observed ligand poses became implausible. It was around this LE cut-off that the fragment poses 
became implausible and unrealistic in a similar manner to the benchmark fragments. 3500 
Compounds remained after the cut-off was enforced, a set small enough to be manually inspected.  
2.4.4 Visual Inspection 
Two rounds of visual inspection were conducted. The first round of visual inspections focused on 
eliminating improbable poses and interactions. These poses predominantly contained improper metal 
binding and H-bonding interactions. Examples of these interactions include incorrect H-bond 
donor/acceptor pairings, polar groups in the hydrophobic regions and hydrophobic groups blocking 
protein donor/acceptor groups. As a bare minimum, each ligand needed to have a good metal 
chelating interaction and at least one H-bond with the target. This round of visual inspection reduced 
the set of remaining compounds down to 878 compounds. 
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The second round of visual inspection was more rigorous due to the smaller set while closely focusing 
on the space occupied by the cocrystallised ligands of ACE. All the ligands cocrystallised with ACE 
occupy a specific space or footprint. Priority was given to compounds with a favourable Arg381 
interaction. Ligands in this set, which fell outside this observed crystal footprint were discarded. Figure 
2.4 shows an example of both an accepted ligand and a rejected one. Figure 2.4A shows a ligand 
(yellow) where half the molecule fell outside the established ACE ligand footprint occupied by its 
native ligand, RXP407 (cyan). In contrast, SF37 (Figure 2.4B) passed this round of visual inspection due 
to its occupation of this footprint and its salt bridge with Arg381 of the N-domain.  
Following two rounds of visual inspection, 350 compounds remained. Of the remaining 350 
compounds, only 120 were available for purchase. 
2.4.5 Clustering 
To maximise the remaining 120 commercially available compounds, the ECPF4 clustering algorithm 
was applied. This sorted the 120 compounds into 24 clusters. A final set of 60 compounds (Appendix 
2.1) was selected with each cluster represented. Special consideration was then given to compounds 
with a potential to interact with the Arg381/Glu403 residues. 
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2.4.6 Fragment Screen Overview 
Figure 2.5 summarises the fragment screening protocol.  
2.4.7 Inhibition Assays 
Of the 60 compounds tested (Appendix 2.1), only two displayed more than 50% inhibition of the total 










    SF43     SF49 
Figure 2.6: Structure of Fragments SF43 and SF49 
Compounds SF43 and SF49 were then tested at lower concentrations (Figure 2.7). When both inhibitor 
concentrations were reduced to 100 µM, the enzyme returned to full activity. SF43 exhibits the typical 
dose response behaviour at these high concentrations with the almost full inhibition observed at 500 
µM with the enzyme returning to full activity at 100 µM concentrations. SF49 on the other hand 
displayed a slight inhibition of both domains at 500 µM with the enzyme returning to close to full 
activity at 100 µM. Both SF43 and SF49 contain carboxylic acid ZBGs and chemical groups novel to ACE 
inhibition while neither compound displayed any selectivity towards the N-domain. 
ZINC Database ~ 13 million 
Compounds 
Leads Now Subset ~ 1.2 million 
Compounds 
Metal chelator substructure 
filter ~ 16 000 compounds 
Constrained Glide docking LE 
Cut-off of -0.3 ~ 3500 
Visual Inspection round 1 ~ 878 
compounds 
Visual Inspection round 2, 
space occupation comparison 
~ 350 compounds 
Availability check ~ 120 
compounds 
ECPF4 clustering ~ 60 
compounds purchased 
Figure 2.5: Summary of the implemented docking procedure. 
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Figure 2.7: Inhibition of SF43 and SF49 against the N-and C-domains of ACE. These compounds were tested at concentrations of 500 µM, 250 µM and 100 µM. Both enzymes returned to full activity when inhibitor concentrations were dropped below 100 µM. 
2.5 Discussion 
2.5.1 Hit Molecules 
This fragment screen returned two hits out of 60 compounds screened. A hit rate of 3% for a fragment 
screen is about par for the course for this type of screen. It is also possible that screening at 1 mM 
may have brought more fragments to attention. However, with the existence of such potent ACEis, it 
would be misleading to classify such fragments as hits. Both the hit compounds share some chemical 
similarity with the current set of known ACEis such as a carboxylic acid ZBG and hydrophobic side-
chain mimicking groups such as a the pyridyl group in SF49  
While SF43 and SF49 may be potential leads for designing novel inhibitors from scratch, neither 
compound showed any domain selectivity with IC50s 4-5 orders of magnitude weaker than the current 
set of ACEis. Despite returning two potential hit compounds, this exercise has not furthered the cause 
of finding a potential lead within the context of domain selective ACE inhibition.  
The reason for the lack of domain selectivity among SF43 and SF49 is obvious when considering their 
docked poses (Figure 2.8). Neither compound is capable of forming a salt bridge with the Arg381 of 
the N-domain nor an unfavourable interaction with Glu403 of the C-domain. Adding a carboxylic acid 
to the biaryl system of SF43 might have helped. While both these compounds contain similar core 
elements required for a strong ACEi, such as a metal chelator and peptide-like branching, they both 
lack sufficient H-bond donors and acceptors to rival established ACEis. Fragments are deliberately 
small with fewer chemical groups and interact with a small portion of the enzyme active site.  
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Figure 2.8: The docked poses of SF43 (beige) and SF49 (lime) in both the ACE N- (cyan) and C- domain (green). A. SF43 docked in the ACE N-domain with its large heteroaromatic group occupying the S2 pocket close to the region of the Arg381. B. SF49 docked into the C-domain in an almost identical pose to the one seen in the N-domain. C. SF49 docked in the ACE N-domain with its THF and pyridine groups sitting comfortably in the S1’ and S2’ pockets respectively. D. SF49 docked into the ACE C-domain with the THF and pyridine groups occupying the S1 and S2’ pockets respectively. 
2.5.2 Shortcomings 
The failure of this approach to provide potential domain selective leads on domain selectivity 
highlights the difficulty in applying VS techniques to problems relating to target selectivity. VS relies 
on the brute force of numbers to help find a hit from a huge screening set. In the case of ACE, a 
potential domain selective lead hinges on one or two key interactions. VS by its very nature has a low 
hit rate. Typically, under 5% of compounds tested display activity against the target. Expecting one or 
two highly specific interactions from a hit was possibly too optimistic.  
As shown during the benchmark docking, looking for a salt bridge between the ligand and the Arg381 
in the N-domain is the only viable way to pick up on a possible N-domain selective compound using 
this model. Since the different domains represent distinct protein-binding systems, GlideScore and LE 
cannot be compared between the two domains for selectivity. Such an interaction requires a diacidic 
fragment with one acid binding to the Zn while the other remains free to interact with Arg381/Glu403. 
Diacids are rare in fragment screening databases as fragments usually focus on a few key functional 
groups while keeping the fragments within the bounds of strict physicochemical parameters. Too 
many charged groups on a fragment sized molecule would make it very polar resulting in poor cell 
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listed in a fragment screening database. Examining the final set of compounds screened, only two 
diacids were present (SF2 and SF37; Figure 2.9). Two acids on each molecule should have been a 
condition on all compounds purchased. 
  
Figure 2.9: Fragments SF2 and SF37 
2.5.3 Conclusion 
In retrospect, it appears that the conditions required for an N-domain selective inhibitor were 
improbable from the outset. This outcome changed the direction and focus of the project. The existing 
ACEis are much more potent than what could be expected from any fragment hit. At this point it 
became clear that a much more targeted approach than VS was required. A decision was made to 
pursue a de novo approach starting with existing ACEis rather than reinventing the wheel by searching 
for novel leads from a random set. 
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Chapter 3 – Enalaprilat Analogue de novo Design 
3.1 Introduction 
3.1.1 Background 
Following the failure to find a novel N-domain selective inhibitor with a fragment screen in Chapter 2, 
a different approach was required to achieve this objective. As explained, the structural requirements 
of an N-domain selective ACE inhibitor appeared to be too specific to find in a set of 16 000 metal-
chelating fragments. To improve upon the fragment screen, a new approach was required to find N-
domain selective ACEis. This new approach focussed on the existing set of diverse ACEis which were 
not utilised during the fragment screen. 
The SAR accumulated over four decades of ACEi development has fortuitously left behind a vast 
dataset of tens of thousands of compounds with varying degrees of ACE inhibition. The SAR 
accumulated over this period includes a large set of inhibitors displaying low to sub nanomolar 
inhibition. These inhibitors are several orders of magnitude stronger than can be expected from any 
fragment-based screening hit. 
The extensive structural and inhibition data of ACE is ideally suited for de novo drug design methods. 
In a drug discovery context de novo design refers to the practice of starting from drug fragments or 
scaffolds and exploring the SAR required to build them into full sized drug molecules108. While the 
shortcomings of a fragment-based approach focused on a highly specific interaction were discussed 
in Chapter 2, some of the methodology can still be adapted to feed into certain de novo drug design 
protocols. 
De novo drug design is a broad term encompassing a wide range of drug discovery techniques. These 
techniques are varied and have been developed to suit a variety of different systems. The most 
common de novo drug design techniques include methods based on (1) structural alignment, (2) 
molecular force-fields and docking, (3) fragment assembly, and (4) retrosynthesis and plausible 
reactions. As the names of these techniques suggest, optimising these fragments requires either 
knowledge of an inhibition pharmacophore or protein target as well as a basic understanding of the 
synthetic viability of the proposed structures. Like VS, de novo drug design is prone to the same 
problem of combinatorial explosion. It is therefore no surprise that many of tricks from VS are carried 
over into this discipline.  
3.1.2 De Novo Drug Design Approaches 
Alignment-based methods (Figure 3.1) require a large library of crystal structures of the target in 
complex with different ligands. Aligning the ligands within the same binding site can highlight the 
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space in the binding pocket not occupied by known inhibitors. It can also help link inhibitors to 
additional functional groups to expand its binding footprint within the binding site109. Alternatively, 
forcefield110 and docking-based methods rely on creating combinatorial libraries of designed 
compounds which are then ranked based on docking experiments and other force-field-based energy 
calculations. 
 
Figure 3.1: An illustration of alignment-based de novo drug design. Two different inhibitors (molecule A and B) from the same target are aligned and their spatial occupation is compared.The key features of the two drugs are then combined around the circled bond to create two alignment combintions which maximise the target binding space. 
Fragment assembly methods are statistically-based algorithms, which cycle through large databases 
of fragments and connectivity options to generate vast libraries of designed molecules within a set of 
pre-specified parameters111. Retrosynthetic chemistry and reaction-based approaches involve the 
deconstruction of inhibitors into core fragments via retrosynthesis and identifying biologically active 
core compounds, which can be developed into novel potent inhibitors112. Such protocols allow one to 
remain mindful of the synthetic viability of proposed compounds. 
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3.1.3 Synthetic Chemistry Considerations 
Theorising designed molecules is only helpful if one considers the synthetic viability of the suggested 
compounds. Examining the set of ACEis and their co-crystallised poses within the binding site of ACE, 
it can be deduced that Enalaprilat and Lisinopril (Figure 3.2) are the simplest ACEis that bind within 
the active site in reach of the P2 Arg381/Glu403.  
 
Figure 3.2: The structures of Enalaprilat and Lisinopril 
Enalaprilat and Lisinopril were first synthesised via the reductive amination of a C-terminal proline 
dipeptide and an α-keto acid using a cyanoborohydride reducing agent (Figure 3.3). This reaction 
creates a third chiral centre in the molecule but is not diastereoselective. The two diastereomers were 
then separated via column chromatography. Inspecting this reaction helps to deconstruct these ACEis 
into the core scaffolds for de novo drug design. As previously discussed, the core scaffold of an ACEi 
consists of a central ZBG, a P2’ terminal carboxylic acid and a pseudopeptidic structure in the P1’ and 
P2’ positions. The most common P1’-P2’ moieties are a pseudo Ala-Pro structure but other 
combinations were also investigated.  
 
Figure 3.3: The reaction used by Patchett et al113 in ACEi synthesis to attach P1 groups. 
Most of Patchett’s work investigated the SAR around the P1 substituent on the Ala-Pro scaffold where 
extensive testing was performed after introducing the chiral centre indicated in Table 3.1.113 When 
comparing the merits of using Lisinopril and Enalaprilat as core scaffolds, the lysine moiety of Lisinopril 
greatly increases the MW of the compound while adding an amine which would need to be protected 
in many potential synthetic manipulations. The Ala-Pro backbone of Enalaprilat has a lower MW and 
the P1’ methyl group does not need any protection. This makes Enalaprilat a better candidate for 
synthetically exploring the SAR around the P2 substituent 
Chapter 3   – Enalaprilat Analogue de novo Design 
61  Stephen Fienberg – PhD Thesis 
 
Table 3.1: The SAR data of selected compounds tested by Patchett et al113 examining the effect on inhibition caused by the introduction of a third chiral centre (*) and a P1 phenyl group to the Ala-Pro backbone. 














3.1.4 Combinatorial Library Screening 
Combinatorial library screening follows a similar methodology to VS. The major difference being that 
the library screened is of hypothetical molecules generated to deliberately probe specific SAR. Many 
docking programmes have a feature enabling the user to generate combinatorial libraries to feed into 
their docking protocol. In the case of Glide, there is an extension called CombiGlide that can be used 
to generate combinatorial libraries and feed them into Glide docking. It only requires input fragments 
and an input core structure. The points of attachment on both the core structure and additional 
fragment can then be specified with optional alkyl linkers of variable lengths. CombiGlide then 
generates all the possible permutations for the specified points of attachment and the alkyl linker 
length between the scaffold and the attached group. Once the library is generated, it is docked just 
like any database of real drug-like compounds.  
Combinatorial library screening methodologies differ from traditional VS methodologies in the ranking 
step. Docking scores are designed to rank the viability of a pose above a certain cut-off. In this manner 
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they serve as an aid to help identify hit molecules from a diverse screening set. When investigating 
the virtual SAR (VSAR) in a particular region, one looks for subtle changes in binding energy. These 
subtle changes add a new quantitative aspect to docking protocols not seen in VS. To help quantify 
these subtle changes in binding energy, binding energy calculations have been developed.  
3.1.5 Rescoring and Energy of Binding Calculations 
Docking scores are used as a tool to qualitatively evaluate a predicted binding pose but they correlate 
poorly with experimentally determined ligand binding energies. For the purpose of predicting ligand 
binding energies with an improved experimental correlation, the more computationally demanding 
molecular mechanics Poisson-Boltzmann Surface Area114 (MM-PBSA) and molecular mechanics 
Generalised Born Surface Area115 (MM-GBSA) calculation algorithms were developed. Both these 
approximations begin with the same approach. The binding energy (ΔGbind) can be approximated with 
equation 3.1. Here the enthalpy term is equated to the sum of molecular mechanical energy within 
the system (ΔEMM) and a new term ΔGsolv represents the energy change created by adding solvent to 
the gas phase system under which the calculations are performed.  ΔEMM is the sum of the molecular 
mechanical changes to the system in gas phase. It is described using equation 3.2.  
 ∆G =  ∆H − T∆S ≈  ∆E +  ∆G − T∆S (3.1) 
 ∆E =  ∆E + ∆E + ∆E  (3.2) 
The change in energy brought about by solvating a gas phase system, ΔGsolv needs to be calculated by 
computing the difference in solvation energy between the free ligand and the protein target as 
described in equation 3.3. Each ΔGsolv term is then approximated with the PBSA or GBSA method 
(equation 3.4). This equation has two terms, one for the energy change originating from a change in 
polarisation energy (ΔGPB/GB) and the other term covering the non-polar contribution to the change in 
energy (ΔGSA). These two methods use the same non-polar term but different polarisation terms. 
 ∆G =  ∆G − (∆G + ∆G ) (3.3) 
 ∆G / =  ∆G / + ∆G  (3.4) 
Benchmarking comparisons between the two algorithms have shown that while the PBSA method is 
more computationally demanding than GBSA, it is also more accurate116. Despite this, GBSA energy 
calculations are still useful for comparing a homologous set of ligands. GBSA however, does not cope 
as well with highly charged or polar species. Both these methods have only been recently adopted in 
the field of CADD but their use is now widespread. 
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MM-GBSA energy predictions are included in Schrödinger’s PRIME software suite. PRIME was 
originally developed for homology modelling, structure prediction and minimisation. A MM-GBSA 
algorithm was then added as an addition to its minimisation protocol. PRIME-MM-GBSA rescoring of 
GLIDE predictions are commonly used today in de novo studies as they are less concerned with 
whether the compound will bind and more interested in the effect that proposed VSAR modifications 
will have on ligand binding. Coupling an MM-GBSA prediction algorithm to the PRIME minimisation 
protocol (as provided with the Schrodinger software suite) generally produces a more accurate 
reflection of the ligand pose in the protein as small side-chain movements within the protein are 
permitted. This gives the MM-GBSA algorithm a more realistic structure to evaluate. Since 
minimisation protocols are easily caught in local minima, the minimisation and rescoring works on the 
assumption that the starting geometry predicted in the docking procedure is accurate and close to the 
minimised structure. 
3.2 Aims and Objectives  
3.2.1 Aim 
The Aim of this chapter was to design a novel N-domain selective ACEis via a de novo approach. 
3.2.2 Objectives 
 Generate a combinatorial library via the modification of Enalaprilat exploring the P2 SAR with 
the intention of forcing an Arg381/Glu403 interaction. 
 Dock the combinatorial library into the two catalytic domains of ACE. 
 Rescore the docked library poses using the MM-GBSA algorithm. 
 Formulate a set of compounds for synthesis 
3. 3 Methods 
3.3.1 Constrained Docking Grid Generation 
The first step in establishing a docking protocol for the N- and C-domain systems was to generate 
constrained docking grids. As in Chapter 2, the pdb structures 3NXQ and 1O86 were used to prepare 
docking grids for the respective N-and C-domains (Figure 3.4). The Grids for each domain were 
generated using the same settings as in Chapter 2 with the exception of grid length, which was set to 
the default 14 Å.  
A new docking grid was created with the same metal binding constraint from Chapter 2 and two new 
H-bonding constraints both Lys511/489 and Gln281/Gln259. The grid centre was set to default centred 
on the native ligand. Figure 3.4 shows a representation of the native co-crystal ligands of RXP407 and 
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Lisinopril from the PDB structures of 3NXQ and 1O86 respectively placed at the centre of the docking 
grid box. The space in which the metal chelator must be found is indicated with a red-sphere in each. 
 
Figure 3.4: An illustration of the docking constraints implemented on the two domains of ACE. The N- (left) and C-domains (right) with their native ligands of Lisinopril and RXP407 respectively. The Metal chelation constraint is illustrated with a red sphere, indicating the space in which a metal chelator must be found. The second constraint of a H-bond between either Lys511/489 or Gln281/259 
3.3.2 Docking Protocol 
All docking performed in this chapter was done using the following settings: 
 In the settings tab of Schrödinger GLIDE, the docking precision was set to extra precision (XP), 
while the remaining settings on this tab were left at default.  
 In the ligands tab the ligand file was selected and the remaining settings remained at default.  
 No core structure constraint was used as the constraints were deemed sufficient to fix the 
position of the core scaffold. 
 In the constraints tab, all three constraints created for these grids were selected. A minimum 
of two of the three constraints was set. 
 The remaining settings were all left as default. 
3.3.3 System Validation 
The docking systems of the N- and C-domain underwent a two-stage validation. Firstly, the set of 19 
ACEis (Table 1.2) were docked into both prepared grids. A binding footprint for this set was established 
in both domains. The Enalaprilat ligands docked into the N and C-domain systems were then aligned 
with each other. The predicted poses of Enalaprilat were then overlaid with the C-domain crystal 
structure of the ligand of the PDB structure 1UZE.   
The second stage of the validation was performed by aligning the Lisinopril ligand from the N-domain 
structure 2C6N with RXP407 from the N-domain structure 3NXQ. Two hybrid ligands were created 
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were then docked into the prepared docking systems for both domains while the predicted poses 
were inspected. 
3.3.4 Combinatorial Library Generation 
After validating the protocol for these two systems, Enalaprilat was deconstructed into a core scaffold 
and then grown into the S2 subsite of ACE by adding various negatively charged species. The core 
scaffold with the variable R group is depicted in Figure 3.5. A combinatorial library (Appendix 3.1) was 
then constructed using an assortment of carboxylic acids and acid bioisosteres reported by Ballatore 
et al.117 Various alkyl chain lengths were tested as well as hydrophobic P1 groups. A few non-acidic 
counter examples were included for benchmarking. This combinatorial library was created using 
CombiGlide’s automated protocol. All the Fragments are listed in Appendix 3.1. A naming template 
for each ligand was established using the format FxLy with Fx indicating the fragment x attached to 
the core scaffold and Ly indicating an alkyl linker of y carbons inserted between fragment Fx and the 
core scaffold. The combinatorial library was then docked into both the N- and C-domains using the 
validated protocol 
 
Figure 3.5: R-group substitutions made to the Enalaprilat Scaffold. These substitutions probe the SAR in the S1’ and S2’ subsites of ACE. 
3.3.5 MM-GBSA Free Energy of Binding calculations and Rescoring 
Prime MM-GBSA simulations were run on the docking outputs using the VSGB118 solvent model. For 
the minimisation step, flexibility was tolerated for all protein atoms within a 15 Å radius of the ligand. 
The set was then reranked according to their ΔGGBSA and a special note was made of the compounds 
with the most promising Arg381 interactions and the largest discrepancy between the N- and C-
domain scores. 
3.4 Results 
3.4.1 ACEi Docking 
To identify the space already occupied by the set of 19 clinically approved ACEis, the set was docked 
in the active sites of the N- and C-domains of ACE. When docked, the ACEis could all be easily overlaid 
in their analogous and neatly conserved poses within the S1, S1’ and S2’ subsites. More importantly 
Enalaprilat was among this set. Docking this entire set showed that in addition to being the most 
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chemically suitable ACEi for combinatorial library design, its poses are no closer to the Arg381/Glu403 
residues than the rest of the set. 
The entire set followed the outline of an ACEi with a ZBG chelating the Zn atom and a P2’ carboxylic 
acid falling into the electropositive hole of the S2’ subsite. The majority of these ACEis have both a P1 
phenyl group and the P1’ methyl group. By and large, the docked poses of these ACEis show the ZBG, 
P1’ and P2’ in the same positions within the active sites. There is some movement seen in the resting 
poses of the P1 phenyl group in the S1 subsite, which is known to be large and cavernous affording the 
ligand a fair degree of flexibility in this region.   
Figure 3.6 shows an alignment of the docked ACEi poses within each domain. Some ligands place their 
phenyl group within one or two carbon bonds of Arg381 suggesting an interaction with this residue is 
not present yet is attainable through synthetic additions to this ring.  
 
 















Chapter 3   – Enalaprilat Analogue de novo Design 
67  Stephen Fienberg – PhD Thesis 
3.4.2 Enalapril Docking Validation 
Docking the ACEi set successfully validated the docking protocol for Enalaprilat, the parent compound 
of the combinatorial library dock. The docked poses were compared with the crystal pose of 
Enalaprilat from the PDB structure 1UZE. At first inspection, the crucial Zn chelation and H-bonds 
between the P2’ carboxylic acid and the respective Gln and Lys residues in each domain were 
reproduced. When aligned with the crystal pose of Enalaprilat from 1UZE, the only variation observed 
in this region was the conformation of the Phenyl group (Figure 3.7). An RMSD of 4.7 Å was observed 
between the crystallised Enalaprilat and the structure docked into this C-domain. 4.7 Å is high for two 
poses of a small molecule like Enalaprilat but all the variation appears to originate from the phenyl 
group forming a different rotamer to the crystal structure. The S1 subsite is known to be a large and 
cavernous hydrophobic pocket. It is plausible that the phenyl group oscillates between these two 
poses under dynamic biological conditions. If the phenyl group is ignored, the RMSD is reduced to 0.38 
Å providing a respectable validation of the docking algorithm using this system. 
 
Figure 3.7: Overlays of the docking validation exercise. Enalaprilat is docked into the N-domain (green) the C-domain (orange) while being compared against the crystal structure of 1UZE (turquoise) with Enalaprilat co-crystalised with the C-domain. The docked structures of Enalaprilat superimpose exactly into each other. They also align closely in the P2’, and P1’positions against the crystal pose. There is a big deviation in the P1 position in the S1 subsite indicating the presence of two competing local minima of torsional movement around the bond adjacent to the chelating acid. 
Glide generated a docking score for Enalaprilat of -12.78 and -11.13 for the C- and N-domains 
respectively. While nominal comparisons between Glide scores are meaningless, the score may give 
an indication as to whether strong binding between the protein and ligand exists. Glide scores below 
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3.4.3 Alignment and Recombination of RXP407 and Lisinopril 
Lisinopril/Enalaprilat and RXP407 are important ACE ligands as the former represents the chemical 
space of the ACEi set while RXP407 represents the chemical space of the most N-domain selective 
ACEi. Although RXP407 is a large peptide and an unsuitable drug molecule, its Arg381 binding motif 
can be adopted by more drug-like compounds. Aligning Lisinopril/Enalaprilat with RXP407 is therefore 
useful for suggesting where to add a new acidic Arg binding functionality. 
Aligning the N-domain crystal structures 3NXQ and 2C6N with their respective RXP407 and Lisinopril 
ligands clearly illustrates the effect that a P2 carboxylic acid has on the orientation of Arg381. RXP407 
extends into the S2 subsite forcing Arg381 to swing in towards the binding site and form a salt bridge 
with the acid (Figure 3.8). The close alignment of these two ligands suggested two points of 
attachment where an acidic moiety may be attached to Enalaprilat. These points of attachment are a 
meta phenyl ring substitution and an alkyl carbon β to the phenyl group. 
 
Figure 3.8: The alignment of the crystal structures of RXP407 (cyan) and Lisinopril (green) in the respective 3NXQ (cyan) and 2C6N (green) PDB structures. A small extension from the P1 group of Lisinopril with a carboxylic acid causes Arg381 to swing in to face the ligand forming a salt bridge interaction with the carboxylic acid of RXP407. 
Since Enalaprilat has been observed to bind in a structurally identical pose to Lisonopril, it is an ideal 
scaffold for the design of N-domain selective inhibitors via the use of a combinatorial library. The 
observed crystal pose of Enalaprilat within the active site of both domains suggests only minor 
synthetic additions will be sufficient to create an interaction with Arg381 and Glu403 in the S2 subsite 
of the respective N- and C-domains. 
The alignment and recombination of RXP407 and Lisinopril led to the design of two theoretical 
molecules (Figure 3.9). Docking these two molecules (Figure 3.10) returned the predicted interactions 
of a salt bridge with Arg381 in the N-domain and an unfavourable interaction with Glu403 of the C-
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Figure 3.9: Two theoretical molecules created by aligning the crystal poses of Lisinopril and RXP407 
  
 
Figure 3.10: Docked poses of the two theoretically combined molecules in the N-domain (left) and the C-domain (right). Both these molecules form a salt bridge interaction with Arg381 (left) and an unfavourable interaction with Glu403 (right). 
3.4.4 Combinatorial Library Preparation 
The combinatorial library was generated using the 197 introduced fragments and attaching them with 
a linker of 0-4 alkyl carbons in length. Generating the library using these conditions created 985 
compounds. The fragments which were too long to fit in the binding site were eliminated, reducing 
the set to 415 compounds (Appendix 3.1). 
3.4.5 Docking and Visual Inspection of Binding Poses 
After validation, the revised library of 415 compounds was docked into both domains. A thorough 
visual inspection of each compound in both domains found the core scaffold pose to be retained in 
each instance thus achieving the key objective of designing a system where flexibility was only allowed 
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the P2 acidic moiety. Conversely, when placed within close proximity of Glu403, negatively charged 
moieties were strongly repelled and thus assumed highly strained conformations. Such strained 
conformations were not as prominent with positively charged moieties in the N-domain. This is likely 






Figure 3.11: A comparison of poses of two potential N-domain selective ligands F3_L1 (A) and F7_L1. The green ligand is the structure docked into the N-domain and the orange ligand is the structure docked into the C-domain. C-domain residues are coloured turquoise and N-domain ones are coloured yellow. These two ligands form comfortable salt bridges with Arg381 and are strongly repelled by Glu403.  
3.4.6 MM-GBSA Rescoring 
The Prime MM-GBSA free energy of binding calculations rescored and re-ranked the compounds from 
the Glide-score metrics (Appendix 3.2). Comparing the calculated energy of binding (ΔGGBSA), there 
was no discernible correlation between GlideScore and ΔGGBSA (Figure 3.12). The plots of Glide Score 
vs ΔGGBSA are extremely scattered showing R2 values below 0.1 in each case. Figure 3.12 therefore 
reinforces the fact that docking scores cannot be used to quantitatively predict the strength with 
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Figure 3.12: Scatter Plots of the Predicted ΔGGBSA and Glide Score for each compound in the N-(Top) and C-domain (bottom).  
3.4.7 Data Summary and Analysis 
The docking scores and ΔGGBSA for each compound in the individual domains were compared. Since 
the docking scores and calculated binding energies between different systems cannot be compared, 
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that the inhibition of the N- and C-domain by Enalaprilat are equivalent. The Ki  of Enalaprilat has been 
measured at 2.60 and 0.63 nM for the N- and C-domains respectively3b. A four-fold difference in Ki 
exceeds the precision of the MM-GBSA method, hence this assumption is fair. Given the similar Ki 
values for Enalaprilat binding to the two domains they were approximated to be equivalent for the 
sake of the predictions. The ΔGGBSAs were then normalised to 1.00 against the calculated ΔGGBSA of 
Enalaprilat in that specific system by dividing each ΔGGBSA by the ΔGGBSA of Enalaprilat. Selectivity 
factors were then calculated by dividing the normalised N-domain binding energy by the normalised 
C-domain binding energy. 
Table 3.2 shows a representative selection of the docking and MM-GBSA results for a selection of 
compounds from the combinatorial library (see Appendix 3.2 for the full results). With the library 
sorted by the selectivity factor, a few examples from the top, the middle and bottom sections are 
displayed. Acidic compounds were found throughout the range and the highest selectivity factors 
were assigned to the compounds where the acidic groups were able to make the desired Arg381 salt 
bridge interaction.  
Compounds containing proximal acidic groups showed less discrimination in terms of the selectivity 
factor were often constrained by their geometry. It is also worth noting that the discrimination in 
favour of N-domain selectivity is significantly greater as the highest selectivity factor was 2.6 while the 
lowest was 0.6. None of the compounds can therefore be considered C-domain selective while there 
is strong evidence to suggest N-domain selectivity. 
According to this selectivity factor, the most N-domain selective compound was F146-L0 with a 
selectivity factor of 2.6. It then follows that the most C-domain selective compound was F63-L2 with 
a selectivity factor of 0.60. This is encouraging as out of the 415 compounds predicted, 235 proved to 
be N-domain selective with selectivity factors over 1.00 while another 100 were in the marginal range 
with factors of 0.9 – 1.0. On the top end of the scale, factors of over 2.0 were observed while nothing 
below 0.5 on the bottom end was observed. These results are consistent with the hypothesis that the 
S2 subsite can only induce N-domain selectivity.  
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Table 3.2: A summary of the docking data of the combinatorial library against the two domains of ACE. The docking score, ΔGGBSA and the normalised (norm) are given for each ligand. The selectivity factor is calculated as N ΔGGBSA Norm/ C ΔGGBSA Norm. Selectivity factors over 1.0 indicate N-domain selectivity and factors below 1.0 indicate C-domain selectivity.  
 
 C-Domain N-Domain Selectivity 
Top 5 
Rank R-Group Glide Score ΔGGBSA ΔGGBSA Norm Glide Score ΔGGBSA ΔGGBSA Norm Nnorm/Cnorm 
1 
 F46_L0 
-11.283 -41.465 0.622 -10.791 -75.425 1.628 2.614 
2  F187_L1 
-10.989 -26.263 0.394 -10.051 -39.480 0.852 2.160 
3  F12_L1 
-11.640 -27.544 0.413 -10.400 -38.464 0.830 2.007 
4  F36_L2 
-12.347 -50.858 0.763 -11.534 -69.203 1.493 1.956 
5 
 F61-1_L1 




-12.241 -59.384 1.201 -11.460 -41.343 0.928 0.772 
233 
 
-12.538 -77.816 1.168 -11.512 -54.148 1.168 1.000 
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3.5 Discussion 
3.5.1 System Validation 
The validation of the molecular docking protocol in this chapter was multi-faceted as many aspects of 
this approach needed to be tested. The first aspect of the validation was to show that S2 interactions 
F95_L1 
234  F43_L2 (Enalaprilat) 
-12.777 -66.596 1 -11.131 -46.326 1 1 
235 
F165_L0 
-11.972 -81.025 1.216 -10.868 -56.288 1.215 0.998 
236  F59_L0 




-11.890 -70.177 1.420 -11.145 -32.641 0.732 0.516 
412 
F11_L1 
-11.941 -65.623 1.328 -10.331 -30.483 0.684 0.515 
413 
F87_L1 
-11.789 -64.765 1.310 -10.827 -29.586 0.664 0.506 
414  F7_L0 
-11.479 -65.231 0.979 -10.344 -27.838 0.600 0.6135 
415  F63_L2 
-11.595 -74.851 1.123 -10.275 -31.616 0.682 0.607 
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do not occur in the clinically available ACEis and that these interactions lie outside the S1, ZBG, S1’ and 
S2’ footprint in which these ACEis have been observed to operate. The ACEis in question (table 1.2) 
are structurally homologous to the compounds that have been crystallised while most of the variation 
was introduced in the P1’ group. It is therefore a fair assumption that the ACEis all follow the binding 
pattern observed with the cocrystallised Enalaprilat, Lisinopril and Captopril ligands. The purpose of 
docking the set of ACEis was to test the docking protocol against the cocrystalised ligands in these two 
distinct catalytic domains of ACE. The close reproduction of the crystal poses of Captopril, Lisinopril 
and Enalaprilat demonstrated that the protocol with its implemented constraints was adequate to 
accurately predict binding poses in this system. The further docking of the uncrystallised ACEis 
confirmed these homologous drugs bind within the known footprint further justifying the VSAR 
exploration of S2 interactions. 
The alignment and recombination suggest that small synthetic additions to the established ACEi drug 
scaffold can create an interaction with the Arg381/Glu403 residues. Native peptides have a branched 
structure while a new chiral centre is introduced with each residue. Molecules with more than three 
chiral centres can be potentially challenging to synthesise while excessive branching can raise the MW 
unnecessarily high. Aligning the cocrystal RXP407 and Lisinopril structures in the N-domain of ACE 
suggested two points of attachment for adding the P2 groups of RXP407 to a Lisinopril-like ACEi. The 
first position was the alkyl carbon α to the ZBG carboxylic acid and the second was a meta substitution 
on the phenyl ring (Figure 3.8).  
Before devoting considerable resources to docking an entire combinatorial library, it was necessary to 
verify whether ACEi attachments proposed by the alignment had a realistic chance of producing the 
desired Arg381/Glu403 interactions. Since the docking protocol had been verified against known 
crystal ligands, docking the compounds created in Figure 3.8 would predict an accurate pose in both 
domains. Fortunately docking these two compounds produced the desired Arg381 salt bridge and 
Glu403 repulsion (Figure 3.9). 
These two theoretical molecules introduce an additional H-bond donor, acceptor and chiral centre to 
an already polar molecule with three chiral centres. More polar groups would have a detrimental 
effect on the already poor permeability of ACEis while an additional chiral centre can make the 
synthesis prohibitively challenging. The purpose of the combinatorial library is to mimic some of these 
introduced features while keeping the ACEi within acceptable physicochemical parameters and the 
realm of synthetic viability. 
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3.5.2 Library Generation 
Combi-Glide simplified the task of generating a combinatorial library from the input set of chemical 
groups. More than half of the ligands did not properly fit in the binding site due to the large variation 
in size of the attached groups. Most of the entries with large introduced groups and a long alkyl chain 
linker needed to be manually eliminated as they became too large to fit into the binding pocket. A 
molecular length constraint filter would have prevented these oversized ligands from being 
generated.  
Many of the groups introduced a third additional chiral centre. Seeing as ACE is a protease, each 
subsite binds selectively to a side-chain of the native peptide while each additional residue adds 
another chiral centre. The absolute stereochemistry at a given stereogenic centre of each compound 
is therefore extremely important for this class of inhibitor. With the introduction of each stereocenter, 
many diastereomers needed to be generated. This created a fair amount of redundancy but all 
diastereomers needed to be considered when docking against proteases. 
The primary focus of the combinatorial library was to attach a negatively charged group, which could 
interact with Arg381/Glu403. While this was the primary objective, the lipophilic nature of the S1 
subsite could not be ignored. A wide array of both aromatic and non-aromatic lipophilic groups were 
therefore inserted between the carboxylic acids and the scaffold in order to maintain strong S1 
binding. The library also contained a few basic negatively charged, pure lipophilic and non-ionisable 
polar groups. These are virtual negative controls to reinforce the hypothesis that no domain selectivity 
would be observed in the absence of a strong electrostatic repulsive interactions with Glu403. 
3.5.3 Enalaprilat Benchmarking 
In order to develop a scoring system capable of discriminating between C- and N-domain selective 
compounds, it was important to Benchmark the docking protocol against Enalaprilat, the library’s 
parent ligand. The first objective of successfully finding the correct backbone orientation was 
achieved. The top five poses for each domain all placed the correct acid in the position chelating the 
Zn and the C-terminal acid was in the electropositive pocket of the S2’ subsite. The only variation 
brought about by these constraints was amongst the phenyl group. This variation is acceptable as the 
S1 subsite is large and cavernous and can therefore accommodate the movement. The docking 
algorithm seems to have found another local minima and it is conceivable that in a dynamic system 
the phenyl group regularly switches between the two positions. 
The two docked poses returned excellent docking scores both below -10.0. While it is impossible to 
compare docking scores between two different systems, these scores indicate highly probable ligand 
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binding poses. These poses are shared by Enalaprilat in the PDB structure 1UZE. This excellent 
correlation between the docked and the observed crystal pose of Enalaprilat successfully validated 
the docking protocol. 
3.5.4 Library docking 
A final library of 415 compounds was easily docked at the GLIDE XP level of precision. When inspected, 
each compound conformed to the expected pose for the Enalaprilat scaffold. The only variation in 
ligand pose was in the P2 position where the ligand was free to move by design. The majority of the 
ligands had acidic or negatively charged P2 groups while most of the variation was introduced with 
different linkers. Not every introduced acidic group was capable of forming the desired interaction 
with Arg381/Glu403 given the spatial constraints in place. Every example inspected showed that the 
desired Arg381 salt bridge also displayed an unfavourable repulsion with Glu403.  
Despite this interaction being the assumed cause of N-domain selectivity, the docking score did not 
suffer much of a penalty as a result of this perceived unfavourable interaction. A good example of this 
is compound F7_L1 (Figure 3.11B). While the desired C-domain repulsion is visible, the docking scores 
for the C- and N-domains were -11.418 and -11.254 respectively. These similar docking scores gave no 
indication of the selective binding alluded to by the docked pose. This is a possible consequence of 
Glide not assigning a low penalty to the Glu403 electrostatic repulsion.  
These poses seem to suggest that N-domain selectivity hinges on a poor Glu403 interaction more than 
any other N-domain interaction. Glide has been shown to be a powerful tool for predicting the correct 
geometry of a ligand within a binding site. Conversely Glide docking scores are useful tools for 
discriminating against ligands, which do or do not bind to a given target yet they provide a poor 
comparison of relative binding strengths.89 In theory, rescoring using MM-GBSA predictions is better 
suited for the task of predicting relative binding energies.  
3.5.5 MM-GBSA Rescoring 
Rescoring is an essential exercise for the target binding of a chemically similar set of molecules such 
as this combinatorial library. Running the MM-GBSA prediction on this set appeared to provide 
reasonable values for the binding of these ligands (Table 3.2). For both domains there appears to be 
no correlation between the ΔGGBSA and the docking scores assigned to these ligands by Glide. Most 
importantly, the poor interaction between a negatively charged group and Glu403 appears to have 
incurred a binding penalty.  
While the binding penalty reflected in ΔGGBSA suggests this method is capable of accurately predicting 
binding energies relative to other ligands in the same protein system, a problem still exists when 
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comparing the ΔGGBSA between two different protein systems such as the N- and C-domains of ACE. 
To devise a metric, which can be compared across the two systems, the ΔGGBSAs for each ligand needed 
to be normalised against a common ligand. The only ligand in the set with known biological activity is 
Enalaprilat.3b Theoretical binding energy, the quantity calculated by the MM-GBSA protocol is 
proportional to the log of Ki (ΔGBind = -RTlnKi).  This works out to a binding energy of -50 and -54 kJ/mol 
for the N- and C-domains respectively at a biological temperature of 310 K.  
When visually inspecting docking results, the non-polar and basic side-chains were mainly 
concentrated in the middle of the table with selectivity factors close to 1. The flexibility of Arg381 
during the minimisation step seems to make the N-domain completely tolerant of positively charged 
groups in the S2 subsite with no discernible penalty attached to the placement of such groups in this 
position.  
3.5.6 Strengths and Shortcomings  
There are two major shortcomings to this approach. Quantitative binding energy predictions for a set 
of molecules this size usually form part of a quantitative SAR (QSAR) study. While there is a vast wealth 
of binding data for sACE on many open access databases, the drug inhibition data for the individual 
domains of ACE is almost entirely restricted to a single study conducted by Wei et al over 20 years 
ago, a few phosphinic peptide studies56,58 as well as the work performed on keto-ACE analogues60, 66. 
In total, there are less than 20 molecules with which to build a QSAR training set. These molecules 
vary from phosphinic peptides to drugs with a carboxylic acid or thiol ZBG. An effective QSAR training 
set would need to be more homologous than this set. In the absence of an adequate training set, an 
effective QSAR model is not possible.  
The other shortcoming of this approach is that the constraints in place forced many of the ligands into 
an unnatural position within the C-domain binding site. This implies that many of the C-domain poses 
are inaccurate making MM-GBSA calculations for these poses meaningless. The selectivity factor 
therefore needs to be considered with a fair degree of scepticism as it is unlikely that much correlation 
would be observed between the C-domain ΔGGBSA and experimental Kis. These results therefore need 
a more qualitative interpretation as scoring penalties do not accurately reflect the impact these 
interactions have on binding.  
Identifying ligands with strong Arg381 interactions and pronounced Glu403 repulsions via a visual 
inspection is therefore the best use of this method. The selectivity factor may help emphasise some 
promising compounds but it is unlikely to show a strong experimental correlation with any measured 
binding.  
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Another point of contention is the synthetic viability of some of these compounds, especially ligands 
that introduced multiple chiral centres. While it is true that many of these compounds are unlikely to 
be synthetically viable, they can become synthetically viable with some simple modifications. It is easy 
to rerun these predictions on slightly modified ligands from this set if necessary. Even if these 
compounds are not synthetically viable, they can still elucidate new chemical space which can be 
explored via more synthetically viable analogues. 
3.5.7 Concluding Remarks 
Combinatorial library docking coupled with MM-GBSA rescoring is an attractive method for designing 
new ligands and exploring targeted VSAR around a particular ligand. Large libraries can be generated 
and docked at a relatively low computational cost. Challenges, however, arise when comparing two 
similar homologous targets. In the absence of extensive enzyme binding data for the individual 
domains, it is impossible to create a training set to test this prediction model. This prediction model 
therefore has provided some ideas for synthesis when considered on a purely qualitative level. On the 
other hand, these predicted binding energies and the selectivity factors need to be treated with a 
touch of scepticism before it has been correlated with any in vitro data. 
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Chapter 4 – Enalaprilat Analogue Synthesis 
4.1 Introduction 
4.1.1 Enalaprilat Scaffold 
In Chapter 3 the VSAR of the ACE S2 subsite was undertaken to explore the possibility of adding an 
acidic P2 group to an Enalaprilat scaffold. In order to test the hypothetical molecules conceived via 
VSAR studies, a viable synthetic pathway allowing for small changes at the P1 position needed to be 
established. The scheme in which Patchett et al113 synthesised Enalaprilat was centred around the 
reductive amination of an α-keto acid and Ala-Pro using sodium cyanoborohydride (Figure 4.1)  
 
Figure 4.1:Patchett's synthesis of Enalaprilat113 
While this scheme produced both Lisinopril and Enalaprilat, it has one major drawback. The reductive 
amination step is non-diastereoselective resulting in an equimolar ratio of both the SSS and RSS 
diastereomers. As a protease, ACE is a highly stereospecific target showing a strong preference 
towards the SSS diastereomer of Enalaprilat (SSS IC50 1.2 nM vs RSS IC50 820 nM)113. Patchett et al 
synthesised many P1 analogues of Enalaprilat while performing inhibition assays on diastereomeric 
mixtures, only separating the diastereomers once strong hits had been identified.  
Since the synthesis of this pioneering series, a handful of diastereoselective synthetic routes have 
been published.119 These routes centre around nucleophilic substitution of a secondary bromo group. 
The nucleophilic substitution of secondary halogens progresses either via SN1 or SN2 mechanisms 
depending on the stability of the dehalogenated carbocation intermediate. An SN2 substitution entails 
a stereocentre inversion and is therefore diastereoselective while an SN1 mechanism proceeds via a 
carbocation intermediate producing both diastereomers with the degree of selectivity depending on 










Figure 4.2: A generalised nucleophillic substitution reaction to synthesise P2 analogues of Enalaprilat. 
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In the context of Enalaprilat P1 analogues (Figure 4.2), a nucleophilic substitution would entail the 
substitution of a secondary Br group from a 2-bromopropanoic acid proline. Since the Br in 2-
bromopropanoic acid is on the chiral carbon adjacent to an electron withdrawing carbonyl group, the 
expected stabilisation of a carbocation intermediate may not be feasible. Thus, a diastereoselective 
SN2 mechanism would be expected as the favoured mechanism. If stabilisation of the carbocation 
intermediate were to occur, it would likely constitute the minor pathway producing a small proportion 
of the other diastereomer via a hybrid SN1/SN2 mechanism. The net result would be a partially 
diastereoselective substitution. 
4.1.2 Accessing the P2 VSAR series 
The VSAR study undertaken in Chapter 3 delivered a large variety of Enalaprilat variants. Replacing 
Patchett’s reductive amination with a diastereoselective SN2 nucleophilic substitution provides an 
alternative. A scheme centred around a substitution reaction would require the protection of acids to 
facilitate such a reaction.  
A diastereoselective synthesis of Enalaprilat analogues would therefore be highly advantageous if it 
could provide a simpler synthetic route to P2 Enalaprilat analogues. There are a few published 
examples of a nucleophilic Br substitution applied specifically to the synthesis of ACE inhibitors (Figure 
4.3)119c. In such reactions, the substitution was highly diastereoselective making a strong case for its 
adoption in the synthesis of Enalaprilat derivatives. 
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Figure 4.3: Published examples of a nucleophilic substitution successfully employed in the diastereoselective synthesis of ACEis.119 
In contrast to the key amination step of Patchett et al, the nucleophilic substitution reactions require 
the protection of acid and amine groups to ensure the correct regioselectivity. Selecting a protecting 
group for both acid and amine groups has the potential to play an important role in the final yield and 
purity of the compound. Boc is the most commonly used amine protecting group while a variety of 
acid protecting groups have been employed including methyl, ethyl and t-Butyl esters.  
4.1.3 Novel ACE N-domain selective SAR 
Until now the existing SAR on the individual ACE domains has been restricted to a set of bradykinin 
potentiating peptides,120 Ang-I metabolites,52 phosphinopeptides56, 58 and peptidomimetic ACEis.3b 
These studies have explored P2’ SAR in search of C-domain selectivity. While the core contribution of 
P2’ P1’, ZBG and P1 moieties of Enalaprilat towards binding in the two domains is well understood62, 
the vacant P2 position is a novel site with which to exploit interactions in the S2 subsite.  
The effect of the Arg381/Glu403 mutation on domain selective ACE inhibition has only been explored 
using phosphinic peptides.56, 72 Targeting these S2 residues via modifications to the Enalaprilat scaffold 
would be the first attempt designing N-domain selective drug-like ACE inhibitors.  
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4.2 Aims and Objectives 
4.2.1 Aim 
The aim of this chapter was to explore a novel diastereoselective synthetic route for the synthesis of 
Enalaprilat analogues. This route was intended to provide easy access to the set of Enalaprilat 
analogues modelled in Chapter 3. 
4.2.2 Objectives 
In pursuit of this novel synthetic route, the following objectives were laid out: 
1. Establish a new diastereoselective synthetic route to Enalaprilat analogues. 
2. Synthesise Enalaprilat analogues for SAR studies. 
3. Test the analogues in ACE competitive inhibition assays to determine their potency and 
domain-selectivity. 
4.3 Methods 
4.3.1 Enalaprilat Analogue Synthesis 
 
Scheme 4.1: Synthetic route used to synthesise an Enalaprilat P1 analogue. i. EDC/HOBt, N-methyl morpholine, DCM  0 °C 2 hrs, 25 °C 12 hrs (43%). ii. NaHCO3, MeCN 80 °C 36 hrs (73%). iii NaOH, H2O, 25 °C, 2hr (39%). 
An Enalaprilat analogue was synthesised according to Scheme 4.1. For reaction i 2-(R)-bromo 
propanoic acid, N-hydroxy benzatriazole (HOBt) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) were dissolved in chilled dichloromethane (DCM) with stirring for 30 mins. Proline methyl ester 
was then added together with N-methylmorpholine (NMM) after which the mixture was allowed to 
warm to 25 °C and stirred for 12 hours. In reaction ii, compound 3 and an amino acid methyl ester 
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were added to MeCN together with NaHCO3 under inert conditions. The reaction was then refluxed at 
80 °C for 24 hours. After purification, product 4 was then deprotected by dissolution in a 1 M aqueous 
NaOH at 25 °C with stirring for 2 hours. 
4.3.2 in vitro Competitive ACE Inhibition Assay 
Once synthesised the compound was tested in vitro for ACE inhibition. The ACE assays followed the 
same methods described in Chapter 2, section 2.3.5. After the initial screening of the compounds, IC50 
values were determined for compounds displaying sub-micromolar inhibition.  
4.4 Results 
4.4.1 Peptide Coupling 
The first conditions attempted utilised EDC and HOBt in DMF without an organic base.121 These 
conditions produced a poor  yield of 31% with a by-product formed in equal mass quantities. In an 
attempt to improve the yield of this reaction, a variety of different reagents and solvents were tested. 
The best yields were obtained using the combination of EDC and HOBt in DCM with NMM. Compound 
3 (SF05) formed in a roughly 1:1 mass ratio with a by-product. A yellow-brown residue was purified 
over silica (10:90 EtOAc/Hexane) to yield SF05, a white crystalline powder (mp 107-110 °C), in a yield 
of 43%. 
4.4.2 Nucleophilic Bromine Substitution 
The most popular conditions for this reaction, are a weak inorganic base such as K2CO3 or NaHCO3 with 
an aprotic solvent such as MeCN or DMF.119a, 119c For this reaction NaHCO3 was utilised with the mixture 
refluxed in MeCN for 36 hours at 80 °C.122 
The first amino acid chosen was Glutamic acid dimethyl ester based on availability and modelling 
results described in Chapter 3. The newly formed amine bond from reaction ii was easily visualised 
using a ninhydrin TLC stain. The product was purified over silica (2 : 98, MeOH : DCM) and obtained as 
a yellow-brown oily residue with a yield of 73%.  
 
Figure 4.4: SF06 
The diastereomeric purity of SF06 (Figure 4.4) was then evaluated. With a mixture of two 
diastereomers around a single chiral centre, 1H NMR peak duplication would be expected for the 
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protons attached to either the chiral carbon or diastereotopic protons as these protons are shared by 
two analogous peaks in slightly different environments, hence the slightly different chemical shifts. 
The SF06 proton H-11 is attached to the chiral carbon C* while the H-12 protons belong to a methyl 
group attached to this chiral carbon. In the presence of a diastereomeric mixture, the H-11 and H-12 
protons would be found in slightly different environments for each diastereomer.  
Considering the crude 1H NMR of SF06 (Figure 4.5), a clear peak duplication was observered for H-12 
in its 1H NMR spectrum. The H-12 peak is characterised by a doublet (J = 6.82 Hz) with a shift in the 
1.0 ppm region. In Figure 4.5, two doublet peaks of almost identical J-values (J = 6.82, 6.60) but 
different heights and integrations were observed. The large peak labelled 12M was assigned to H-12 
from the major SF06 diastereomer while the smaller peak labelled 12m was assigned to the minor 
diastereomer. The relative integrations of the major and minor peaks can now be compared to 
determine the diastereomeric excess of this substitution reaction. 
 
Figure 4.5: An extract from the 1H NMR spectrum of a crude SF06 sample showing the duplication of the doublet peak for the H-12 methyl group. 
The 12M major peak integrated for 3 protons when normalised relative to single proton peaks (Figure 
4.5). With this major peak normalised to 3 protons, the integration of the minor peak was measured 
at 0.68 protons. The ratio of areas for the minor and the major peak is therefore 1:4.41 translating to 
a diastereomeric excess (de) of 63%. 
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This reaction is therefore moderately diastereoselective following a presumed hybrid SN1/SN2 
mechanism. A de in excess of 50% suggests the SN2 mechanism is the dominant substitution pathway 
while the SN1 mechanism still makes an important contribution. Assigning these two diastereomer 
peaks would require a diastereomer separation and 2D NMR methods. Based on precedence, these 
diastereomers can be assigned using ACE inhibition data, therefore no attempt was made to separate 
the diastereomers at this stage. 
4.4.3 Methyl ester Deprotection 
The three methyl esters present in SF06 were hydrolysed by stirring the compound in aqueous NaOH 
for two hours. As this is an aqueous phase reaction, it was monitored via LC-MS instead of TLC. Initially 
0.25 M NaOH was used but, at this concentration the only mass seen was the product of SF06 with 
just two hydrolysed esters. In an effort to hydrolyse the third methyl ester, the NaOH concentration 
was increased in increments of 0.05 until the mass of the triple hydrolysed ester product was observed 
via LC-MS using a NaOH concentration of 1.00 M. 
After the workup involving HCl neutralisation, the resultant product was obtained as a salt mixture. In 
a similar reaction by Greenlee et al,123 the salt was removed by running the sample through a Dowex 
ion exchange resin but in this case, the sample was loaded directly onto the Prep-HPLC. SF07 was 
isolated as a sticky transparent-white paste with a post HPLC recovery yield of 39% and a purity of 
97%. 
4.4.4 Racemisation 
An unforeseen consequence of raising the NaOH concentration to achieve a triple ester hydrolysis was 
the racemisation of chiral centres adjacent to the ester groups. Base-catalysed ester hydrolysis has 
been documented to cause racemisation via a reversible side reaction (Figure 4.6)124. Despite the 
diastereoselectivity around the methyl group introduced in reaction ii, SF06 contains two methyl ester 
groups attached to chiral carbons. The base-catalysed ester hydrolysis reaction has a significantly 
lower activation energy than the racemisation reaction, hence racemisation is minimal at low base 
concentrations. The presence of a third methyl ester in SF06 required the NaOH concentration to be 
increased to a point where the racemising side reaction became a significant factor. 
 
Figure 4.6: The reversible base catalysed racemisation of chiral acid groups. 
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Two of the esters in SF06 are adjacent to chiral centres, which can undergo base-catalysed 
racemisation during the ester hydrolysis. As a mixture of two diastereomers around the methyl group, 
racemisation at the two chiral methyl esters creates four diastereomer permutations for each of the 
two existing diastereomers, bringing the total number of diastereomer permutations to eight. All eight 
diastereomer permutations from the three chiral centres of SF07 are now possible. With four charged 
groups, SF07 is a highly polar compound in solution. This high polarity results in short HPLC retention 
times. The short retention times made diastereomer separation difficult. The diastereomerism was 
clearly seen in the 1H NMR spectrum with multiple duplicates of the methyl peak H-12 (Figure 4.7). 
 
 
Figure 4.7: An extract from the 1H NMR spectrum of SF07 showing the peak duplication of several doublets for the methyl H-12 protons indicating several distinct diastereomers. 
Racemisation is often the reason the base concentration is kept low during ester hydrolysis. In the 
case of SF07, racemisation was an unavoidable consequence of the higher base concentration 
required for the triple ester hydrolysis. Scheme 4.1 was devised to introduce diastereoselectivity in 
the reaction. However, the triple ester hydrolysis unfortunately resulted in up to eight diastereomers 
instead of the original two. The final HPLC purified sample of SF07 showed a high purity despite the 
high degree of diastereomerisation present.  
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4.4.5 Characterisation of SF07  
The high level of diastereomerism in SF07 meant its 1H NMR peaks needed to be compared directly 
with those of SF06 for the correct assignment. The assignment of the 1H NMR of SF06 (Figure 4.8) 
begins with a quartet (J = 4.08 Hz) at 4.31 ppm that can be assigned to H-11 with an adjacent methyl 
group. As there is only one proton in the H-11 position, the integration of this peak can be normalised 
to 1.0. The doublet (J = 6.77 Hz) at 1.09 ppm can be assigned accordingly to the methyl at H-12. The 
broad multiplet at 3.61 ppm integrates for two protons corresponding with the two deshielded 
cycloalkyl protons at H-2 with an adjacent N. The three methyl ester peaks of H-23, 24 and 25 appear 
as singlets at 3.61, 3.60 and 3.58 ppm respectively. Two peaks each integrating for one proton are 
seen immediately upfield from the methyl ester peaks. The peak at 3.67 ppm is a sharp multiplet 
corresponding to the chiral proton H-14. A broad multiplet integrating for another single proton 
immediately upfield from the sharper multiplet corresponds to the proton at position H-5 on the 
pyrrolidine ring adjacent to both a N and an ester. The two protons at H-19 can be assigned to the 
multiplet at 2.32 ppm. These protons are slightly deshielded by the adjacent ester while its expected 
quartet has been distorted by the diastereomerism of the compound creating two interfering peaks 
for H-19 resulting in the multiplet. The only peak remaining is a large broad multiplet at 1.87 ppm 
integrating for six protons. These six protons match the six remaining unassigned downfield protons 
of H-3, H-4 and H-15. 
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Figure 4.8: 1H NMR spectrum of SF06 at 300 MHz 
With the 1H NMR spectrum of SF06 assigned, it was stacked onto the spectrum of SF07 (Figure 4.9) as 
this spectrum was harder to assign due to peak duplication on account of a mixture of eight possible 
diastereomers. Protons attached to stereocentres can show a pattern of distinct yet repeated peaks 
while broader peaks tend to remain together with their multiplicity merged into multiplets. Figure 4.9 
shows the stacking of the spectra of SF06 and SF07. As expected, the defining difference between 
these two spectra is the absence of the three methyl ester peaks (3.68-3.57 ppm) following the 
deprotection. In the absence of these peaks, the multiplets for the cycloalkyl protons H-2 and the 
single chiral proton H-14 peaks are observed in this region.  
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Figure 4.9: Stacked SF06 (red) and SF07 (cyan) 1H NMR spectra 
With the peaks of SF06 mapped to the 1H NMR spectrum of the diastereomerically diverse SF07, its 
1H NMR spectrum (Figure 4.10) could now be assigned. To normalise the integration, the total area of 
the six doublet peaks (J = 6.95 Hz) between 1.35 and 1.60 ppm was set to 3 protons on the assumption 
that they cumulatively add up to the three methyl H-12 protons with contributions from each 
diastereomer present. Peaks in the 4.05 to 4.50 ppm range appeared to be a mixture of quartets (J= 
6.94 Hz) and triplets (J = 5.66 Hz). These peaks collectively integrated for two protons matching the 
individual protons at H-14 (quartet) and H-5 (triplet). These two peaks are duplicated several times 
with different areas as these protons are both attached to chiral carbons whose environment varies 
significantly with each diastereomer. The peak for the chiral proton H-14 is split between multiplets 
at 3.84 and 3.71 ppm which collectively sum to a full proton. The broad multiplets found between 3.46 
and 3.66 ppm integrate to a total of two protons matching the expected shift pattern of the 
deprotected cycloalkyl protons at H-2. The multiplet at 2.58 ppm integrates for two protons coinciding 
with the expected shift of the two protons found at H-19. The broad repeated quintet or multiplet 
expected for the two diastereotopic protons at H-15 is seen between 2.3 and 2.5 ppm. Multiple 
diastereomers and overlapping chemical shifts have caused some overlap and interference, hence the 
pattern of this peak is messy. The two remaining unassigned proton pairs at H-3 and H-4 can now be 
assigned to the multiplets at 2.28 and 2.09 ppm respectively. The multiplet of H-4 is duplicated with a 
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minor peak at 1.91 ppm. This peak is split due to the different environments arising from different 
through space interactions with the different configurations of the acid at C-5. Collectively these two 
peaks integrate for two protons.  
 
 
Figure 4.10: 1H NMR spectrum of SF07 at 600 MHz 
4.4.6 ACE Competitive Inhibition Assay 
SF07 as a diastereomeric mixture, was sufficiently pure for a competitive inhibition assay against the 
N- and C-domains of ACE. The SF07 mixture was initially screened at 100 and 1 μM (Figure 4.11). At 
100 μM nearly 70% of the C-domain activity remained while the N-domain was almost completely 
inhibited. At 1 μM, there was no inhibition of the C-domain while the N-domain still showed 82% of 
the total enzyme activity remaining. This preliminary screen suggests the IC50 for the N-domain lies in 
the low μM range while the IC50 for the C-domain is over 100 µM giving a selectivity factor of roughly 
two orders of magnitude.   
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Figure 4.11: The enzymatic activity remaining after the two ACE domains were screened with SF07. A 1 μM Lisinopril was used as a negative control. 
With an IC50 > 100 μM for the C-domain, only the N-domain IC50 of the diastereomeric SF07 mixture 
was determined (Figure 4.12). 
 
Figure 4.12: Dose response curve measuring the IC50 of SF07 against the ACE N-domain. The IC50 was measured at 5.722 µM with an R2 of 0.9948 
This low micromolar inhibition of the N-domain and only 33% inhibition at 100 μM for the C-domain 
unambiguously confirms the N-domain diastereomeric selectivity of the SF07 mixture. Based on the 
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domain was expected to be in the low nanomolar range. However, the IC50 of SF07 was measured to 
be in the low micromolar range, 2-3 orders of magnitude higher than what was expected. Low 
micromolar inhibition is consistent with the wrong diastereomer or a mixture of different 
diastereomers. Patchett et al measured the IC50 of the RSS Enalaprilat diastereomer to inhibit sACE 
with an IC50 of 820 nM as opposed to 1.2 nM for the SSS diastereomer while the mixture of the two 
diastereomers inhibited sACE with an IC50 of 3.8 nM.113 The 6-8 diastereomers present in this SF07 
sample adequately explains the lower than expected potency observed for the N-domain. Based on 
these preliminary results, SF07 is a potentially promising N-domain selective ACE inhibitor. The 
synthesis, however, does need to be refined to avoid racemisation during deprotection.  
4.4.7 Rationalisation of Domain Selectivity 
To explain the ACE domain selectivity behaviour of SF07, its predicted binding pose was analysed in 
greater detail. SF07 was named compound F1_L1 in Chapter 3.  Based on MM-GBSA binding scores, 
F1_L1 was predicted to bind strongly to both catalytic domains of ACE. SF07 (F1_L1) was the only 
compound from the modelled set, which was synthesised hence it deserves a closer look. Apart from 
the strong MM-GBSA binding scores towards both ACE domains, the predicted binding pose between 
the SF07 and the two domains was now analysed.  
The distance between an oxygen the SF07 P1 acid and the nearest oxygen atom of Glu403 of the C-
domain is 12.1 Å while the distance between an oxygen atom of this acid and the nearest nitrogen of 
Arg381 in the N-domain is 6.3 Å (Figure 4.13). At a distance of 12.09 Å, it is safe to say that Glu403 has 
no influence on the binding of SF07 to the C-domain. At a distance of 6.0 Å from SF07, it is plausible 
that Arg381 is involved in a water mediated H-bond with SF07. However, it must be noted that this 
interaction is not essential for strong binding between SF07 and ACE.  
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Figure 4.13: The docked and MM-GBSA minimised poses of SF07 in the ACE N- (magenta) and C- (green) domains. The measured distance between the SF07 P1 acid and Arg381 in the N-domain was measured at 6.27 Å while the distance between this acid and Glu403 in the C-domain was measured at 12.09 Å. 
With no discernible interaction between SF07 and Glu403, the interaction responsible for the poor C-
domain interaction must lie elsewhere. Judging from the predicted pose, the most likely candidate 
would be Glu143 in the C-domain, which is replaced with Ser119 in the N-domain. Glu143 lies 5.99 Å 
from the P1 acid in the C-domain. This negatively charged residue is now close enough to influence the 
binding of SF07 to the C-domain while replacing this residue with a polar-neutral Ser119 in an 
analogous N-domain position provides a possible explanation for the stronger N-domain binding of 
SF07.  
4.5 Discussion 
4.5.1 Diastereoselectivity of Substitution Reaction 
Despite the lack of any diastereomeric purity in the deprotected SF07, the substitution reaction ii 
appeared to be largely diastereoselective. As already indicated, the Br leaving group of secondary 
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intermediate is stabilised by the groups attached to this carbon. In the case of SF05, the chiral carbon 
is bonded to both a methyl and a carbonyl group. While a methyl group has a slight stabilising effect 
on a carbocation intermediate, the electron-withdrawing carbonyl group destabilises it. Given this 
combination of groups attached to this secondary chiral carbon, minimal stabilisation of the 
carbocation intermediate was predicted favouring the SN2 mechanism. Despite this prediction, a 
significant proportion of the reaction progressed via an SN1 pathway to create a hybrid SN1/SN2 
mechanism. A 50:50 mixture of two ACEi diastereomers will theoretically increase the IC50 by roughly 
a factor of two as observed by Patchett et al during the synthesis and evaluation of Enalaprilat. 
Given the apparent high diastereomeric excess of this reaction, a methyl ester deprotection free of 
racemisation may, by all indications, have yielded the preferred SSS diastereomer without changing 
the diastereomer composition from SF06. The expected factor of two order of magnitude drop in 
inhibition present in a 50:50 diastereomeric mixture around a single diastereomer is not too significant 
to mask ACE inhibition while constituting 50% of the mass, as demonstrated by Patchett et al. While 
this substitution reaction has proven to be a diastereoselective alternative to Patchett’s reductive 
amination, the subsequent deprotection negated all efforts of reaction ii to impart diastereoselectivity 
into the synthesis of this Enalaprilat analogue. 
4.5.2 Ester Deprotection 
Generic base catalysed ester hydrolysis conditions were used for the deprotection. In an analogous 
reaction by Greenlee et al,123 only double methyl esters were deprotected using 0.25 M NaOH. LC-MS 
reaction monitoring of the SF06 deprotection at this concentration only showed the presence of the 
double hydrolysed product. The required triple hydrolysis necessitated incremental increases in NaOH 
concentration resulting in the observed racemisation. 
Replacing the methyl ester protecting groups with a Bn protecting group could provide a viable 
alternative that avoids racemisation during deprotection. Bn protecting groups have been used 
successfully in a diastereoselective synthesis of Captopril by Fisher et al.125 Adapting  Scheme 4.1 to 
use Bn protection groups would require different starting materials.  
Patchett et al observed a two-fold decrease in potency when measuring the inhibition of a mixture of 
RSS and SSS enalaprilat diastereomers as opposed to the pure SSS diastereomer. Crystal data would 
suggest a uniform drop in potency across both ACE domains when tested against a diastereomeric 
mixture. These predictions were confirmed during the inhibition assays.  
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4.5.3 ACE Competitive Inhibition Assay 
The IC50 of SF07 towards the N-domain was predicted to be in the low nanomolar range for a 
diastereomerically pure SSS stereoisomer. However, the IC50 of the given diastereomeric mixture was 
measured at 5.722 μM, two orders of magnitude greater than the expected inhibition. This is 
consistent with a mixed diastereomer sample containing 6-8 diastereomers with the SSS diastereomer 
constituting only a small fraction of the mixture. It was impossible to assign the different 
diastereomers evident in the 1H NMR without separating them individually. Separating six different 
diastereomers of a 36 mg sample would be a challenging task given the short HPLC retention time of 
SF07.  
The SF07 diastereomeric mixture inhibited the C-domain with an IC50 above 100 μM suggesting a 
possible two order of magnitude N-domain selectivity. While a diastereomeric mixture cannot be 
assumed to uniformly weaken the binding towards both domains by the same factor, the specific 
ligand-protein interactions around these stereocentres need to be considered. There are no structural 
differences between the two domains present around the three stereocentres in the ACE binding 
footprint of SF07 making a uniform drop in binding strength plausible.  
4.5.4 Conclusion 
These results provide some motivation to rework the synthetic route to avoid racemisation. There is 
room to expand upon this work by synthesising and testing a SAR series to further refine the structural 
motifs and chemical space responsible for ACE N-domain selectivity.  
SF07 serves as further validation of Dive et al’s observation that an interaction with an acid in the S2 
subsite is responsible for N-domain selective ACE inhibition.56 The longer distance predicted between 
the P1 acid of SF07 and both Arg381 and Glu403 meant the observed N-domain selectivity was 
unexpected. It was thought that a minimum of one additional alkyl carbon in length was required to 
effect an interaction with Arg381/Glu403. The observation of N-domain selectivity with the first and 
only compound tested in this series holds encouraging prospects for future SAR work on this series.  
SF07 is potentially the first documented Enalaprilat analogue compound to display ACE N-domain 
selectivity via an interaction with an acidic S1 group. A thorough evaluation of the predicted binding 
pose of this Enalaprilat derivative would require a cocrystal of SF07 with the two ACE catalytic 
domains. This would clarify the role that the C-domain Glu143 plays in disrupting the binding of SF07. 
The predicted distances between the P1 acid of SF07 and Glu403/Arg381 suggest that these residues 
have little to no involvement in the binding of SF07 to either domain of ACE. Interactions with the 
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oppositely charged Glu403 and Arg381 residues cannot rationalise the N-domain selectivity observed 
in the inhibition assay of SF07. 
A closer inspection of the binding suggested that Glu143 of the C-domain could play a more pivotal 
role in the disruption of SF07 binding. Glu143 is replaced with Ser119 in an analogous N-domain 
position. This substitution has the potential to expand upon the current hypothesis of Arg381/Glu403 
as the sole source of N-domain selectivity. The S1 subsite could therefore also contribute to N-domain 
selectivity in certain compounds with appropriate P1 groups. 
A P1 acid would experience no adverse effect on its binding from an interaction with a polar-neutral 
Ser residue while a Glu in that position has the potential to cause an electrostatic clash with a P1 acid. 
The 5.99 Å distance between the P1 acid of the docked SF07 and Glu403 is not generally associated 
with an interaction but is close enough to suggest this acid has been forced into an unfavourable 
position in order to avoid this residue. It was therefore surprising, in light of the existing ACE domain 
selectivity data, that SF07 displayed any N-domain selectivity.  
To date, P1 SAR contributions towards N-domain selectivity have not been documented. SF07 is an 
encouraging example justifying a further investigation. Acidic P1 attachments to ACE inhibitors are 
better suited in the context of drug-like N-domain selective ACE inhibition as it would allow for 
compounds of the same length as traditional ACEis. While it is impossible to draw any conclusions 
from just one example, the SF07 inhibition data warrants a deeper P1 ACEi SAR investigation. 
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Chapter 5  – Database Mining for Old ACEis 
5.1 Introduction 
5.1.1 Chemical Databases for Drug Discovery 
Drug screening and SAR optimisation against drug targets has been in practise for well over a century 
and while millions of compounds have been patented, the number of compounds synthesised and 
tested in the process far exceeds this. This research has left behind vast archives of drug-like 
compounds with their accompanying biological data. The advent of chemoinformatics has 
necessitated the need to convert these archives into digital chemical databases. These databases have 
been adapted to suit many different types of software and applications. A noteworthy development 
from these databases is the invention of the simplified molecular-input line-entry system (SMILES),103 
which uniquely specifies a molecule in a one line string of characters. This one-line entry system has 
created a low-data method for specifying molecules allowing for the construction of databases with 
millions of entries.  
As already discussed, virtual screening is one of the most common uses of drug discovery databases. 
Many software applications have been developed to analyse and manipulate these databases 
according to the requirements of the user. This has led to the development of a new discipline in the 
field of chemoinformatics termed database mining. Modern software and processors can sort, filter, 
analyse and run simulations on these databases at a rate many orders of magnitude faster than what 
can be achieved manually. Databases can now be mined on an unprecedented scale to find specific 
target-binding patterns. 
Database mining may be undertaken using a variety of computational tools. Substructure searching 
and pharmacophore screening are two of the most popular tools. While these tools help facilitate the 
processing of immense datasets, they are not a complete substitute for human intuition. Effective 
database mining protocols usually combine computational tools with manual inspections to 
effectively utilise the database. 
The organisation and indexing of chemical databases can vary depending on the application. As 
previously mentioned, ZINC is a free database of diverse commercially available compounds for virtual 
screening.102 The entries in the ZINC database are indexed with their physicochemical properties to 
enable the filtering of databases based on a custom set of parameters. Other databases are better 
suited to mining as each compound is indexed against measured biological data from the original 
publications in which they were reported. The most common examples of such free databases are 
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ChEMBL126 and BindingDB127. More extensive subscription databases are available but these charge a 
large fee for sharing this IP.  
5.1.2 ACE and the Drug Discovery Databases 
Database mining should prove useful in the search for domain selective ACE inhibitors due to the 
target’s extensive cumulative SAR data. ChEMBL and BindingDB, the open access databases of drug-
like compounds indexed with biological data both contain entries for human ACE. BindingDB contains 
ACE inhibition data on 2252 compounds while ChEMBL contains ACE data on 1154 compounds. The 
subscription database GVK contains 24 958 entries with some form of biological data pertaining to 
ACE.  
An important aspect of this pre-existing ACE inhibition data is the nature of the assays that were 
performed. The pioneering competitive inhibition studies were performed on sACE using the HHL 
substrate.128 ACE inhibition was evaluated on the vast majority of entries in these databases using this 
assay. Since the C-domain is responsible for over 90% of the HHL hydrolysis,3a it follows that the sACE 
inhibition of the HHL hydrolysis can be roughly equated to C-domain inhibition data. N-domain 
selective inhibitors would have likely been missed by the assays since N-domain selective inhibition 
would leave the C-domain free to hydrolyse the substrate.    
This chapter deals with the efforts to search the available chemical databases of compounds 
containing ACE inhibition data for potential ACE N-domain inhibitors. It is possible that such N-domain 
selective compounds have remained hidden for decades due to the lack of structural information 
available in the early days of ACE drug discovery. If an N-domain selective ACEi is hidden in any 
database, the ACE entries in the GVK database would be an ideal place to look. 
5.2 Aims and Objectives 
5.2.1 Aim 
The Aim of this chapter was to search for potential N-domain selective ACEis among the vast databases 
of existing sACE inhibitors. 
5.2.2 Objectives 
 Analyse the set of database compounds, which have been tested on ACE. 
 Apply filters to the set of compounds to keep them within the confines of strict chemical 
parameters conducive to ACE inhibition. 
 Run docking simulations on the most promising set of compounds. 
 Recommend compounds for purchase/synthesis and in vitro competitive inhibition assays. 
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5.3 Methods 
5.3.1 Database Selection 
Access to the GVK database was granted through the Novartis Institute of Biomedical Research (NIBR). 
All the compounds containing biological data on ACE were extracted. The entries pertaining to ACE 
were compared to those in the open access databases of ChEMBL and BindingDB. GVK was chosen 
due to its greater size, diversity of compounds and an almost complete overlap with both ChEMBL and 
BindingDB.  
5.3.2 Inspection and Filtering 
Once all the entries with biological data pertaining to ACE had been selected, a filter was applied to 
reduce the database to compounds with a maximum of 15 rotatable bonds. This is a common filter to 
remove larger biopolymers like peptides to make the set more drug-like. All compounds remaining in 
this set had been tested on human ACE with inhibition reported in the IC50 form. The set was then 
imported into Schrodinger’s Maestro GUI. 
The remaining set was separated according to their ZBG using the Maestro filtering tools. Only drugs 
containing carboxylic acid ZBGs were selected for further scrutiny. The remaining set was visually 
inspected for esterified prodrugs and peptides. All the esterified prodrugs were manually converted 
into their bioactive form while peptides which had passed the 15 rotatable bond filter were removed. 
Duplicate compounds created by de-esterifying the prodrugs were removed using Maestro’s remove 
duplicate tool. Only compounds with polar groups that could potentially interact with the S2 subsite 
were selected.  
This smaller reduced set was further scrutinised and subjected to a second round of visual inspection. 
The second round of visual inspection identified core binding motifs in each compound and considered 
the reported biological data. Only compounds with IC50s in the nanomolar range and a P2 polar group 
passed this round of inspections. 
5.3.3 Ligand Docking 
Ligands which passed the two rounds of visual inspection were all docked into the constrained ligand 
docking system created in Chapter 3. This set of docking constraints was defined as set C1. Ligands 
which failed to find a suitable pose using the C1 set of constraints were docked into either one of two 
newly created constraint systems defined as C2 or C3.  
Conditions C2 and C3 were created by introducing three optional positional constraints to the docking 
grid based on the crystal pose of Lisinopril in each domain (Figure 5.1). The first positional constraint 
was for an alkyl C or an amine to be placed in a sphere centred on the alkyl carbon of Lisinopril in a 
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positon adjacent to the ZBG on the non-prime side. This constraint was named α. An analogous 
positional constraint was added to the system centred on the secondary N of Lisinopril in the other 
position adjacent to the ZBG but on the prime side. This constraint was named α’. A third positional 
constraint was placed on the amide N of Lisinopril. This constraint was named ε’. Each constraint was 
set to only allow poses with either an N or C atom within a 1 Å radius sphere centred on these Lisinopril 
atoms.  
 
Figure 5.1: An illustration of the docking constraints employed against the two domains of ACE. These consisted of three possible positional constraints α, α’ and ε’, the metal binding constraint and the two H-bond constraints overlaid on the native Lisinopril ligand. 
From these three new positional constraints, two additional sets of docking constraints were defined 
(Table 5.1). The first constraint condition C1, can be defined as the set of constraints used in Chapter 
3. The second condition C2 was defined as a metal-ZBG chelation with the ε’ positional constraint 
sphere containing an amide/amine N. The third constraint condition was defined as the same two 
constraints as C2 with the addition of positional constraint α, which must contain either an alkyl C or 
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Table 5.1: A summary of the three docking constraint conditions defined as C1, C2 and C3. 
Condition Constraints 
C1 Carboxylic acid – Zn chelation, H-bond with Lys511/489 or Gln281/Gln259 
C2 Carboxylic acid – Zn chelation, amide/amine N in ε’ constraint sphere 
C3 Carboxylic acid – Zn chelation, amide/amine N in ε’ constraint sphere, amine N of alkyl C in α constraint sphere 
 
Once plausible binding poses had been created for each entry on the list, the potential of each 
compound to interact with Arg381/Glu403 was assessed. Compounds from the same chemical series 
were grouped together. The series that were most likely to interact with Arg381/Glu403 were then 
considered for in vitro testing in competitive ACE inhibition assays. 
5.4 Results 
5.4.1 Database Mining Overview 
 Figure 5.2: A schematic outlining the database mining protocol. 
Figure 5.2 illustrates an overview of the procedure used to filter this database and identify the most 
promising N-domain selective ACEis. To begin with, a total of 24958 compounds in the GVK database 
were found to have been tested on ACE, many of which were peptides. This set was reduced to 5392 
compounds after applying a rotatable bond limit of 15 and limiting the selection to only include 
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compounds with IC50 inhibition data. The set was then reduced to 1832 compounds after it was 
restricted to compounds containing only a carboxylic acid ZBG. The remaining set contained many 
esterified prodrugs and small peptides, which had escaped the rotatable bond filter. After removing 
these small peptides, de-esterifying the prodrugs and removing the duplicates, 1358 compounds 
remained. The first round of visual inspection reduced it to 126 compounds of which only 13 passed 
the second round of inspection for docking. 
5.4.2 GVK Database Sorting of ACE inhibitors 
A total of 5392 compounds in the GVK database had been tested on human sACE in a competitive 
inhibition assay with their IC50 values reported. The majority of these IC50 values were obtained via 
competitive inhibition against a HHL substrate. However, different substrates were used in some of 
the more recent studies. There was a much smaller subset of compounds with reported Ki values but 
these were later all found to be duplicates of compounds in the IC50 subset. This set of 5392 
compounds was investigated further. 
Upon rendering the SMILES into 2D structures, it was evident that the three main classes of ACE ZBG 
(carboxylic acid, thiol and phosphinic acid) were well represented. Many peptides were still present in 
addition to the traditional ACEis. The majority of the peptides were removed by the maximum 15 
rotatable bonds filter. Since thiol ZBGs have been shown to be prone to toxicity issues129 and 
phosphinic acids suffer from poor permeability, only compounds with carboxylic acid ZBGs were 
retained. This reduced the set down to 1832 compounds. 
A set of 1832 compounds is usually small enough to dock. However, this was not possible using ACE 
as a target. No blanket set of constraints could find plausible poses for a diverse set of compounds 
when docked against ACE.  Test runs were performed and on average, 45% of the set could be docked 
plausibly with any one set of constraints. A low docking accuracy is unacceptable for evaluating 
possible domain selectivity within this set of known ACEis.  
5.4.3 Visual Inspection and Manual Filtering 
Upon first inspection of the remaining set of 1832 compounds, it was apparent that many small di- 
and tripeptides had escaped the 15 rotatable bond filter. Another concern was the presence of many 
prodrugs in the set with at least one ester group. These remaining peptides were removed and the 
prodrugs were de-esterified. The de-esterification created a few duplicates, which were easily 
removed using Maestro’s remove duplicate tool. This step reduced the set to 1358 compounds before 
the visual inspection could officially commence. 
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While a pharmacophore filter with an Arg381 interaction pattern was considered, the dataset was 
now small enough for visual inspection. To ensure adequate ACE binding, compounds with a 
prominent P2’ carboxylic acid and a known P2’ moiety of Pro, Trp or Phe analogous structure were 
prioritised. With an ACE binding core established, compounds containing a polar group with the 
potential for a polar interaction with Arg381/Glu403 were selected from the set. 
Drug-like compounds with the most promising P2 moieties were selected for docking. The set 
considered for docking consisted of 13 compounds. Of the 13 compounds, 10 compounds belonged 
to one of four series (Table 5.2): Series 1 – Diprolyl; Series 2 – Benazeprilat analogues; Series 3 – 
Quinaprilat analogues; Series 4 – Nicotianamine natural product derivative. Three of the series (Series 
1-3) were related to existing ACEis while the fourth consisted of two natural products isolated from 
buckwheat. These 13 compounds were then docked against both domains of ACE. 
Table 5.2: The compounds of interest which were selected from the GVK database for docking studies. 
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5.4.4 Molecular Docking of Selected Compounds into the N-domain 
Thanks to an extensive collection of ACEis co-crystalised with both catalytic domains, the most 
important ligand-target interactions are well understood. The P1’ group is always an amino acid or 
pseudo amino acid residue with a carboxylic acid. The most common P2’ moiety is a Pro residue but 
Trp, Phe and many artificial peptidomimetic non-polar rings and fused aromatics have been 
documented to bind to this subsite. This outline for ACEi binding gives a good indication of what 
docking poses to expect, making it easy to identify when the docking protocol has found a plausible 
pose.  
Unlike the Enalaprilat-derived combinatorial library docked in chapter three, these compounds of 
interest are not structurally homologous. As expected, no one set of constraints was found to be 
capable of docking all 13 of these ligands in plausible poses. To work around this problem, three 
different constraint conditions (C1-C3) were tested to find convincing or reasonable poses for the 
diverse set of ligands.  
In the N-domain, plausible poses for compounds DM1-9 were obtained using constraint conditions C1 
while plausible poses for DM9 and DM10 were obtained using constraint conditions C2. Acceptable 
poses for DM11 and DM12 could not be obtained using any of the three constraint conditions. This is 
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likely due to the bulky P2’ indole or saturated bicyclic moiety. Such bicyclic P2’ groups have been shown 
to cause selective inhibition of the C-domain.58 
When docked in the C-domain, acceptable poses were obtained for all compounds except DM6 using 
one of the three constraint conditions (Table 5.3). The poor docking results for DM6 were probably 
due to the presence of a lysine moiety. Long alkyl chains push the limits of docking algorithms due to 
the many degrees of freedom and the raised entropy of the system with the addition of each rotatable 
bond in an alkyl chain. 
Once each compound was docked, the distance between Arg381/Glu403 and the nearest heavy atom 
on each ligand was measured. If the predicted pose is plausible and the ligand falls within 5 Å of these 
residues, an interaction with either of these residues can be expected to make a significant 
contribution towards ligand binding. 
Table 5.3: A table cataloguing the docking constraint conditions required to help each mined ligand find its correct binding pose. The Proximity between the ligand and either Arg381 in the N-domain and Glu403 in the C-domain in each correct pose is given. 
Entry N-domain Distance from Arg381 (Å) C-domain Distance from Glu403 (Å) 
DM1 C1 2.85 (Salt-bridge) C3 5.93 
DM2 C1 5.62 C1 7.59 
DM3 C1 4.05 C1 5.09 
DM4 C1 9.10 C1 6.69 
DM5 C1 9.74 C2 12.47 
DM6 C1 8.19 -  
DM7 C1 10.18 C1 12.25 
DM8 C1 8.75 C2 9.52 
DM9 C2 6.01 C2 9.47 
DM10 C2 6.01 C2 9.47 
DM11 - - C2 7.64 
DM12 - - C1 9.86 
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DM13 C1 6.54 C1 9.99 
 
5.4.5 Docking Poses 
Figure 5.3 illustrates a few docking poses achieved for some of the ligands from the set of 13 ACEis. In 
Figure 5.3A, DM1 found its core H-bond interactions in the S2’ subsite. In the S2 subsite, the terminal 
carboxylic acid forms a salt bridge with Arg381 in the N-domain while in the C-domain it appears that 
this acid has been held in place by the constraints have forced it into raised energy conformation to 
avoid an interaction with Glu403.  
In Figure 5.3B, the same Zn chelation and S2’ H-bonding interactions are observed for DM10. Its 
terminal carboxylic acid lies 5.10 Å from Arg381, too far away for an interaction. Lengthening the 
compound by one or two alkyl atoms could probably help it reach this residue.  
Figure 5.3C shows an example of a compound which is too large and cumbersome to accurately dock.  
Long alkyl chains add too many degrees of freedom to the simulation, hence the docking algorithm 
struggles to correctly place the carboxylic acid in the S2’ subsite. It also shows that this Benazepril-like 
core is only capable of getting close to the Arg381/Glu403 residues at the end of a long alkyl chain 
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Figure 5.3: Sample poses of DM1 (A), DM10 (B) and DM4 (C) docked into the N-(green) C-domains (grey). Each image depicts an overlay of selected N- and C-domain residues around the central Zn atom. The two key features are a carboxylic acid Zn chelation and a second carboxylic acid acting as an H-bond acceptor in the S2’ subsite. All H-bond interactions are indicated with a yellow dotted line. The P2 group of each ligand is then allowed to freely interact with Arg381/Glu403 in the S2 subsite. Figure A shows a near perfect example of a N-domain selective pose with an ionic interaction between the charged species of a carboxylic acid and Arg381. The ionic interactions between this acid and Glu403 in the C-domain creates an unfavourable torsion to avoid this residue. Figure B shows a ligand which almost makes the desired interactions with Arg381/Glu403 but ends up 5.10 Å short of these residues. Figure C illustrates the issues associated with docking large compounds with long alkyl chains. This ligand almost makes interactions with Arg381/Glu403 but the entropy of the Boc-Lys is too high to accurately predict the binding pose. 
Zn 
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5.4.6 ACEi Series with Potential for N-domain Selectivity 
Considering the docked poses of all the selected compounds, some compounds stood out as promising 
domain selective inhibitors. The most promising series by a considerable margin is Series 1 (Table 5.1) 
reported by Greenlee et al.123 Series 1 is an ideal scaffold with which to probe Interactions in the S2 
subsite. Pro-ZBG-Ala-Pro is known to bind tightly with S1, Zn, S1’ and S2’ subsites from peptide studies. 
 
Figure 5.4: Series 1 scaffold 
The best compound from this set (DM1) easily fitted into the binding pocket of the N-domain forming 
a salt-bridge with Arg381 (Figure 5.3A). Since the R-group in this series only varies around a peptide 
bond, a large range of fragments can be attached at this position. Of the three compounds selected 
from the database, DM1 contained an acid in this position.  
The second most promising series was series 4 (Figure 5.1). This series was derived from a natural 
product extraction performed by Aoyagi et al.132 They found two compounds with a cyclobutyl 
analogue of the terminal Pro observed in some ACEis. These two compounds were selected due to 
their strong ACE inhibition and the crucial third acidic group which could interact with Arg381/Glu403. 
Unfortunately, docking simulations showed these two compounds to be too short to interact with 
Arg381/Glu403 as well as the Zn and the S2’ group. Another point of consideration was that these two 
compounds were derived from natural products for which a synthetic pathway has not been 
established. 
Series 2 and 3 seemed interesting as the long alkyl chains emanating from their core structures 
seemed capable of reaching Arg381/Glu403. Upon closer inspection, it became apparent that only a 
lys attachment gave the ligand the ability to reach these residues. Deconstructing these compounds 
back to that point of attachment leaves a distance of over 10 Å between the scaffold and the 
Arg381/Glu403 residues. This distance is too great to access with the simple synthetic introduction of 
a new chemical group. 
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5.5 Discussion 
5.5.1 Mining Protocol 
There are many approaches to follow in a database mining exercise. Database mining protocols are 
developed on the merits of the target and the available ligands. Finding N-domain selective ACE 
inhibitors posed a unique challenge due to the wealth of existing sACE inhibition data. Since crystal 
structures have almost conclusively shown the Arg381/Glu403 mutation to be one of the origins of N-
domain selectivity, an effective N-domain inhibitor needs to retain its core ZBG and P2’ carboxylic acid 
before it can interact with Arg381/Glu403. These stringent requirements left a very narrow window 
of permissible structural features. The reduction of the set of compounds down to 1832 after the 
appropriate filters left a set which was suitable for manual inspection. While much consideration was 
given to constructing a pharmacophore model comprising of the core ACE binding motifs, a set of 1832 
compounds was small enough to inspect manually. A visual inspection also ensured that none of the 
interesting compounds would slip through undetected due to a flawed automated screen.  
The two thorough rounds of visual inspection returned 13 interesting compounds from this set. Not 
all of them had an acid in the P2 position but they all showed some potential for a polar interaction 
with the S2 subsite. Faced with the twin challenges of poor Zn binding predictions and a set with no 
common scaffold, finding plausible binding poses via docking required some innovation. The three 
constraint conditions were devised to test a range of ligand-binding motifs observed in crystal 
structures with the hope that at least one combination of constraints could help guide these ligands 
into a plausible pose. It was also important to give Glide enough freedom to ensure that the poses it 
returned were indeed minimised. As expected, docking with different constraints yielded varying 
degrees of success against the two domains of ACE.  
5.5.2 Docking Overview 
The C1 set of constraints found a plausible pose for 9/13 inhibitors in the N-domain and 6/13 inhibitors 
in the C-domain. The ligands for which a plausible pose could not be found in the N-domain belonged 
to either series 4 or were ungrouped. The docking algorithm likely struggled to find the correct poses 
for compounds in series 4 under these conditions because the distance between the ZBG and the 
cyclobutyl is one bonded C less than the analogous length in Enalaprilat. Its predicted poses 
consequently appear to be more strained. Series 4 is of a fundamentally different shape to the other 
ACEis and peptides but its ACE inhibition is reported to be in the low nM range. It is likely that the 
protein experiences small side-chain shifts when binding to this ligand compared to the peptides and 
peptidomimetics. It is therefore possible that the final pose of series 4 is compromised as the side-
chains around the binding site are optimised to fit a peptidomimetic compound. 
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Compounds DM11 and DM12 likely experienced difficulty docking into the N-domain active site on 
account of their bicyclic P2’ groups in a manner similar to RXPA380. A more polar S2’ subsite in the N-
domain is a possible explanation for the failure to find the pose for these compounds using any of the 
tested combination of constraints. The difficulties in finding the correct pose using the docking 
protocols can be interpreted as evidence of possible C-domain selectivity. 
The constraint conditions, which helped a ligand find the correct pose in the N-domain did not always 
work for the same ligand in the C-domain. A prime example of this is ligand DM1. Judging by its salt 
bridge with Arg381 in the N-domain, its Glu403 interaction was expected to have a detrimental effect 
on C-domain binding. A consequence of this poor interaction was that Glide failed to find a plausible 
pose with this orientation in the C-domain using conditions C1 or C2. Only in the most constrained 
system C3, was a plausible pose found but with unfavourable torsions around the P2 group. The 
unfavourable torsions seem to indicate that in a relaxed system, the protein conformation would be 
slightly altered to better accommodate the clash between the P2 acid and the Glu403. The ease with 
which Glide found the correct pose for this ligand in the N-domain compared with the C-domain is 
further evidence to suggest favourable N-domain binding. The other two compounds from series 1 
(DM2 and DM3) easily found the correct pose in the C-domain using the C1 constraint conditions on 
account of the more agreeable Gly and 4-amino P2 groups.  
There were also some difficulties docking Series 2 into the C-domain. These difficulties can be 
attributed almost entirely to the existence of a long alkyl chain challenging the limits of Glide’s 
simulation due to excessive rotatable bonds in a high entropy alkyl chain. Docking series 4 into the C-
domain and N-domain yielded similar poses. Its P1 acid was not capable of getting close enough to 
Glu403 to make a meaningful interaction. Compounds DM11 and DM12 were able to dock into the C-
domain with either C1 or C2 constraint system, which was not possible with the N-domain. This again 
suggests that P2’ bicyclic groups bind favourably towards the C-domain.  
5.5.3 Compounds Overview 
After a thorough analysis of each docking pose for this selected set of potentially domain selective 
ACEis, the most promising compound is unequivocally compound DM1. This compound has also 
revealed a very important chemical series as it supplies a versatile molecular framework with which 
to explore the P2 SAR of an ACEi. The second most promising series was series 4 but as already 
mentioned these compounds were unable to interact with Arg381/Glu403. At the same time natural 
products limit the synthetic options for probing P2 SAR. 
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Upon docking series 2 and 3, it is clear that neither series had much potential to interact with the S2 
subsite. Apart from their inability to access the S2 subsite, their bicyclic P2’ groups may be detrimental 
to N-domain selectivity ironically resulting in C-domain selectivity. As for the ungrouped molecules, 
DM11 and DM12 also contain bicyclic P2’ groups and DM13 contains a disulphide group with no novel 
leads regarding S2 interactions. 
Examining Table 5.3, the docking protocol appears to treat each ligand in one of three ways. A ligand 
can easily find a plausible pose in both domains, the N-domain only or the C-domain only. DM1, the 
compound with the most overtly N-domain selective motif easily found a plausible pose in the N-
domain but not the C-domain. The converse was observed with compound DM11, which carries a 
known C-domain selective P2’ bicyclic moiety. While this is not conclusive evidence of domain 
selectivity, it is an indication. The docking protocol ran into difficulty evaluating the poses of 
compounds with long entropically disordered chains (series 2) and compounds, which did not fit the 
binding pattern embedded into the crystal pose of the protein by native peptides or peptidomimetic 
ligands (Series 4). 
5.5.4 Potential for N-Domain Selectivity 
Since series 1 was overwhelmingly the most promising series, it warranted a closer look. Greenlee et 
al synthesised two series of ACEis using the Enalaprilat prime side scaffold of ZBG-NH-Ala-Pro-COOH 
scaffold.  Series 1 follows a R–Pro-ZBG-NH-Ala-Pro-COOH format and seven of these compounds are 
described in Appendix 5.1123. The groups attached were an acetyl, Benzyl, Gly, Phe, BnPhe and pGlu-
Lys. The seven compounds from this series did not match the 11 compounds reported to belong to 
this series in the GVK database. The four unaccounted compounds contained IC50 data matching 
compounds within this set. Upon closer inspection of the reported structures and a reconstruction of 
the synthetic scheme, it became clear that these four compounds were duplicates of compounds from 
the set of seven entered into the database using incorrect SMILES containing small errors.   
Comparing Greenlee’s reported structures and the rendered structures, it was easy to determine 
which structures where incorrectly reported (Table 5.4). Unfortunately, mined compounds DM1 and 
DM3 correspond to incorrect renderings of compounds 34 and 36 respectively from the Greenlee 
publication. Even more disconcerting is the fact that the most promising mined compound (DM1) is 
not a published compound as confirmed by SciFinder. The only additional mention of this compound 
was found in the BindingDB database again incorrectly recorded and referencing the same Greenlee 
paper.  
Table 5.4: An illustration comparing the correct entries as reported by Greenlee et al123 and  the incorrect renderings of these compounds found in the GVK database. The numbering scheme used is the same as in the cited paper. The incorrect entries 
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column compares the compounds synthesised (left) vs incorrect renderings of these compounds (right) found in the GVK database. 
 
Compound 
Number Correct Structure Incorrect Rendering 






5.5.5 The Improvisation of Series 1 
Despite the most promising hit from Series 1 not being a known compound, the R-Pro-ZBG-NH-Ala-
Pro-COOH still appears to be an excellent platform for probing S2 SAR of ACE. A simple peptide 
coupling can add a multitude of carboxylic acid containing groups including the acidic amino acids Glu 
and Asp. Coupling Glu and Asp to this scaffold would place a carboxylic acid in the ideal position to 
interact with Arg381/Glu403. Despite the failure of this database mining exercise to find a promising 
N-domain selective ACEi, it has found a promising new drug-like scaffold with which to probe the very 
SAR under investigation.  
Series 1 is an ideal example of a chemical series synthesised in the early days of ACEi development 
using an sACE competitive inhibition assay against the ZFHL substrate to measure ACE inhibition. Had 
crystal structures of the two domains been known back then, it is possible that a more comprehensive 
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SAR study in the S2 subsite would have been undertaken. The seven variants of Series 1 explored a 
very limited chemical space using P2 substitutions.  
The P2 SAR of this series is now understood to be key to probing the key interactions responsible for 
inducing N-domain selectivity. With just three compounds from this series docked, DM1 made a polar 
salt bridge interaction with Arg381 while showing a strong repulsion towards Glu403. DM2 appeared 
to form a favourable π-stacking interaction with Arg381 while the amine group of DM3 was positioned 
close enough to these residues to interact with these residues (Figure 5.5).  
 
Figure 5.5: An overlay of all the series 1 compounds docked into the N- (green) and C- domains (grey). The common backbone for each compound is held firmly in place with the central carboxylic acid ZBG and the P2' carboxylic acid H-bonding to the S2' subsite. All observed variation occurs in the P2 position where each group interacts differently with Arg381/Glu403. 
5.5.6 Concluding Remarks 
While finding an N-domain selective ACEi mining the GVK database was never guaranteed, it has 
provided an opportunity to rediscover older ACEi binding patterns. ACE is a special case since a vast 
database of inhibition data exists from decades of drug discovery research. Revisiting these archives 
in search of N-domain-selective inhibitors added much more stringent chemical parameters to the 
requirements of the inhibitor. A thorough search for the chemical signature responsible for N-domain 
selectivity was conducted and turned up a meagre 13 compounds with the potential to make polar 
contacts in the S2 subsite. Out of the 13, only one chemical series showed promise. 
Unfortunately, the best compound from series 1 (DM1) turned out to be an undocumented compound 
rendered as a result of an incorrectly archived entry in the GVK database. DM1 is structurally similar 
to two compounds which can be synthesised via simple modifications to the published synthetic 






P2 Salt Bridge 
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Chapter 6 – Synthesis of the Diprolyl Inhibitor Series 
6.1 Introduction 
6.1.1 Diproline Series 
The database mining protocol followed in Chapter 5 failed to identify potential N-domain selective 
ACE inhibitors. Despite the failure to find a potent N-domain-selective inhibitor, Greenlee’s diprolyl 
series (Figure 6.1) did show promise as reported.123 The original kinetic data and docking studies 
showed the diprolyl backbone to interact strongly with the S1, Zn, S1’ and S2’ subsites of both ACE 
domains. The last step in the synthesis of this series attaches a unique P2 group to the scaffold. 
Greenlee et al attached seven different groups to this position, none of which contained the requisite 
P2 acidic group required to selectively compromise C-domain binding. Following Greenlee’s synthetic 
approach (scheme 6.1), it seemed feasible to attach an acidic group at the P2 position in the last step 
of the synthesis. 
 
Figure 6.1: Greenlee et al’s diprolyl scaffold, an ideal molecular scaffold for exploring ACE S2 SAR.123 
The seven compounds in this series were tested in vitro using competitive ACE inhibition assays ( 
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Table 6.1).  It was from this series that the most promising compound DM1 was identified. As already 
mentioned, DM1 was shown to be the result of an erroneous entry of compound 34 in the GVK 
database. Despite the error, the diprolyl series appeared to be an ideal platform with which to probe 
SAR in and around the S2 subsite of ACE. This series provides a promising drug-like scaffold with which 
to exploit the Arg381/Glu403 mutation elucidated by Kroger et al77 in the crystal structure 3NXQ. 
6.1.2 Synthetic Scheme 
As discussed in Chapter 3, Enalaprilat is synthesised via the reductive amination of an α-keto acid and 
Ala-Pro using sodium cyanoborohydride. The diprolyl series was synthesised via an analogous scheme 
(Scheme 6.1). Scheme 6.1 modifies the reductive amination step used by Patchett et al113 coupling a 
Boc protected pyrolidine aldehyde to Ala-Pro in the presence of KCN. This step creates a new chiral 
centre around the introduced cyano group yielding equimolar quantities of the two diastereomers 
around the new chiral centre. The cyano group is then converted into an amide after which the 
unprotected amine is Boc protected. An acidic Amberlyst 15 ion exchange resin then converts the 
amide and the acid groups into methyl esters. The resulting product is the diproline scaffold with 
methyl ester protected acids. Seven different groups were added to the diprolyl amine via an amide 
coupling. The amide was formed using either N-hydroxy succinimide (HOSu) or N,N’-




































Scheme 6.1: An outline of the synthetic scheme by which Greenlee et al123 synthesised the diprolyl Series 1 
6.1.3 Revisiting the Series 
Of the seven compounds published in this series (Table 6.1), not all were relevant for studying 
Arg381/Glu403 interactions. In this set only compounds 32, 34 and 36 are of a suitable size to probe 
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the S2 subsite. Three compounds from this series were docked in Chapter 5, of which only DM2 was a 
published compound corresponding to compound 34. DM1 contains a urea group which is a chemical 
deviation from the published synthesis. DM3 can be synthesised using this scheme via the amide 
coupling of 4-amino benzoic acid to the scaffold. Docking simulations on these three compounds 
suggested Glu and Asp attachments to the scaffold could create a highly favourable interaction with 
Arg381/Glu403 residues. 
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Table 6.1: The three compounds extracted from the GVK database mining exercise (prefixed with DM) and the seven compounds in the Diprolyl series synthesised by Greenlee et al with the reported sACE IC50 and the original numbering from the paper. 
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While providing a strong platform for investigating S2 interactions, this scaffold is not particularly drug-
like. Two amide bonds together with an acid and amine terminus make this scaffold too peptidic. A 
strong hit from this series can always be modified at a later stage to better adapt into a true 
peptidomimetic. Another point of contention is the high level of chirality with up to five chiral centres 
present in these compounds. This level of chirality can create synthetic complications when it comes 
to obtaining absolute diastereomeric purity. Such chirality is characteristic of peptides and protease 
targets. As such, mimicking the chirality of this natural peptide is crucial for strong ACE inhibition.  
6.1.4 Competitive Inhibition Assay 
ACE inhibition assays have been performed since the 60s133. Since then, both protein expression and 
inhibition assays have seen considerable advancements. The first spectrophotometric assays 
measuring the rate of ACE hydrolysis on synthetic peptides were developed independently in the early 
70s by both Roth et al133 and Cushman et al128. Roth’s assay made use of a Cbz-Phe-His-Leu (ZFHL) 
substrate while Cushman’s assay used Hip-His-Leu (HHL). Cushman later went on to develop Captopril 
with Ondetti17 in 1977 hence the greater prevalence of HHL assays in the early days of ACEi research. 
Both ZFHL and HHL are N-terminal capped peptides with the same HL dipeptide product of ACE 
hydrolysis. The rate of hydrolysis for both substrates can be determined by quenching the reaction 
with NaOH after a fixed time interval and derivatising the product with O-pthaldehyde. The uncapped 
N-terminus of HL forms a fluorogenic complex under basic conditions while the concentration of this 
complex can be measured fluorometrically. Km values for HHL and ZFHL sACE hydrolysis are 2.6 mM 
and 40 μM respectively which are both suitable for competitive inhibition assays.133   
Since the elucidation of the two domains of ACE, the Km of HHL has been shown to be roughly 
equivalent in both domains while for ZFHL the Km of the N-domain is roughly five times that of the C-
domain at 0.93 and 0.18 mM respectively134. With the two domains assayed separately, no 
competitive hydrolysis is experienced between the two domains, hence the choice of substrate for 
assaying the two domains individually is irrelevant. 
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An alternative to these quenched fluorometric assays is a continuous fluorogenic assay developed by 
Araujo et al135 using the internally quenched Abz-FRK(Dnp)P-OH substrate. This substrate displays 
similar kinetic properties towards the two catalytic domains of ACE. Despite the benefits of a real-time 
assay, Abz-FRK(Dnp)P-OH is considerably more expensive than both ZFHL and HHL making them more 
appropriate for broad based inhibitor screening assays. 
6.2 Aims and Objectives 
6.2.1 Aim 
The aim of this chapter was to probe the P2 SAR of the Greenlee et al’s diprolyl series for N-domain 
selective ACE inhibition. 
6.2.2 Objectives 
 Design a series of diprolyl ACE inhibitors with different P2 groups. 
 Carry out molecular docking of the diprolyl series against the N- and C-domains of 
ACE. 
 Synthesise a small library of diprolyl derivatives using the approach of Greenlee et al. 
 Determine the IC50 values of all the compounds for the N- and C-domains of ACE. 
6.3 Methods 
6.3.1 Redocking and Expanding Dataset 
Compounds 32, 34 and 36 from the Greenlee publication were docked into the two catalytic domains 
of ACE using Glide XP with the C1 set of constraints and the docking grids created (Chapter 5; section 
5.3.2). Once satisfactory binding poses were determined, a search for chemical monomers with a 
potential for peptide coupling to the diprolyl scaffold were investigated. The availability, price and 
likelihood to induce a strong Arg381/Glu403 interaction were considered. A small VSAR set of 
compounds was constructed using some of these building blocks. New variations to this scaffold were 
then proposed, docked and evaluated.  
6.3.2 MM-GBSA Binding Energy Predictions 
Once satisfactory docking poses had been determined for each compound in the extended set, the 
binding energy of each pose was evaluated using the Prime MM-GBSA binding energy prediction 
protocol described in Chapter 3 with the calculation preceded by a minimisation of all residues within 
a 10 Å radius of the ligand.  
Using the predicted binding energy and final pose as a guide, binding hypotheses were made to predict 
the domain selectivity of each compound in this extended set. Considering these hypotheses, starting 
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material availability and chemical space representation, a final set of compounds was decided upon 
for synthesis.  
6.3.3 Diprolyl Series Synthesis 
The contract research organisation (CRO) Syngene International Ltd was contracted to synthesise a 
selection of compounds from the published diprolyl series and the additional modelled compounds. 
The compounds were synthesised via Scheme 6.1 as published by Greenlee et al. Each compound was 
separated into their respective diastereomers with each diastereomer pair unassigned for in vitro ACE 
competitive inhibition assays.  
6.3.4 Competitive Inhibition Assays 
ACE N- and C-domain competitive inhibition assays were performed using the ZFHL substrate to 
determine IC50s for each compound. The same assay described in Chapter 2 (section 2.3.5) was 
followed but with different inhibitor concentrations.  
Initially, each compound was screened against the two catalytic domains of ACE at concentrations of 
100 μM and 1 μM. Compounds displaying sub micromolar inhibitions were then screened in a 10-fold 
serial dilution series from 1 μM down to 1 nM. These serial dilutions identified the concentration range 
in which the IC50 for each compound could be found. 
Once an estimate of the IC50 had been made, a 2-fold serial dilution series of nine inhibitor 
concentrations was constructed spanning the range of the IC50 estimates. The remaining activity was 
plotted against the logarithmic inhibitor concentration and sigmoidal dose-response curves were 
fitted using the least squares algorithm with the removal of statistical outliers. Once the data was fit 
to a dose response curve within acceptable R2 parameters (R2 > 0.95), the IC50 was read off the curve 
(GraphPad Prism, v6.0). 
6.4 Results 
6.4.1 P2 Monomer Considerations 
Only three compounds published in the diprolyl series appeared capable of probing the S2 subsite of 
ACE. A search for additional RCO2H groups was conducted to find similar interactions. Some of the 
cheapest and most readily available R groups suitable for attachment to the scaffold were Boc and 
methyl ester protected Glu and Asp monomers. 4-Amino benzoic acid, the building block required to 
make DM2 was also readily available. Many different options for adding an acidic substitution to a P2 
benzyl ring were explored. 13 Compounds (Table 6.2) in the diprolyl series whose R-group were readily 
available were selected for further analysis. These compounds tested both standard amino acid 
monomers and non-peptidic moieties focussing on phenyl ring substitutions and varying chain lengths. 
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This set was kept small and probed only a few specific P2 variations to stay within reasonable time and 
cost constraints.  
 
Table 6.2: Proposed R groups and the corresponding protected RCO2H starting material required to attach to the diprolyl scaffold 
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4-methyl ester Benzylic acid 
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2-(3-phenyl methyl ester) 











6.4.2 Molecular Docking of Diprolyl Compounds into the N- and C-Domains 
The set of 13 compounds in the diprolyl series were docked into the N- and C-domains of ACE. Docking 
constraints C1 (Chapter 5; section 5.4.4) only found a plausible pose for 5/13 compounds in the C-
domain and 9/13 compounds in the N-domain. To improve consistency, a core docking constraint was 
employed. When docked using the C1 constraints system defined in Chapter 5, DPI5 displayed an 
idealised pose for the core scaffold in the C-domain while DPI1 displayed this idealised pose in the N-
domain. The docking was then repeated by setting the core scaffold in each compound to be held 
within a 1 Å RMSD tolerance of the core atoms of the chosen reference ligands. This restriction only 
permitted significant movement for the P2 region of each ligand as desired.  
Many of the compounds with P2 acids interacted with Arg381 at awkward or unnatural dihedral angles 
to which Glide assigned no docking score penalties. This is a clear work-around built into the rigid 
receptor model specifically designed to be lenient with interactions involving highly flexible residues 
like arginine and lysine. Minimisation can make small adjustments to the side-chains giving the ligand 
a better fit. The minimised complex is therefore a more suitable model for evaluating binding energy. 
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6.4.3 MM-GBSA Analysis and Interactions Between the Diprolyl Series and the Two 
Domains of ACE 
Prime MM-GBSA minimisation and binding energy predictions were performed to further guide the 
selection of compounds for synthesis. Minimised poses were evaluated and the binding energies were 
calculated to provide an additional metric with which to compare differential binding and establish a 
selection threshold to further reduce the set. 
Predicting differential binding between two targets is not a function for which docking software is 
explicitly designed. A docking algorithm is a minimisation protocol which converges on the most 
favourable pose for a ligand within a given system. Evaluating the binding energy of such poses only 
gives comparable predictions once the ligand has been relaxed and minimised within its binding site. 
Ligands with poor binding avoid certain interactions resulting in poses being hard to predict. If the 
pose cannot be predicted accurately, binding energy predictions hold no merit. This problem is 
exacerbated when the constraints used for docking force the compound into a position where it makes 
unfavourable and highly unlikely interactions with the protein, as was observed for some compounds 
docked into the C-domain. Such forced binding poses need to be evaluated qualitatively as 
quantitative binding energy predictions of such poses are meaningless.   
With the predictive power of these energy calculations for some of these systems in doubt, a 
qualitative selectivity hypothesis was introduced. The selectivity hypothesis predicts the domain 
selectivity of each compound based upon an analysis of the predicted pose for each ligand in their 
respective domain. The compounds were hypothesised to be either non domain-selective (NS) or N-
domain selective (N). C-domain selectivity was not predicted for any of the compounds. 
Some compounds are flagged as strained in the Arg381 distance and hypothesis columns. This flag 
indicates ligand strain when interacting with Arg381. In reality, this residue would likely reposition 
itself to a greater extent than what energy minimisations are capable of predicting. These ligands have 
had to force themselves into improbable and strained conformations disrupting the Arg381 salt bridge 
and weakening the overall N-domain binding. Conversely, the C-domain inhibition would probably 
receive a greater penalty as some of these compounds bring an acid even closer to Glu403. These 
compounds would therefore have a poor interaction with the C-domain while the introduced strain 
would also compromise the N-domain inhibition to a degree.  
Table 6.3 summarises the minimised docking poses, the MM-GBSA binding energy and selectivity 
hypothesis for each compound. The distance between each ligand and either Arg381 or Glu403 was 
measured to assess the likelihood of an interaction with these two residues. The strain of each pose 
Chapter 6   – Synthesis of the Diprolyl Inhibitor Series 
127  Stephen Fienberg – PhD Thesis 
was evaluated and then compared with the predicted ΔG of binding for each domain. The combination 
of predicted binding poses and binding energy helped to formulate the binding hypothesis. 
Compounds 32, 34 and 36 were all 3.5 Å or more away from Arg381 or Glu403, too far for a direct 
interaction. None of the docked poses for these three compounds were strained hence the predicted 
binding energies were valid. The binding energies of these three compounds were generally of the 
order of -50 kJ/mol or lower suggesting strong ligand binding against both domains.  
The compounds with P2 acid moieties (DP-Asp, DP-Glu, DPI1, DPI2, and DPI3) all docked with strained 
poses in the C-domain but showed relaxed poses forming salt-bridges with Arg381 in the N-domain. 
The ΔG of these five compounds were all calculated to be strong below -50 kJ/mol while the ΔG of its 
strained C-domain pose was often significantly higher than the N-domain ΔG. Due to the strained C-
domain poses of these compounds, the ΔG values cannot be considered accurate. The strong N-
domain binding predicted for these compounds coupled with a strained C-domain pose strongly 
suggested N-domain selectivity. Compounds DPI4, DPI5 and DPI6 produced strained docking poses in 
both domains as a consequence of their larger size. This suggested weaker binding in both domains of 
ACE. 
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Table 6.3: A summary of the docking and MM-GBSA predictions for the expanded diprolyl series. The measured distance between the nearest heavy atom of the ligand and a N from Arg381 in the N-domain or an O from Glu403 in the C-domain is given. Some of these interactions are described as either in plane with the Arg381 or forming a salt bridge while unnatural torsions are described as strained, crowded or cramped. Such descriptors indicate an implausible pose was created due to the strict docking constraints. The last column provides a selectivity hypothesis. Compounds are classed as either non-selective towards either domain (NS), N-domain selective (N), or N-domain selective but strained leading to an overall weaker interaction with both domains despite the N-domain selectivity. Binding energy values marked with an asterix (*) are those run using input ligand poses which were already implausible.  
Compound Arg381 distance Glu403 distance C ΔG (kJ/mol) N ΔG (kJ/mol) Hypothesis 
32 5.63 8.78 -47.14 -59.24 NS 
34 6.85  10.02 -52.14 -53.50 NS 
36 3.50 (In plane) 7.86 -82.72 -56.41 NS 
DP-Asp 2.64 (salt Bridge) 6.85 -51.57* -71.76 N 
DP-Glu 2.94 (Salt Bridge) 7.90 (Strained) -52.10* -70.32 N 
DPI1 2.71 (Salt Bridge) 4.85 -54.82* -51.62 N 
DPI2 2.82 (Salt bridge) 9.96 (Strained) -43.86* -62.44 N 
DPI3 2.89 (strained salt bridge) 6.50 (crowded) -39.55* -65.84 N 
DPI4 2.82 (Salt Bridge) 5.28 (crowded) -48.63* -70.40* N (strained) 
DPI5 2.89 (strained salt bridge) 6.85 (cramped) -53.82* -60.10* N (strained) 
DPI6 2.90 (Improbable salt bridge) 
9.68 (cramped) -34.90* -58.15* N (strained) 
DPI7 5.43 7.01 -62.94 -73.82 NS 
DPI8 6.37 (In plane) 6.88 -53.46 -53.88 NS 
 
Some of the poses described in Table 6.3 are illustrated in Figure 6.2. It is important to bear in mind 
that all N-domain docking simulations were performed using the 3NXQ crystal structure where Arg381 
is bent inwards to face the ligand and make a salt bridge contact with the said ligand. Ligands with no 
P2 acid lack the ability to draw this residue inwards. Since Glide does not allow protein flexibility, all 
compounds were therefore docked with Arg381 in this orientation. 
Figure 6.2A and 6.2B show the P2 phenyl group of compound 34 sitting snugly in the S2 pocket of both 
domains. The slight changes in orientation of this group between the domains is acceptable as there 
is sufficient space to move in this region allowing for the possibility of two conformers of similar 
energies to exist in this region. For compound DP_Glu docked into the N-domain (Figure 6.2C), this 
ligand easily makes contact with Arg381 while it is forced into an energetically strained position to 
avoid a contact with Glu403. In Figure 6.2E, the acid substituted phenyl of DP12 makes an ideal contact 
with Arg381 but is forced into a highly unfavourable dihedral angle around the indicated bond. Figures 
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6.2G and 6.2H show the ligand DPI4, which can make the required contact with Arg381 but only under 
a fair amount of steric strain on the benzylic acid group. Figure 6.2H shows that DPI4 makes another 
unfavourable interaction with Glu403 as it is forced into a strained conformation to avoid this residue 
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Table 6.1 and Figure 6.2 reinforce the notion that phenyl groups bind strongly to the S2 subsite. 
Coupling acidic residues Asp and Glu to the diprolyl scaffold creates favourable interactions with 
Arg381 and unfavourable interactions with Glu403. Of the substituted phenyls, it was shown that the 
introduction of an acid directly onto the phenyl group created a ligand of the ideal length to interact 
with both the Arg381 and Glu403. An extra C linker in this region as is seen in DPI4 appears to make 
the ligands too long resulting in a strained binding pose. Glu and Asp additions are good substituents 
to test the effect of different chain lengths interacting with the S2 subsite.  
6.4.4 Selection Criteria 
With insights from molecular modelling, a set of compounds most likely to yield an effective proof-of-
concept was selected for synthesis. Out of the 13 compounds in this set, only three have been 
previously documented. Two of the compounds require the addition of natural amino acid 
substituents while the remaining compounds require the attachment of unnatural amino acids.  
Table 6.4 shows the seven compounds selected for synthesis. It was crucial to resynthesise the 
published compounds (32, 34, and 36) as they could be compared against the published sACE 
inhibition. These compounds will also help test the domain selectivity hypotheses that have been 
made. DP-Glu and DP-Asp showed promising poses as a natural extension of the set attaching two 
additional standard amino acid residues. The substituted phenyls were also very important as they 
began to depart from the peptidic characteristics of the scaffold in the search for more drug-like 
compounds.  
Rather than synthesise all 13 compounds, the initial focus was testing the hypothesis around 
compounds in Table 6.3 with a representative sample size. Priority was therefore given to compounds 
32, 34, 36, DP-Asp and DP-Glu. Two substitutions to the phenyl ring of compound 32 were selected to 
begin investigating this chemical space. DPI1 and DPI7 were chosen to test the opposing amino- and 
carboxy-4-phenyl substitutions. The final series chosen is shown in Table 6.4. For ease of reference, 
each selected compound was assigned a code SG1-SG7 for the purpose of the synthesis. 
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Table 6.4: A summary of the final chosen series and its renaming of the final series before its synthesis 
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6.4.5 Diprolyl Synthesis 
 
Scheme 6.2:  i. TMSCN, MeOH/NH4+Cl-, 25 °C 36h, 36% ii. a. HCl in MeOH, 25 °C, 2d. b. (Boc)2O, Et3N/MeOH, 72% iii. a. Amberlyst 15, MeOH, 60°C, 10 days b. HCl/Dioxane 25 °C, 12hr, 40% iv. a. RCO2H, T3P, Et3N, DCM, 0 °C – 25 °C b. LiOH, THF/H2O, (c. HCl/Dioxane) 
Seven compounds were synthesised via Scheme 6.2. Reaction i was first attempted using KCN in a 
AcOH/MeOH solvent as published by Greenlee. Replacing KCN with TMSCN in a NH4Cl/MeOH solvent 
returned superior yields and quicker reaction times. This reaction delivered a diastereomeric mixture 
around the newly introduced chiral carbon to which the cyano group is attached. Reaction ii converted 
the cyano group to an amido group after reacting compound 3 in saturated HCl/MeOH at 25 °C for 
two days. The crude product 6 formed in a 4:1 ratio with a side-product. This side-product was 
removed using silica chromatography. In reaction iii, compound 6 was loaded onto the acidic 
amberlyst-15 resin in MeOH for 10 days. The compound was then eluted from the resin with 0.25 M 
Et3N in MeOH. Once eluted, compound 7 was deprotected using HCl in dioxane at 25 °C for 12 hours 
to yield compound 7. 
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Compound 7 branched off into seven different compounds. The RCOOH groups (Table 6.4) were each 
coupled to the core scaffold using a propylphosphonic anhydride (T3P) coupling reagent. 
Diastereomers were separated via Chiral Prep-HPLC. The diastereomer separation was performed 
before the deprotection at the compound 8 stage of the synthesis. This was due to the final 
compounds all being extremely polar giving them inadequately short retention times on a C-18 
stationary phase. Once separated, these diastereomers were deprotected first using LiOH in 
THF/MeOH/H2O to hydrolyse the esters then HCl in dioxane if the R-COOH group contained a Boc 
protected amine. These final products were each purified via Prep-HPLC. 
6.4.6 Diastereomer Separation 
Successful diastereomer separations were achieved using HPLC with a reverse phase C-18 chiral 
column. The separation was performed at the penultimate stage of the scheme where the compounds 
had the ideal retention time for an effective separation in a water/MeCN mobile phase.  
Theoretically, the diastereomerism created in reaction i should yield both diastereomers in equal 
quantities but the ratios were difficult to gauge with such close peaks. Figure 6.3 shows the HPLC 
readout from the protected form of compound SG1 at the compound 8 stage of scheme 6.1. It shows 
a clear example of an HPLC chromatogram before and after diastereomer separation. The unseparated 
mixture (Figure 6.3a) shows the two diastereomers of the compounds as a split peak with retention 
times of 8.661 and 8.814 minutes respectively. There is a fair amount of overlap at the base of these 
peaks. Figure 6.3B and 6.3C show the purified diastereomers with their own sharp peaks and similar 
but slightly different retention times of 7.957 and 8.269 minutes respectively. 
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Figure 6.3:The HPLC chromatograms for the separation of the two diastereomers of SG1. Before the separation (A), two sharp peaks are visibly overlapping on account of the diastereomeric mixture. The subsequent HPLC runs show the separated disastereomers run on the same method with individual peaks and retention times comparable to the mixture in A. 
While a separated diastereomer may appear clean on HPLC, 1H NMR is a more sensitive method for 
evaluating the diastereomeric purity of a compound. The methyl peak from this series often showed 
a clear duplication with a smaller copy of itself. Figure 6.4 shows an example of a peak duplication. 
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of Figure 6.4, the minor peak constitutes 13% of the total combined area with the remainder belonging 
to the other diastereomer. 
 
Figure 6.4: A duplicated methyl 1H NMR doublet peak from the 1H NMR spectrum of SG4_1. 
Table 6.5 summarises the yields and diasteremeric purity of each compound at the compound 8 stage 
of the synthesis where the diastereomer separation was performed. It is important to note that the 
diastereomers were not assigned and both the SRSS and SSSS diastereomers were later deprotected 
and purified. The final yields varied greatly depending on the success of the separation. The highest 
yielding separation was achieved in the case of SG6 with 38% of the original mass recovered in 
diastereomer 1 and 50% recovered in diastereomer 2. Cumulatively, 88% of the original mixture was 
recovered in this case. SG2 separated poorly with 17% of the total mixture recovered in diastereomer 
1 and 22% recovered in diastereomer 2. In this case only 39% of the original mixture was recovered. 
The protected form of each compound is referred to as SGX-8 to indicate the protected compound 8 
of this scheme. 
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From here on, the compounds were named as either SGX_1 or SGX_2 indicating the chronological 
order in which they eluted during the separation. This assignment is arbitrary as the two 
diastereomers were not yet assigned. According to Greenlee’s study, the SSSS diastereomer displays 
an IC50 2-3 orders of magnitude lower than the SRSS diastereomer in each instance. The ACE inhibition 
assays were therefore performed on both diastereomers allowing for them to be assigned according 
to their differential ACE inhibition.  Comparing the activity between the two diastereomers, a vastly 
superior ACE inhibition by one diastereomer would be expected over the other. 
6.4.7 Characterisation of Diprolyl Series 
Post separation, the SGX-8 compounds were deprotected then purified on the Prep-HPLC. The purity 
of these compounds was then analysed via HPLC, LC-MS and 1H-NMR. The diprolyl series is highly 
analogous hence all the spectra shared the same core 1H NMR peaks. All compounds with the 
exception of SG3_1 were recovered with a purity above 95% with their mass verified via LC-MS. For 
the purpose of analysing the 1H NMR spectra of the series, SG4 has been selected as a representative 
example.  
The 1H shifts (Figure 6.5) for this series are characterised by a doublet peak (J = 7.0 Hz) at a shift of 
1.40-1.50 ppm corresponding to methyl protons H-16. This doublet is duplicated with a much smaller 
peak. This smaller peak appears to belong to the other diastereomer which is present in small 
quantities after the separation. 86% of the combined area of the two peaks belongs to the larger major 
peak. Three broad multiplets are found with shifts in the 1.75-2.25 ppm range. These broad multiplets 
are consistent with constrained alkyl protons found in the two pyrolidine rings. These three peaks 
integrate for 8 protons cumulatively and correspond with protons H-2, H-3, H-8 and H-9. Compounds 
with a full amino acid residue in the P2 position introduced a chiral centre with two diastereotopic 
protons on the β-carbon of this residue. In the case of SG4, protons H-12a and H-12b are 
diastereotopic and correspond to a symmetrical pair of doublets of doublets (J = 14.7, 5.5 Hz) and (J = 
14.8, 7.8 Hz) at the respective shifts of 3.06 and 3.23 ppm. Further downfield two additional broad 
multiplets can be seen at 3.47 and 3.64 ppm corresponding to the deshielded cycloalkyl protons of H-
10 and H-1 respectively, both found on C atoms adjacent to the N atoms. A doublet at 3.82 ppm (J = 
4.4 Hz) corresponds to the proton H-6. This proton is attached to the chiral carbon from which the two 
diastereomers in this system originate. In the SG4_2 diastereomer, the coupling value changes from 
4.4 Hz to 5.8 Hz. These two coupling constants suggest different through space environments for H-6 
and H-7 as expected in the two diastereomers.  
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Two of the remaining H-4, and H-7 protons are bonded to chiral carbons on similar alkyl rings in almost 
identical environments. These protons therefore share a broad multiplet peak overlapping with the 
expected quartet of H-5. The multiplet at 4.36 ppm therefore corresponds to the overlapping peaks 
of these 3 protons. The triplet (J = 7.6 Hz) at 4.51 ppm corresponds to proton H-11. The two downfield 
multiplets at 7.25 and 7.32 ppm integrate for two and three protons respectively. These five aromatic 
protons can be unambiguously assigned to the aromatic phenyl group.  
Despite slight variations in the peak shifts, all compounds showed the same set of core peaks 
corresponding to the shared core structure. Chiral P2 groups all showed the distinctive pair of doublets 
of doublets while 4 or 5 protons were observed in the aromatic region depending on the aromatic 
group. A crucial feature of these spectra are the chiral peaks seen at H-6 with contrasting J-values.  
 
 
Figure 6.5: 1H NMR spectrum of SG4_1 
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6.4.8 Determination of Binding Affinities for the Diprolyl Derivatives 
An initial inhibition screen was performed for each compound at concentrations of 100 μM and 1 μM 
where all but one compound displayed strong to moderate inhibition of the two domains of ACE at 1 
μM. SG6_1 showed no inhibition of the C-domain at 1 μM and only moderate inhibition of the N-
domain at this concentration. SG6 was immediately flagged as a potentially N-domain selective 
compound. Sub-micromolar inhibition for almost all compounds in the initial screen served as a 
secondary validation of both the assay conditions and the high purity of the compounds. 
IC50 values were determined in a 2-fold serial dilution series of the inhibitor spanning the activity range. 
Each dataset was successfully fitted to a dose response curve with R2 > 0.95 using Graphpad Prism. 
Dose-response curves of all inhibitors against both ACE domains are given in Appendix 6.1. Figure 6.6 
shows an example of a dose-response curve from the set.  
 
Figure 6.6: The dose response curve used to determine the IC50 of a compound. Normalised activity is plotted against the log of the inhibitor concentration. These data-points are fitted against a sigmoidal dose-response curve and the IC50 is read as the point of inflection where the curve passes the midway point between the top and bottom plateaux. 
Table 6.6 lists the IC50 values measured for each compound against the two catalytic domains of ACE. 
In the absence of any NMR-based diastereomer assignment, both diastereomers were tested with 
each compound. In the case of SG3, only the second diastereomer was tested as it was the only 
diastereomer recovered. Competitive ACE inhibition assays are a reliable method for assigning these 
two diastereomers. Greenlee et al123 observed a roughly 200-fold difference in ACE inhibition activity 
between between (S)SSSS and (S)SRSS diastereomers of each compound in this series using the same 
ZFHL substrate but with the full sACE enzyme. In this study, a roughly two order of magnitude 
difference in IC50 values was observed between each diastereomeric pair agreeing with the values 
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cited by Greenlee et al. This allowed the diastereomers to be unambiguously assigned. In the case of 
SG3, the only diastereomer tested appeared to be the active one. 
The Kis were calculated from the IC50s using equation 6.1. [S] is the substrate concentration which was 
set at a constant 1 mM for all assays. The Km of ZFHL was measured at 0.93 and 0.18 mM for the N- 
and C-domain respectively.134 These Kis are directly related to the strength of the protein-ligand 
interaction, hence the Ki of each compound determined for the individual domain was calculated and 
compared with the selectivity factor defined as the C-domain Ki/N-domain Ki.  
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K =  IC
1 − SK
 (6.1) 














SG1_1 9 nM 4.34 nM 2 nM 0.3 nM 0.07 SSSS 
SG1_2 294 nM 142 nM 133 nM 20 nM 0.14 SRSS 
SG2_1 336 nM 162 nM 634 nM 97 nM 0.60 SRSS 
 SG2_2 35 nM 19 nM 15 nM 2 nM 0.14 SSSS 
SG3_2 7 nM 3 nM 1 nM 0.15 nM 0.05 SSSS 
SG4_1 580 nM 279 nM 311 nM 47 nM 0.17 SSSSS 
SG4_2 1.1 μM 530 nM 831 nM 127 nM 0.24 SSRSS 
SG5_1 146 nM 70 nM 1.1 μM 168 nM 2.39 SSSSS 
SG5_2 816 nM 393 nM 1.5 μM 229 nM 0.58 SSRSS 
SG6_1 3.3 μM 1.59 μM > 100 μM - - SSRSS 
SG6_2 24 nM 12 nM 6.3 μM 961 nM 83.10 SSSSS 
SG7_1 1.7 μM 819 nM 3.0 μM 458 nM 0.56 SSRSS 
SG7_2 20 nM 10 nM 114 nM 17 nM 1.80 SSSSS 
 
6.4.9 Domain Selectivity 
The selectivity factors based on the measured Kis can now be compared with the selectivity 
hypotheses. This comparison is important for validating the interpretation of the docking model. By 
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and large, these predictions held true with a few exceptions. Compounds SG1, SG3, SG4 and SG5 were 
predicted to be non-domain selective (Table 6.7) and judging by the measured selectivity factors 
ranging from 0.05 – 2.39, this appears to be largely accurate. Ki is an exponential quantity and is best 
compared on a log scale, hence selectivity factors of 0.1-10 are trivial. Compounds with selectivity 
factors in this range are therefore not domain-selective. SG1_1 and SG3 showed selectivity factors of 
0.07 and 0.05 respectively, these would appear to be marginally C-domain selective but this selectivity 
may be deemed negligible due to experimental uncertainty. 
SG2 was predicted to be N-domain selective yet, surprisingly, SG2_2 proved a potent inhibitor of both 
domains without any significant difference in inhibition between the two domains (Ki = 19 and 2 nM 
for the N- and C-domains respectively). Both diastereomers of SG6 were strongly N-domain selective. 
The selectivity factor of SG6_2 (SSSSS) was measured at 83 while that of SG6_1 (SSRSS) could not be 
measured as no C-domain inhibition was observed at concentrations below 100 μM. SG7 was 
expected to have a similar N-domain selectivity to SG6 but none was observed.  
Table 6.7: Summary of hypothesised domain selectivity vs the observed domain selectivity (NS = non-selective). 
Compound Selectivity Hypothesis Observed Selectivity 
SG1 NS, strong inhibition NS, strong inhibition 
SG2 N-selective NS, strong inhibition 
SG3 NS, strong inhibition NS, strong inhibition 
SG4 NS, strong inhibition NS, moderate inhibition 
SG5 NS, strong inhibition NS, moderate inhibition 
SG6 N-Selective Strongly N-Selective 
SG7 N-Selective NS 
 
6.5 Discussion 
6.5.1 Series Prioritisation 
The database mining exercise proved more complicated than expected. Instead of finding promising 
hits for in vitro testing, the best compound appeared to originate from an incorrect database entry. 
Despite the error, the parent diprolyl series appeared to hold great promise for exploring the P2 SAR 
of ACE inhibitors. A closer examination of the parent diprolyl series was performed leading to an 
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alternative approach involving the attachment of acidic amino acid residues onto the P2 position of 
the scaffold. The docking results for both DP-Glu and DP-Asp were promising as the acid interacted 
with Arg381 in the N-domain, but compromised C-domain binding. DP-Glu and DP-Asp dock in a 
manner reminiscent of RXP407 (Figure 6.7). 
RXP407 shares a P2 acidic group with DP-Glu and DP-Asp but its terminal amine is acetylated. RXP407 
was synthesised alongside a non-acetylated equivalent compound III56. The acetylation weakened the 
C-domain Ki 30-fold from 800 nM to 25 μM while the N-domain Ki only experienced a 5-fold drop from 
5 nM to 25 nM. It is therefore plausible that the positively charged amine lowers the charge separation 
in that region of the molecule negating the clash of two negatively charged species to a degree. 
Acetylating this amine prevents a positive charge from forming, concentrating the negative charge 
and polarity at this end of the molecule. Greater charge polarisation would create a harsher binding 
penalty from a stronger electrostatic clash. The amine group of DP-Asp is in the same position as 
RXP407 with the common Asp making a salt bridge with Arg381. DP-Glu still makes these two 
interactions but with a different orientation around the P2 C-α. The effect of this different P2 
conformation is not yet clear. 
 
Figure 6.7: An overlay of the docked poses of DP-Asp and the crystal pose of RXP407 in the N-domain. 
As promising as DP-Asp and DP-Glu appear to be, they are still peptidic in nature. A major objective 
of this project was to design more drug-like N-domain selective ACE inhibitors than RXP407. These 
two compounds have a significantly reduced MW over RXP407, fewer bulky side-chains and lack the 
phosphinic acid, a major obstacle to cell permeability. These two compounds however, still contain 
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something more artificial and better customised to complement the unique S2 subsite of ACE would 
be preferable. 
Substitutions on the P2 phenyl ring of compound 32 (Table 6.4) could be the first step in exploring a 
more drug-like chemical space with this SAR study. Docking studies suggested a carboxylic acid 
substitution directly onto the phenyl ring of 32 would have a high chance of making a salt bridge with 
Arg381. The rigid receptor dock was promising for both the meta and para substituted phenyl group 
but a choice had to be made and the para position was chosen due to a more readily available starting 
material.  
6.5.2 Diprolyl Synthesis 
The synthetic scheme reported by Greenlee et al was challenging as it required a difficult diastereomer 
separation. For the most part this published scheme was followed. A few minor changes were made 
as some of the reactions have been updated over the years (Scheme 6.2). Reaction i is a good example 
as Greenlee et al introduced a cyano group using KCN in an acetic acid and MeOH solvent. This reaction 
was greatly improved by replacing KCN with TMSCN in NH4Cl/MeOH. 
Reactions ii and iii were easily reproduced but a different amide coupling reaction was implemented 
for reaction iv. In the reference, the R-group amino acids were first activated using N-hydroxy 
succinimide and then mixed with the diprolyl scaffold in an Et3N/DCM solution to complete the amide 
coupling. T3P was chosen as the preferred coupling reagent in this reaction and in many reactions the 
yields showed a marked improvement over the referenced conditions. 
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Scheme 6.2: i. TMSCN, MeOH/NH4+Cl-, RT 36h, 36% ii. a. HCl in MeOH, 25 °C, 2d. b. (Boc)2O, Et3N/MeOH, 72% iii. a. Amberlyst 15, MeOH, 60°C, 10 days b. HCl/Dioxane 25 °C, 12hr, 40% iv. a. RCO2H, T3P, Et3N, DCM, 0 °C – 25 °C b. LiOH, THF/H2O, (c. HCl/Dioxane) 
6.5.3 Diastereomer separation 
The most challenging aspect of this synthesis was the diastereomer separation. Each compound from 
the diprolyl series contained either four or five chiral centres. The first two chiral centres originate 
from the natural optically pure amino acids, LAla and LPro. Reaction i introduces a third chiral centre 
producing both the R and S configurations in equimolar quantities. Studies on analogous Enalaprilat 
and Lisinopril ACEis have demonstrated that the S configuration around this centre is preferable for 
ACE ihibition.113 The fourth chiral centre is then introduced when the R group is an amino acid in the 
natural S configuration. 
The two diastereomers predicted were observed with compound 3 as observed by its twin peaks on 
the HPLC chromatogram. Assigning the two diastereomers spectroscopically is more challenging than 
identifying their presence. Greenlee et al assigned them by converting compound 3 into bicyclic ureas 
and comparing the 1H NMR J-values between Ha and Hb (Figure 6.8). Today improved NMR technology 
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with 2D NOESY techniques and QM predictions are often used alternatively. Fortunately, there is a 
third method mentioned by Greenlee et al.  
 
Figure 6.8: Bicyclic ureas synthesised by Greenlee et al for the purpose of diastereomer assignment via 1H NMR. 
Greenlee et al observed an average 200-fold decrease in ACE inhibition between the SSSS and the 
SRSS diastereomers during the development of the analogous Lisinopril and Enalaprilat ACEis. For 
practical reasons the enzyme assay method was chosen as the favoured method for assigning the two 
diastereomers. Relying on the enzyme inhibition assays to assign the diastereomers was not just the 
easiest method for assigning the diastereomers but also removed the possibility of omit incorrectly 
assigning the compound.  
Another point of deviation from the scheme was the stage at which the diastereomers were 
separated. Greenlee et al separated the diastereomers at the compound 6 stage of the synthesis using 
normal phase medium pressure liquid chromatography (MPLC). 
Diastereomer separation was first attempted at the compound 6 stage using a chiral HPLC column. 
Although the retention time of compound 6 was good, the peak separation was poor. The compound 
8 stage of the synthesis proved favourable over compound 6 for diastereomer separations. Superior 
separations were observed with larger molecules and longer retention times.  
6.5.4 Domain Selectivity of the Diprolyl Series 
The reported 200-fold difference in IC50 between (S)SSSS and (S)SRSS diastereomers is consistent with 
the Ki values reported in Table 6.6. Since two different enzyme constructs were used for the two 
domains, it is more appropriate to compare N- and C-domain inhibition using the Ki metric. Despite 
the exceptions of SG4 and SG5, a roughly two order of magnitude difference in Ki was observed across 
this set of inhibitors between the two stereoisomers separated for each compound. SG1_1, SG4_1 
and SG5_1 correspond with compounds 32, 36 and 34 from the Greenlee et al paper respectively. The 
Ki values of SG1_1 were calculated at 4 and 0.3 nM for the N- and C-domain respectively. These values 
corroborate with the low nanomolar IC50 reported by Greenlee. The Ki values of SG4_1 were a bit 
higher than what would be expected from the Greenlee’s values but not alarmingly so.  
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Of the compounds added to this set, SG3 was predicted to be a strong non-selective inhibitor of both 
domains. The 4-amino benzyl moiety served as a counterexample of the acid dependent selectivity 
hypothesis. It was predicted that when presented with this 4-amino benzyl moiety, Arg381 would 
swing away from the ligand allowing it to settle comfortably. Despite only recovering one 
diastereomer of this compound, the recovered diastereomer appears to be the favoured one. As 
predicted, SG3 proved to be a potent inhibitor of both ACE domains with a 20-fold selectivity towards 
the C-domain while the N-domain Ki is still potent at 3 nM. 
SG2 was predicted to be N-domain selective. Docking simulations showed the 4-carboxyl phenyl 
moiety easily formed a strong interaction with Arg381 while in the C-domain it appeared trapped in a 
position proximal to Glu403. The lack of observed N-domain selectivity suggests a shortcoming in this 
docking model. A possible explanation is the shielding of an unfavourable interaction between the P2 
acid and Glu403 by an unexpected residue. Another possibility is the ligand finding a lower energy 
conformation violating the constraints. Such a conformation could shield the compound from an 
unfavourable interaction between these two acids.  
In contrast to the lack of domain selectivity observed with SG2 and SG7, SG6 behaved exactly as 
predicted. SG6 binds strongly to the N-domain while unfavourable interactions between the P2 acid 
and Glu403 compromises the C-domain binding with a high 83-fold Ki penalty in line with the 
predictions.  
The respective Asp and Glu groups of SG6 and SG7 differ from each other by a single alkyl carbon. 
RXP407 contains an Asp residue in the same position as SG6 and is of a similar length. Comparing the 
docked poses of SG6 and SG7, both compounds make a salt-bridge with Arg381 while a strong N-
domain interaction was observed. When it comes to disrupting the unfavourable interaction with 
Glu403, an extra alkyl carbon adds an additional torsional degree of freedom to the ligand. This extra 
degree of freedom could possibly allow the ligand to find a new conformation shielding this acid from 
Glu403.  
Figure 6.9 provides a direct comparison between the predicted poses of SG6 and SG7 docked into the 
C-domain. The additional strain experienced by SG7 to avoid a contact with Glu403 was thought to 
contribute to the unfavourable interaction with Glu403. In reality, the extra carbon in the chain 
appears to have enabled the ligand to find a new pose shielding it from this unfavourable interaction. 
The failure to predict this behaviour is a shortcoming of the rigid receptor model. A minimisation of a 
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greater portion of the protein or dynamics simulation would have improved the chances of predicting 
such behaviour.  
  
Figure 6.9: A side by side comparison of SG6 (left) and SG7 (right) docked into the C-domain of ACE. The raised energy pose experienced in the P2 region is a result of an unfavourable interaction with Glu403. 
The strong inhibition displayed by this set of compounds and the discovery of a novel N-domain 
selective ACEi makes a compelling case for the expansion of this set to include all the ligands docked 
against the two ACE domains. Expanding the SAR series would improve the approximation of the 
chemical space in which N-domain selectivity can be expected. In addition to defining this chemical 
space, crystal structures would help explain the interactions responsible for the N-domain selectivity 
of SG6 and the lack thereof observed in SG2 and SG7. 
Despite only SG6 showing the desired domain selectivity, a direct comparison between the inhibition 
of SG6 and SG7 provides invaluable SAR data. These two compounds have elucidated an important 
structural aspect of N-domain selective ACE inhibition. Cocrystalising these two ligands with the C-
domain would confirm these assertions and improve the ability of this model to predict domain 
selectivity. 
The database mining and subsequent docking, synthesis and in vitro assays produced one success in 
the form of SG6. While SG6 is certainly less peptidic than RXP407, it still contains two peptide bonds 
and three carboxylic acids. In a similar manner to most ACEis, one or two of these acids can be 
esterified into a prodrug. The P1 pyrolidine and amine bond can be altered without too much difficulty. 
Aromatising this pyrolidine would remove a stereo centre and could facilitate the replacement of the 
second amide bond. While SG6 does not appear to be drug-like, it is a step closer to a peptidomimetic 
compound than RXP407 and provides a suitable platform from which a more drug-like compound can 
be derived. 
6.5.5 Concluding Remarks 
This chapter demonstrates an example of the disconnect, which still exists between the predictive 
power of the ACE docking model and what one can expect to observe in vitro. While docking can be a 
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great aid in lead optimisation and SAR studies, when applied to N-domain selective ACE inhibition 
there were some caveats. The dual-domain and off-target docking was able to correctly predict one 
N-domain selective inhibitor but incorrectly suggested two additional compounds. These results 
reinforce the notion that N-domain selective ACE inhibition exists within a small and precise chemical 
space. The comparative docking model can help approximate this space but not pinpoint it. A more 
extensive SAR series introducing more variety in this P2 region would help to better define this 
chemical space while this diprolyl series has been shown to be an ideal scaffold with which to probe 
this SAR. 
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Chapter 7 – Summary, Conclusions and Recommendations for 
Future Work 
7.1 Premise 
A well-established drug target such as ACE is an unlikely novel therapeutic target. The elucidation of 
the dual-domain structure of ACE has revealed a more intricate synergistic relationship between the 
two catalytic domains of ACE. 
The collection of high resolution crystal structures for the two domains of ACE and the availability of 
powerful molecular modelling software provided a unique opportunity to develop drug-like N-domain 
selective ACE inhibitors using CADD software. 
7.2 Summary 
7.2.1 Docking Constraints 
Since docking simulations form the foundation of most CADD protocols, it was important to find 
docking conditions capable of accurately reproducing plausible ligand poses given this challenging 
metalloprotease binding site. The two most important ACEi interactions have been identified as the 
Zinc chelation and a polar hydrogen bonding interaction between the P2’ acid and S2’ donors. 
Introducing docking constraints to fix these two interactions allowed for the recreation of the ACEi 
poses observed in crystal structures, thus demonstrating the docking protocol to be capable of 
predicting the binding pose of an ACEi. 
With a constrained docking system against the two catalytic domains successfully validated, a CADD 
approach was devised. Constrained docking formed the basis of three CADD approaches that were 
devised to maximise the chances of finding an N-domain selective ACEi. 
7.2.2 Fragment-Based Screening 
A fragment-based approach was attempted in order to find novel inhibitors beyond the known ACEi 
chemical space. This set of fragments was restricted to compounds containing metal-binding groups 
to maximise its chances of finding hits.  
Following a standard fragment docking procedure, two potential hits were identified with IC50 values 
in the 500 µM range. Despite the inhibition, these two compounds produced no lead on domain 
selectivity. This lack of selectivity was attributed to the highly homologous domains. The interactions 
responsible for domain selectivity were too specific to be found in a set of 16 000 compounds. Two 
borderline inhibitors were identified from a set of 60 that were tested. This is usually an acceptable 
outcome for a fragment screen where weak fragment inhibitors are built into stronger drug-sized 
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inhibitors. The absence of a lead on domain selectivity coupled with the availability of many potent 
sACE inhibitors meant closer attention was paid to the structural features of existing ACEis.  
7.2.3 Combinatorial Library Screening 
In response to the failure of the fragment screen to find an N-domain selective ACEi, a de novo 
approach was devised to better utilise the existing clinical ACEis, some of which are highly potent. 
Enalaprilat was deemed the simplest ACEi from which Arg381 in the S2 subsite is accessible. The non-
prime side of Enalaprilat was deconstructed to replace the phenyl group with a large range of acidic 
moieties and alkyl linkers of variable length extending into the S2 subsite. A library of Enalaprilat 
analogues was generated and docked against both domains. Many compounds from the library 
showed promise following docking and binding energy calculations. These results prompted the 
progression from modelling these Enalaprilat analogues to synthesising them. 
Despite difficulties with diastereomerism and racemisation, one Enalaprilat analogue, SF07 was 
synthesised and found to be N-domain selective. This is an encouraging result and warrants further 
investigation into the structural causes of this observed N-domain selectivity. 
7.2.4 ACEi Database Mining 
The search for novel N-domain selective ACEi provided an opportunity to explore the extensive 
archives of sACE inhibitors. Almost 25 000 ACEis were extracted from the GVK database and 
investigated for potential selectivity towards either domain.  Several structure filters were applied to 
the database to reduce the dataset to a smaller set of drug-like compounds. After applying these filters 
and manually inspecting the best 1800 compounds, one chemical series in particular stood out. This 
series of diprolyl compounds synthesised by Greenlee et al contains a carboxylic acid ZBG coupled 
with an Ala-Pro in the P1’-P2’ position and a pseudo-pro P1 moiety. Attached to this scaffold is a variable 
P2 group, the exact position being probed for N-domain selectivity. 
This series was modelled using the same constrained docking protocol developed for the fragment-
based docking. Docking studies suggested this series to be an excellent platform from which to probe 
interactions with the S2 subsite. The synthesis of this series was deconstructed and four additional P2 
groups were added to the series and modelled accordingly. Seven of the best compounds were then 
synthesised and tested in vitro. One of the seven compounds (SG6) was shown to have an 88-fold Ki 
selectivity towards the N-domain of ACE, thus validating the predictive power of this docking protocol.  
7.3 Conclusion 
This project has developed a constrained docking model capable of accurately reproducing the poses 
of ACE ligands inside the binding site. Applying constraints to fix the position of metal-chelator pairs 
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helped to overcome previously reported problems originating from poorly approximated metal 
chelation interactions. Docking constraints fixing a specified chelating group in a position proximal to 
the Zn atom proved capable of reproducing the natural pose. However, each set of docking constraints 
needed to be optimised for a given chemical series leaving them unsuitable for screening a large 
database of varied ligands. This constrained docking protocol formed the foundation of all three CADD 
techniques attempted in this project. 
Docking played a vital role in predicting the poses for each CADD method attempted. In the fragment 
screen, docking provided plausible poses for every compound examined. Constrained docking then 
provided a simple yet elegant method for examining the docked poses of the Enalaprilat. It helped to 
identify ligands which were likely to bind to ACE selectively compared to those which failed to fit into 
the binding site. Lastly, constrained docking helped to predict the binding pose of many archival ACEis. 
A potent series of ACEis with a variable P2 group was identified as a promising scaffold with which to 
explore N-domain selectivity.  
Validation of the CADD methodology was only possible with the in vitro inhibition assays. While the 
fragment-based screening procedure proved capable of finding weak ACEi fragments, it failed to find 
a domain selective inhibitor. However, it is also likely that such a fragment was never present in the 
screening database. Many N-domain selective Enalaprilat analogues were predicted but only one such 
analogue was successfully synthesisedand shown to be N-domain selective. A few selective P2 SAR 
manipulations to the diprolyl series identified during GVK database mining yielded another N-domain 
selective drug-like ACEi.  
This project has achieved its primary objective of designing N-domain selective drug-like ACE inhibitors 
with SF07 and SG6. These two compounds are similar in structure and are the products of two 
different CADD approaches centred around constrained docking. The success of these two techniques 
emphasise the initial assertion that high resolution crystal structures and modern docking software 
can make accurate ligand-binding predictions, which have been utilised to achieve the goal of 
designing novel N-domain selective drug-like ACEis. 
 
Figure 7.1: SF07 and SG6 
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7.4 Future Work 
The discovery of an N-domain selective ACEi from the synthesis of just one Enalaprilat analogue 
emphasises the need to explore both the P1 and P2 SAR of Enalaprilat analogues. Scheme 4.1 will need 
to be modified to avoid the hydrolysis of the methyl ester and avoid the racemisation in the final step. 
As suggested, a Bn ester protecting group deprotected through hydrogenation is a possibility. The 
diprolyl series also returned an N-domain selective ACEi. The N-domain selectivity of SG6 also justifies 
the synthesis of a more comprehensive SAR series.  
Apart from a full SAR investigation of these two similar drug-like ACEi scaffolds, there are structural 
questions about the interactions between these ligands and the receptor which need to be answered. 
Crystals structures of both SF07 and SG6 cocrystallised against the N-domain of ACE need to be grown. 
These crystal structures will confirm the accuracy of the predicted binding poses and whether the two 
postulated residues are responsible for N-domain selective ACE inhibiton.  
A complete SAR study on both the Enalaprilat analogue and Diprolyl series will suggest many novel 
drug-like N-domain selective ACEis. Cocrystal structures of SG6 and SF07 and similar compounds 
bound to the N-domain will help to further narrow the chemical space in which N-domain selectivity 
is found, which in turn may drive future SAR series. These future studies would lay the groundwork 
for the future development of N-domain selective ACEi drug development.  
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Chapter 8 – Experimental 
8.1 Chemistry 
8.1.1 Reagents and Solvents 
All chemical reagents and anhydrous solvents used during the synthesis of the Enalaprilat analogue 
were purchased from Sigma Aldrich, South Africa. Analytical Reagent (AR) grade solvents ethyl 
acetate, hexane, DCM and acetone were purchased from Kimix Chemicals. HPLC grade solvents were 
purchased from Sigma Aldrich (ammonium acetate, triflouroacetic acid and DMSO), Merck (glacial 
acetic acid) and Microsep (Acetonitrile and Methanol) for Chromatography, Mass Spec and HPLC. 
The diprolyl series was synthesised by Syngene International in Bangalore India. Their chemical 
suppliers were withheld but all spectra provided for their compounds were verified locally. 
8.1.2 Chromatography 
Thin layer chromatography (TLC) reaction monitoring was performed using Merck F254 aluminium-
backed silica gel 60 plates. Spots were visualised with either ultra violet (UV) light (254/366 nm), 
anisaldehyde or ninhydrin stains. Reaction products were all purified via column chromatrography 
using Merck kieselgel 60:70-230 mesh via gravitational column chromatography and flash 
chromatography. 
8.1.3 Physical and Spectroscopic Characterisation 
Melting points were determined using a Reichert-Jung Thermovar hot-stage microscope.  
The reported compounds were characterised using 1H NMR while novel compounds were 
characterised via 1H-NMR, 13C-NMR and LC-MS.  
HPLC: Peak purity of the Enalaprilat analogue was determined locally using preparatory HPLC with a 
thermo separation system comprising of a Spectra Series P200 pump, an AS100 automated sampler 
and a UV 100 variable wave detector. The UV detector was set to monitor peak absorption at 214 nm. 
A Waters® X-bridge C18 5.0 µm (4.6 x 150 mm) (Phenomenex, Torrance, CA) column stationary phase 
used was fitted to a Supelguard ® Ascentis TM C18 guardcartridge (2cm x 40 mm, 3 µm) (Supelco 
Analytical, Bellefonto, PA).  
The Enalaprilat analogue was purified and analysed using a mixture of mobile phase A; 10 mM 
ammonium acetate in water and mobile phase B; 10 mM ammonium acetate in MeCN running the 
method described in Table 8.1 at flow rate of 1.2 mL/min. 
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Table 8.1: HPLC method used to test the purity of Enalaprilat analogues. 
Time % A % B 
Initial 75 25 
9.00 0 100 
14.00 0 100 
14.10 75 25 
20.00 75 25 
 
Diastereomer separation of the diprolyl series was performed using a thermo separation system 
comprising of an Analytical Technologies® P2230 HPLC pump with an automated sampler and 
Analytical Technologies® UV 2230 variable wavelength detector set to detect absorbance at 214 nm. 
The stationary phase column used was a Gemini® NX – C18 3.5 µm (4.6 x 50 mm) (Phenomenex, 
Torrance, CA). 
This HPLC configuration was run with a mixture of mobile phase A; 10 mM ammonium acetate in water 
and mobile phase B; 10 mM ammonium acetate in MeCN using the method described in Table 8.2 at 
a flow rate of 1.0 mL/min.  
Table 8.2: HPLC method used to separate the two diastereomers of each diprolyl compound. 
Time % A % B 
Initial 90 10 
15.00 0 100 
20.00 0 100 
23.00 90 10 
28 90 10 
Peak purity of the diprolyl series was analysed with the same equipment used for the diastereomer 
separation but with an Atlantis® dC18 5 µm (4.6 x 250 mm) column stationary phase. 
The HPLC was run in this configuration with mixture of mobile phase A; 0.1 % TFA in water and mobile 
phase B; 0.1% TFA in MeCN using the method described in Table 8.3 at a flow rate of 1.5 mL/min.  
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Table 8.3: HPLC method used to test the purity of diprolyl compounds. 
Time % A % B 
Initial 90 10 
15.00 0 100 
20.00 0 100 
23.00 90 10 
30.00 90 10 
 
LC-MS: Liquid chromatography mass spectrometer (LC-MS) analysis on the Enalaprilat analogues was 
performed using an Agilent® 1260 Infinity Binary Pump, Agilent® 1260 Infinity Diode Array Detector 
(DAD), Agilent® 1290 Infinity Column Compartment, Agilent® 1260 Infinity Standard autosampler and 
an Agilent® 6120 Quadruple (Single) mass spectrometer equipped with an APCI and ESI multimode 
ionisation source. Compound purity was determined using an Agilent® LC-MS with a Kinetex Core C18 
2.6 μm column (50 x 3 mm).  
 A mixture of mobile phase A; 0.4% acetic acid in 10 mM ammonium acetate and mobile Phase B; 0.4% 
acetic acid, 10 mM ammonium acetate in a 9:1 ratio was run at a flow rate of 0.9 mL/min. 
Table 8.4: LC-MS method used to analyse Enalaprilat analogue compounds with the described mobile phases A and B. 
Time % A % B 
Initial 75 25 
1.00 75 25 
3.00 0 100 
4.50 0 100 
5.20 75 25 
6.00 75 25 
 
The diprolyl series was monitored via LC-MS using the same Agilent 1200 series equipment with an 
XBridge® C8 column (50 mm x 4.6 mm, 3.5 µM) stationary phase. This LC-MS configuration was run 
using a mixture of mobile phase A; 0.1% TFA in H2O and mobile phase B; 0.1% TFA in MeCN was run 
at a flow rate 0.6 mL/min using the method described in Table 8.5 at a flow right of 0.6 mL/min. 
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Table 8.5: LC-MS method most commonly used for analysis of diprolyl series. 
Time % A % B 
Initial 95 5 
8.00 0 100 
8.50 95 5 
10.00 95 0 
 
NMR: All NMR spectra were recorded on either a Brucker Ultrashield-Plus Spectrometer (1H-300 MHz; 
13C-75 MHz), a Brucker Ultrashield-Plus Spectrometer (1H-400 MHz; 13C-100 MHz) or a Brucker 
Ultrashield-Plus Spectrometer (1H-600 MHz; 13C-150 MHz) with compounds dissolved in either 
deuterated Methanol (MeOD-d4) or deuterium oxide (D2O) solvents. Chemical shifts (δ) are recorded 
in ppm and coupling constants (J) are recorded in hertz (Hz). Abbreviations used in assigning 1H NMR 
signals are: br (broad), d (doublet or doublets), m (multiplets), q (quartet), s (singlet), t (triplet), dd 
(doublet of doublets), ddd (doublet of doublet of doublets) and td (triplet of doublets).  
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8.2 Characterisation 
8.2.1 Enalaprilat Analogue 
SF07 
105 mg of SF06 was dissolved in an aqueous 1 M NaOH solution at 25 °C and stirred for 2 hours. The 
reaction was monitored via LC-MS. The solution was then neutralised with the dropwise addition of 
HCl. The solution was stirred for an additional 30 minutes after the water was evapourated yielding a 
mixture of a white paste and NaCl. The mixture of the compound and NaCl was loaded onto the prep-
HPLC and purified (tr = 3.86 min) to yield 36.6 mg (39%) of an opaque white paste. 
 
1H NMR (600 MHz, Methanol-d4): δ 4.34 (q, J = 4.36 Hz, 1H, H-11), 4.30 (t, J = 5.4 Hz, 1H, H-5) 3.70 (m, 1H, H-14), 
3.64(m, 2H, H-2), 2.62 – 2.51 (m, 2H, H-19), 2.50 – 2.27 (m, 2H, H-15), 2.26 – 2.16 (m, 2H, H-3), 2.15-2.07 (m, 2H, 
H-4), 1.55 (d, J = 6.9 Hz, 3H, H-12); 13C NMR (150 MHz, CD3OD): δ 180.08 175.58, 168.45 (2C), 62.18, 61.62, 60.58, 
53.39, 46.84, 33.53, 29.47, 25.19, 24.13, 20.53; LC-ESI-MS (+ve mode): m/z 317.1 [M+H]+ purity 97.0% (tr = 0.26 
min) 
8.2.2 Diprolyl Series 
General ester deprotection method:  
5 equivalents of a 4.0 M aqueous solution of LiOH was added to a 0.1 M solution of the methyl ester 
protected form of each diprolyl compound in a THF/MeOH/H2O (3:2:1) solution. The mixture was 
stirred for 2 hours at room temperature. The mixture was then diluted with 5 mL of water then 
neutralised by adding 1 N HCl dropwise. The compound was either dried and purified via Prep-HPLC 
or the crude Product was Boc-deprotected. 
General Boc Deprotection method: 
Crude Boc protected compound was dissolved in chilled 4 M HCl/Dioxane under N2 at 0 °C. The mixture 
was stirred for 30 min at 0 °C and monitored via TLC. Upon completion the solvent was evaporated 
and the residue was washed with diethyl ether. The final compound was then purified over prep HPLC. 
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SG1_1 
 
The general ester deprotection was performed on 45 mg SG1_1-8 and then purified via prep HPLC to 
obtain 26 mg (62%) of a sticky white-yellow solid.  
1H NMR (400 MHz, Methanol-d4) δ 7.62 – 7.55 (m, 2H, H-11), 7.55 – 7.44 (m, 3H, H-12, H-13), 4.72 (t, J = 8.7 Hz, 
1H, H-4), 4.52 – 4.47 (m, 1H, H-7), 4.37, (d, J = 1.9 Hz, 1H, H-6), 4.23 (q, J = 6.8 Hz, 1H, H-5), 3.70 (m, 1H, H-1e), 
3.60 (m, 2H, H-1a, H-10e), 3.50 (d, 1H, H-10a), 2.44 – 2.25 (m, 3H, H-2, H-9a), 2.12 – 1.93 (m, 4H, H-3, H-8a, H-
9e), 1.87-1.73 (m, 1H, H-8e), 1.64 (d, J = 7.0 Hz, 3H, H-14). 13C (100 MHz, Methanol-d4): δ 175.9, 175.1, 173.2, 
168.2, 132.3, 129.4, 127.9 (2C), 126.5 (2C), 66.3, 64.2, 59.5, 58.3, 50.5, 49.3, 27.2, 25.3, 23.4, 22.7, 22.1 LC-ESI-
MS (+ve ion mode): 418 [M+H]+ HPLC purity 98%, tr = 8.26 min 
  
Chapter 8   – Experimental 




The general ester deprotection was performed on 75 mg SG1_2-8 and then purified via prep HPLC to 
obtain 55 mg (78%) of a sticky white-yellow solid.   
1H NMR (400 MHz, Methanol-d4) δ 7.60 (m, 2H, H-11), 7.55 – 7.45 (m, 3H, H-12, H-13), 4.67 (q, J = 7.1 Hz, 1H, H-
5), 4.63 – 4.56 (m, 1H, H-7), 4.33-4.23 (m, 1H, H-4), 4.13 (d, J = 6.6 Hz, 1H, H-6), 3.75 – 3.58 (m, 2H, H-1), 3.53 
(m, 2H, H-10), 2.41-2.28 (m, 1H, H-2a), 2.27 – 2.14 (m, 2H, H-2e, H-9a), 2.13 – 1.94 (m, 4H, H-3, H-8a, H-9e), 1.91 
– 1.76 (m, 1H, H-8e), 1.61 (d, J = 6.8 Hz, 3H, H-14). 13C (100 MHz, Methanol-d4): δ 176.3, 174.7, 173.8, 167.9, 
133.2, 129.1, 128.2 (2C), 125.9 (2C), 66.5, 65.2, 58.5, 57.2, 50.1, 48.8, 26.9, 25.1, 23.8, 22.0, 21.5. LC-ESI-MS (+ve 
ion mode): 418 [M+H]+ HPLC purity 98%, tr = 7.96 min 
SG-2_2 
 
The general ester deprotection was performed on 30 mg of SG2_2-8 and then purified via prep HPLC 
to obtain 23 mg (62%) of a sticky white-yellow solid.  
1H NMR (400 MHz, Methanol-d4) δ 8.07 (d, J = 7.8 Hz, 2H, H-12), 7.65 (dd, J = 8.2, 2.9 Hz, 2H, H-11), 4.71 – 4.61 
(t, J = 8.2 Hz, H-6), 4.40 (q, J = 6.9 Hz, 1H, H-5), 4.12 (m, 1H, H-4), 3.96 (m, 1H, H-7), 3.62 (m, 2H, H-1), 3.43 (m, 
2H, H-10), 2.32 (m, 3H, H-2, H-8a), 1.98 (m, 3H, H-3, H-8e), 1.86 (m, 1H, H-9a), 1.74 (m, 1H, H-9e), 1.58 (d, J = 6.4 
Hz, 3H, H-14). 13C (100 MHz, Methanol-d4): δ 175.9, 175.1, 174.5, 171.3, 167.2, 134.3, 128.8, 128.1 (2C), 126.3 
(2C), 67.1, 66.2, 59.3, 57.9, 51.5, 49.1, 27.3, 25.8, 23.1, 22.5, 21.3. LC-ESI-MS (+ve ion mode): 462 [M+H]+ HPLC 
purity 97%, tr = 7.31 min 
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SG3_2 
 
The general ester deprotection was performed on 50 mg of SG3_2-8 after which the crude residue 
was Boc deprotected via the general Boc deprotection method after which it was purified via Prep 
HPLC to yield 30 mg (78%) of SG3_2 as a sticky yellow solid.  
1H NMR (400 MHz, D2O) δ 7.61 – 7.51 (m, 2H, H-12), 7.27 (dd, J = 8.7, 2.9 Hz, 2H, H-11), 4.51 (t, J = 8.5 Hz, 1H, H-
7), 4.33 (q, J = 6.9 Hz, 1H, H-5), 4.29 (m, 1H, H-4), 3.96 (m, 1H, H-6), 3.62 – 3.36 (m, 4H, H-1, H-10), 2.21 (m, 2H, 
H-2), 2.13 – 2.00 (m, 1H, H-9a), 1.98 – 1.79 (m, 4H, H-2, H-8a, H-9e), 1.66 (m, 1H, H-8e), 1.50 (d, J = 6.9 Hz, 3H, 
H-14). 13C (100 MHz, D2O): δ 176.3, 174.8, 174.1, 168.3, 133.9, 128.1, 127.7 (2C), 126.8 (2C), 67.5, 66.1, 60.7, 




The general ester deprotection was performed on 50 mg of SG4_1-8 after which the crude residue 
was Boc deprotected via the general Boc deprotection method after which it was purified vi prep-
HPLC to yield 38 mg (97%) of SG4_1 as a sticky yellow solid.  
1H NMR (400 MHz, D2O) δ 7.32 (m, 3H, H-14, H-15), 7.25 (m, 2H, H-13), 4.51 (t, J = 7.6 Hz, 1H, H-11), 4.40-4.30 
(m, 3H, H-4, H-5, H-7), 3.82 (d, J = 4.4 Hz, 1H, H-6), 3.64 (d, 2H, H-1), 3.54 – 3.39 (m, 2H, H-10), 3.23 (dd, J = 14.7, 
5.1 Hz, 1H, H-12a), 3.06 (dd, J = 14.8, 7.7 Hz, 1H, H-12b), 2.21 (m, 1H, H-2a), 2.07 (m, 1H, H-2e), 2.00 – 1.81 (m, 
6H, H-3, H-8, H-9), 1.48 – 1.36 (m, 3H, H-14). 13C (100 MHz, D2O): δ 177.1, 175.3, 174.8, 171.2, 136.7, 129.1 (2C), 
128.5 (2C), 127.2, 68.3, 67.5, 62.1, 57.3, 53.6, 51.9, 49.2, 40.1, 29.3, 25.7, 24.1, 22.8, 22.1 LC-ESI-MS (+ve ion 
mode): 461 [M+H]+ HPLC purity 97.4%, tr = 5.52 min 
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SG4_2 
 
The general ester deprotection was performed on 20 mg of SG4_2-8 after which the crude residue 
was Boc deprotected via the general Boc deprotection after which it was purified via prep-HPLC to 
yield 12 mg (77%) of SG4_2 as a sticky yellow solid.  
1H NMR (400 MHz, D2O) δ 7.31 (d, J = 7.7 Hz, 3H, H-14, H-15), 7.21 (d, J = 7.1 Hz, 2H, H-13), 4.43 (t, J = 7.6 Hz, 1H, 
H-11), 4.37 (m, 1H, H-4), 4.23 (m, 1H, H-7), 4.13 (q, J = 6.9 Hz, 1H, H-5), 3.71 (d, J = 5.8 Hz, 1H, H-6), 3.51 (m, 2H, 
H-10), 3.30 (m, 1H, H-1), 3.13 (dd, J = 14.6, 7.8 Hz, 1H, 12a), 3.07 (dd, J = 15.4, 6.4, 12b), 2.19 (m, 2H, H-2), 1.87 
(m, 4H, H-3, H-9), 1.67 (m, 2H, H-8), 1.47 (d J = 6.9 Hz, 3H). 13C (100 MHz, D2O): δ 177.8, 176.2, 174.4, 172.1, 
137.1, 130.3 (2C), 127.8 (2C), 127.1, 69.5, 68.4, 63.5, 56.8, 54.1, 52.1, 50.1, 42.2, 30.5, 26.7, 25.5, 23.8, 22.9 LC-
ESI-MS (+ve ion mode): 461 [M+H]+ HPLC purity 95.3%, tr = 6.69 min 
SG5_1 
The general ester deprotection was performed on 90 mg of SG5_2-8 after which the crude residue 
was Boc deprotected via the general Boc deprotection method after which it was purified via HPLC to 
yield 65 mg (97%) of SG5_2 as a sticky yellow solid.  
 
 
1H NMR (400 MHz, D2O) δ 4.42 (m, 2H, H-4, H-7), 4.29 (q, J = 6.9 Hz, 1H, H-5), 3.95 – 3.84 (m, 3H, H-6, H-10), 3.54 
(m, 2H, H-1), 3.48 – 3.33 (m, 2H, H-11), 2.25 (s, 1H, H-2a), 2.15 (m, 1H, H-2e), 2.04 (m, 1H, H-9a), 1.95 (m, 4H, H-
3, H-8a, H-9e), 1.82 (m, 1H, H-8e), 1.50 (d, J = 6.9 Hz, 3H, H-12). 13C (100 MHz, D2O): δ 177.1, 176.2, 174.7, 170.9, 
70.5, 63.1, 56.3, 55.5, 52.3, 51.5, 42.9, 31.8, 26.9, 25.9, 24.1, 23.5 LC-ESI-MS (+ve ion mode): 371 [M+H]+ HPLC 
purity 93.6%, tr = 5.66 min 
  
Chapter 8   – Experimental 




The general ester deprotection was performed on 150 mg of SG6_1-8 after which the crude residue 
was Boc deprotected via the general Boc deprotection method after which it was purified via prep-
HPLC to yield 100 mg (89%) of SG6_1 as a sticky yellow-brown solid.  
1H NMR (400 MHz, D2O) δ 4.53 (m, 1H, H-11), 4.47 – 4.38 (m, 1H, H-5), 4.30 (m, 1H, H-4), 4.04 (m, 1H, H-7), 3.98 
(d, J = 5.6 Hz, 1H, H-6), 3.59 (m, 4H, H-1, H-10), 3.06 – 2.71 (m, 2H, H-12a, H-12b), 2.28 (m, 2H, H-2), 2.11 – 1.82 
(m, 6H, H-3, H-8, H-9), 1.47 (d, J = 6.8 Hz, 3H, H-13). 13C (100 MHz, D2O): δ 177.9, 177.2, 175.4, 173.5 171.2, 72.3, 
67.4, 59.2, 57.5, 52.3, 51.5, 49.4, 43.2, 30.5, 27.5, 26.3, 24.8, 23.1, LC-ESI-MS (+ve ion mode): 429 [M+H]+ HPLC 





The general ester deprotection was performed on 230 mg of SG6_2-8 after which the crude residue 
was Boc deprotected via the general Boc deprotection method after which it was purified via prep-
HPLC to yield 85 mg (49%) of SG6_2 as a sticky yellow-brown solid.  
1H NMR (400 MHz, D2O) δ 4.60-4.50 (m, 1H, H-11), 4.48-4.35 (m, 2H, H-4, H-5), 4.33-4.24 (m, 1H, H-7), 3.85 (d, J 
= 2.1 Hz, 1H, H-6), 3.70-3.48 (m, 3H, H-1, H-10a), 3.47-3.35 (m, 1H, H-10e), 3.03-2.91 (m, 1H, H-12a), 2.84 – 2.71 
(m, 1H, H-12b), 2.23-2.14 (m, 2H, H-2), 2.13 – 1.75 (m, 6H, H-3, H-8, H-9), 1.59 – 1.35 (d, J = 6.1 Hz, 3H, H-13). 
13C (100 MHz, D2O): δ 177.1, 176.5, 175.9, 174.2 170.6, 70.9, 68.5, 59.5, 58.2, 53.8, 50.2, 49.1, 41.9, 31.1, 28.3, 
27.1, 24.1, 23.5. LC-ESI-MS (+ve ion mode): 429 [M+H]+ HPLC purity 97.55%, tr = 4.76 min 
  
Chapter 8   – Experimental 




The general ester deprotection was performed on 70 mg of SG7_1-8 after which the crude residue 
was Boc deprotected via the general Boc deprotection method after which it was purified to yield 4 
mg (8%) of SG7_1 as a sticky yellow-brown solid 
1H NMR (400 MHz, D2O) δ 4.41 (t, J = 4.4 Hz, 1H, H-11), 4.32 (q, J = 5.8 Hz, 1H, H-7), 4.15 (q, J = 6.9 Hz, 1H, H-5), 
3.78 (d, J = 5.7 Hz, 1H, H-6), 3.66 – 3.47 (m, 4H, H-1, H-10), 2.59 – 2.44 (m, 2H, H-13), 2.24 (m, 1H, H-2a), 2.09 
(m, 2H, H-2e, H-12a), 1.98 (m, 2H, H-9a, H-12b), 1.93 (m, 5H, H-3, H-10, H-9e), 1.48 (d, J = 7.1 Hz, 3H, H-14). 13C 
(100 MHz, D2O): δ 177.5, 177.1, 176.4, 174.8 172.4, 71.5, 69.1, 60.3, 57.5, 52.4, 51.3, 49.8, 42.1, 32.5, 29.1, 27.7, 




The general ester deprotection was performed on 80 mg of SG7_2-8 after which the crude residue 
was Boc deprotected via the general Boc deprotection method after which it was purified to yield 6 
mg (10%) of SG7_2 as a sticky yellow-brown solid. 
1H NMR (400 MHz, D2O) δ 4.40 – 4.23 (m, 4H, H-4, H-5, H-7, H-11), 3.76 (d, J = 2.0 Hz, 1H, H-6), 3.65 (m, 1H, H-
1a), 3.53 (m, 2H, H-1e, H10a), 3.39 (m, 1H, H-10e), 2.54 (t, J = 7.5 Hz, 2H, H-13), 2.22 (m, 2H, H-2), 2.13 (m 2H, 
H-9a, H-12a), 1.95 (m, 5H, H-3, H-8a, H-9e H-12b), 1.77 (q, 1H, H-9a), 1.49 (d, J = 6.9 Hz, 3H). 13C (100 MHz, D2O): 
δ 178.2, 177.4, 175.5, 174.9 171.4, 72.3, 68.9, 61.5, 58.1, 51.9, 51.2, 48.3, 41.9, 31.1, 29.7, 28.1, 26.4, 24.2, 22.9. 
LC-ESI-MS (+ve ion mode): 443 [M+H]+ HPLC purity 98.95%, tr = 4.76 min 
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Appendix 3.2 - Full Table of Ligand Docking Scores and MM-GBSA Calculated 
Binding Energies 
 C-Domain N-Domain  
Ligand Docking score ΔG C Norm Docking score ΔG N Norm N/C 
F61-1_L0 -8.129 -18.148 0.367 -9.852 -50.344 1.130 3.078 
F146_L0 -11.283 -41.466 0.839 -10.791 -75.425 1.694 2.018 
F187_L1 -10.990 -26.264 0.532 -10.052 -39.481 0.887 1.668 
F12_L1 -11.641 -27.544 0.557 -10.400 -38.465 0.864 1.549 
F36_L2 -12.347 -50.859 1.029 -11.534 -69.204 1.554 1.510 
F61-1_L1 -12.443 -44.240 0.895 -10.365 -57.132 1.283 1.433 
F76_L0 -11.033 -43.127 0.873 -10.077 -53.393 1.199 1.374 
F141_L0 -13.102 -62.547 1.266 -10.696 -76.269 1.713 1.353 
F161_L0 -12.460 -56.189 1.137 -11.335 -66.489 1.493 1.313 
F21_L0 -11.576 -53.394 1.081 -12.486 -61.978 1.392 1.288 
F119_L0 -10.011 -45.101 0.913 -10.752 -50.834 1.141 1.251 
F21_L1 -12.797 -53.683 1.086 -13.472 -60.314 1.354 1.247 
F64_L0 -11.296 -42.692 0.864 -9.774 -47.255 1.061 1.228 
F32_L0 -11.233 -49.514 1.002 -11.891 -54.074 1.214 1.212 
F38_L1 -12.786 -60.189 1.218 -11.639 -64.852 1.456 1.195 
F171_L0 -12.058 -73.675 1.491 -10.878 -78.354 1.759 1.180 
F75_L1 -11.278 -60.142 1.217 -9.944 -63.530 1.427 1.172 
F160_L0 -12.014 -67.902 1.374 -10.911 -70.982 1.594 1.160 
F191_L3 -12.349 -43.102 0.872 -11.511 -44.966 1.010 1.158 
F179_L1 -11.250 -46.727 0.946 -10.938 -48.589 1.091 1.154 
F35_L0 -12.256 -47.501 0.961 -12.470 -49.251 1.106 1.150 
F22_L1 -13.753 -63.554 1.286 -12.998 -65.831 1.478 1.149 
F123_L0 -11.177 -51.818 1.049 -10.824 -53.670 1.205 1.149 
F50_L1 -11.687 -54.150 1.096 -11.236 -55.635 1.249 1.140 
F4_L2 -11.309 -42.407 0.858 -11.519 -43.553 0.978 1.140 
F191_L2 -11.549 -43.020 0.871 -12.188 -43.877 0.985 1.132 
F188_L3 -12.080 -47.700 0.965 -11.354 -48.630 1.092 1.131 
F72_L2 -12.045 -59.072 1.195 -10.461 -59.666 1.340 1.121 
F19_L0 -9.787 -63.348 1.282 -10.088 -63.974 1.437 1.121 
F100_L0 -11.997 -61.529 1.245 -11.591 -61.578 1.383 1.110 
F35_L3 -12.838 -60.101 1.216 -12.004 -59.274 1.331 1.094 
F107_L0 -10.010 -73.580 1.489 -10.756 -71.855 1.613 1.084 
F5_L2 -11.538 -45.976 0.930 -10.118 -44.390 0.997 1.071 
F196_L1 -11.615 -40.158 0.813 -11.902 -38.701 0.869 1.069 
F69_L1 -11.527 -56.983 1.153 -10.039 -54.884 1.232 1.069 
F143_L0 -12.077 -64.275 1.301 -10.995 -61.760 1.387 1.066 
F111_L0 -12.301 -60.864 1.232 -12.399 -58.382 1.311 1.064 
F142_L0 -12.854 -69.340 1.403 -10.347 -66.060 1.483 1.057 
F191_L1 -11.732 -48.108 0.974 -10.894 -45.800 1.028 1.056 
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F181_L1 -12.719 -51.636 1.045 -11.263 -49.042 1.101 1.054 
F87_L0 -12.321 -54.321 1.099 -9.641 -51.574 1.158 1.053 
F70_L0 -11.333 -59.760 1.209 -10.018 -56.706 1.273 1.053 
F170_L0 -11.906 -76.073 1.540 -10.565 -71.983 1.616 1.050 
F130_L1 -12.565 -65.536 1.326 -11.547 -61.976 1.392 1.049 
F104_L0 -11.482 -65.863 1.333 -10.261 -61.460 1.380 1.035 
F109_L0 -13.158 -55.298 1.119 -11.821 -51.318 1.152 1.030 
F125_L0 -11.727 -62.069 1.256 -11.228 -57.514 1.291 1.028 
F72_L3 -12.745 -72.395 1.465 -10.546 -66.768 1.499 1.023 
F135_L2 -11.932 -72.017 1.457 -11.372 -66.384 1.491 1.023 
F62-1_L0 -11.419 -50.686 1.026 -10.928 -46.623 1.047 1.021 
F17_L0 -10.607 -40.025 0.810 -10.420 -36.705 0.824 1.017 
F182_L1 -12.257 -60.611 1.227 -11.222 -55.375 1.243 1.014 
F2_L1 -12.567 -42.045 0.851 -12.818 -38.408 0.862 1.014 
F44_L0 -11.694 -57.508 1.164 -10.474 -52.436 1.177 1.012 
F86_L3 -12.072 -51.729 1.047 -10.076 -47.106 1.058 1.010 
F197_L2 -12.263 -50.141 1.015 -12.607 -45.521 1.022 1.007 
F181_L2 -12.010 -50.547 1.023 -11.998 -45.862 1.030 1.007 
F155_L0 -12.541 -69.485 1.406 -10.926 -62.993 1.414 1.006 
F116_L0 -11.780 -55.418 1.122 -10.870 -50.083 1.125 1.003 
F189_L2 (Enalprilat) -12.128 -49.413 1.000 -9.964 -44.535 1.000 1.000 
F58_L3 -11.418 -61.708 1.249 -10.873 -55.580 1.248 0.999 
F189_L0 -11.528 -50.716 1.026 -9.936 -45.278 1.017 0.991 
F84_L0 -11.531 -66.542 1.347 -10.209 -59.287 1.331 0.989 
F61_L0 -11.873 -57.337 1.160 -10.266 -50.848 1.142 0.984 
F186_L3 -12.254 -64.496 1.305 -11.160 -57.146 1.283 0.983 
F63_L0 -11.173 -52.027 1.053 -9.887 -46.068 1.034 0.982 
F30_L0 -11.862 -53.398 1.081 -10.931 -47.048 1.056 0.978 
F23_L1 -13.508 -64.817 1.312 -12.264 -57.090 1.282 0.977 
F63_L1 -11.255 -45.768 0.926 -10.882 -40.289 0.905 0.977 
F108_L0 -11.834 -65.125 1.318 -11.973 -57.327 1.287 0.977 
F187_L0 -11.056 -46.578 0.943 -11.106 -40.964 0.920 0.976 
F56_L3 -12.216 -58.305 1.180 -10.790 -51.258 1.151 0.975 
F67-1_L0 -11.296 -55.401 1.121 -10.107 -48.691 1.093 0.975 
F37_L2 -13.018 -76.517 1.549 -12.665 -67.231 1.510 0.975 
F172_L0 -10.350 -80.270 1.624 -10.649 -70.448 1.582 0.974 
F28_L0 -11.778 -57.647 1.167 -10.660 -50.455 1.133 0.971 
F22_L0 -12.193 -61.927 1.253 -11.757 -54.178 1.217 0.971 
F86-1_L0 -13.066 -68.189 1.380 -10.915 -59.547 1.337 0.969 
F18_L0 -9.732 -62.027 1.255 -9.968 -54.105 1.215 0.968 
F117_L1 -11.783 -44.140 0.893 -11.822 -38.404 0.862 0.965 
F31_L0 -11.953 -60.893 1.232 -11.804 -52.758 1.185 0.961 
F115_L0 -11.885 -57.348 1.161 -11.305 -49.658 1.115 0.961 
F180_L1 -12.309 -66.942 1.355 -11.170 -57.953 1.301 0.961 
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F189_L1 -11.376 -48.729 0.986 -11.175 -42.167 0.947 0.960 
F55_L1 -12.056 -53.670 1.086 -10.171 -46.380 1.041 0.959 
F30_L1 -12.371 -75.715 1.532 -11.019 -65.413 1.469 0.959 
F56_L0 -11.387 -66.906 1.354 -10.643 -57.765 1.297 0.958 
F139_L0 -11.995 -78.903 1.597 -12.061 -68.037 1.528 0.957 
F45_L0 -10.082 -59.631 1.207 -10.911 -51.298 1.152 0.954 
F86_L1 -11.034 -43.948 0.889 -10.536 -37.547 0.843 0.948 
F47_L1 -11.652 -68.390 1.384 -10.525 -58.428 1.312 0.948 
F194_L1 -11.732 -47.457 0.960 -11.534 -40.426 0.908 0.945 
F190_L2 -12.528 -41.744 0.845 -10.123 -35.548 0.798 0.945 
F86_L0 -11.080 -51.916 1.051 -10.250 -44.195 0.992 0.945 
F126_L0 -11.355 -56.596 1.145 -11.218 -48.088 1.080 0.943 
F13_L0 -11.920 -61.695 1.249 -10.514 -52.247 1.173 0.940 
F183_L3 -11.921 -65.639 1.328 -11.397 -55.566 1.248 0.939 
F55_L2 -12.005 -63.796 1.291 -11.512 -54.000 1.213 0.939 
F5-1_L0 -11.696 -60.834 1.231 -11.233 -51.438 1.155 0.938 
F186_L1 -12.139 -50.944 1.031 -10.940 -43.038 0.966 0.937 
F4-1_L0 -11.578 -52.181 1.056 -11.348 -44.036 0.989 0.936 
F102_L0 -11.718 -67.838 1.373 -10.130 -57.207 1.285 0.936 
F101_L0 -12.434 -66.192 1.340 -10.528 -55.557 1.248 0.931 
F94_L1 -12.059 -67.051 1.357 -10.013 -56.261 1.263 0.931 
F34_L2 -12.499 -73.498 1.487 -12.256 -61.648 1.384 0.931 
F190_L3 -11.981 -63.742 1.290 -10.309 -53.131 1.193 0.925 
F60_L1 -12.683 -61.811 1.251 -11.207 -51.513 1.157 0.925 
F178_L0 -11.913 -61.055 1.236 -10.556 -50.810 1.141 0.923 
F192_L1 -11.651 -56.052 1.134 -10.437 -46.622 1.047 0.923 
F177_L2 -12.741 -54.704 1.107 -10.407 -45.494 1.022 0.923 
F66_L2 -12.340 -58.710 1.188 -12.212 -48.759 1.095 0.921 
F69_L4 -12.658 -73.142 1.480 -11.789 -60.655 1.362 0.920 
F60_L0 -11.941 -61.953 1.254 -10.341 -51.173 1.149 0.916 
F98_L0 -12.884 -72.197 1.461 -12.901 -59.547 1.337 0.915 
F128_L0 -11.002 -55.785 1.129 -11.018 -45.959 1.032 0.914 
F88_L0 -12.091 -49.486 1.001 -10.247 -40.732 0.915 0.913 
F134_L1 -11.733 -75.537 1.529 -10.868 -62.170 1.396 0.913 
F18_L1 -11.437 -69.287 1.402 -10.333 -56.978 1.279 0.912 
F33_L2 -11.588 -57.690 1.168 -11.873 -47.369 1.064 0.911 
F69_L2 -11.322 -65.787 1.331 -10.259 -53.957 1.212 0.910 
F6_L2 -11.887 -50.563 1.023 -10.711 -41.340 0.928 0.907 
F58_L0 -11.824 -54.228 1.097 -10.000 -44.270 0.994 0.906 
F1_L1 -10.979 -45.920 0.929 -9.591 -37.435 0.841 0.905 
F180_L0 -11.637 -58.410 1.182 -9.852 -47.358 1.063 0.900 
F94_L2 -12.834 -63.990 1.295 -11.740 -51.854 1.164 0.899 
F118_L0 -10.377 -68.468 1.386 -10.328 -55.410 1.244 0.898 
F34_L1 -11.973 -55.730 1.128 -11.608 -45.091 1.012 0.898 
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F49_L1 -11.960 -71.557 1.448 -10.650 -57.752 1.297 0.895 
F184_L1 -12.377 -53.651 1.086 -10.344 -43.246 0.971 0.894 
F57_L1 -11.674 -59.641 1.207 -10.462 -47.920 1.076 0.891 
F57_L3 -11.816 -71.372 1.444 -11.345 -57.264 1.286 0.890 
F180_L2 -13.085 -59.972 1.214 -11.435 -48.039 1.079 0.889 
F195_L0 -11.816 -51.939 1.051 -10.358 -41.502 0.932 0.887 
F87-1_L0 -13.209 -63.786 1.291 -10.626 -50.927 1.144 0.886 
F58_L1 -11.786 -57.276 1.159 -11.598 -45.708 1.026 0.885 
F59_L2 -12.943 -56.170 1.137 -11.252 -44.724 1.004 0.883 
F10_L1 -11.290 -44.066 0.892 -10.187 -35.074 0.788 0.883 
F188_L0 -11.191 -48.296 0.977 -10.433 -38.402 0.862 0.882 
F190_L1 -11.637 -59.768 1.210 -10.239 -47.485 1.066 0.881 
F73_L2 -11.540 -61.207 1.239 -10.450 -48.589 1.091 0.881 
F177_L1 -12.532 -65.230 1.320 -11.026 -51.757 1.162 0.880 
F167_L0 -12.231 -77.514 1.569 -10.861 -61.207 1.374 0.876 
F196_L0 -11.106 -50.481 1.022 -9.960 -39.832 0.894 0.875 
F183_L0 -11.678 -64.149 1.298 -10.256 -50.608 1.136 0.875 
F195_L1 -12.007 -57.745 1.169 -10.965 -45.545 1.023 0.875 
F15_L0 -11.723 -54.764 1.108 -10.608 -43.158 0.969 0.874 
F99_L0 -11.703 -77.992 1.578 -10.835 -61.401 1.379 0.874 
F130_L0 -11.796 -59.878 1.212 -10.383 -47.038 1.056 0.872 
F93_L0 -9.605 -85.116 1.723 -9.957 -66.591 1.495 0.868 
F181_L3 -11.662 -66.507 1.346 -10.693 -52.026 1.168 0.868 
F188_L1 -10.990 -48.210 0.976 -10.909 -37.677 0.846 0.867 
F65_L1 -11.683 -75.567 1.529 -9.625 -59.002 1.325 0.866 
F189_L3 -12.307 -58.409 1.182 -10.669 -45.475 1.021 0.864 
F196_L2 -11.553 -53.895 1.091 -11.419 -41.959 0.942 0.864 
F46_L1 -12.707 -65.792 1.331 -11.765 -51.153 1.149 0.863 
F32_L1 -11.862 -72.671 1.471 -10.611 -56.439 1.267 0.862 
F163_L0 -12.285 -85.462 1.730 -10.757 -66.372 1.490 0.862 
F65_L0 -11.321 -77.243 1.563 -10.512 -59.790 1.343 0.859 
F83_L0 -12.286 -69.125 1.399 -10.974 -53.498 1.201 0.859 
F34_L3 -13.100 -70.553 1.428 -12.995 -54.502 1.224 0.857 
F42_L1 -12.031 -71.029 1.437 -10.135 -54.814 1.231 0.856 
F177_L0 -12.280 -62.916 1.273 -10.349 -48.445 1.088 0.854 
F185_L1 -12.478 -60.966 1.234 -10.733 -46.868 1.052 0.853 
F58_L2 -11.796 -63.966 1.295 -10.272 -49.058 1.102 0.851 
F162_L0 -12.649 -83.881 1.698 -11.062 -64.200 1.442 0.849 
F28_L1 -12.233 -67.482 1.366 -10.886 -51.637 1.159 0.849 
F157_L0 -12.493 -90.429 1.830 -10.744 -68.988 1.549 0.846 
F37_L0 -11.560 -71.733 1.452 -10.088 -54.671 1.228 0.846 
F174_L0 -12.648 -97.195 1.967 -12.467 -73.880 1.659 0.843 
F40_L1 -11.209 -81.859 1.657 -10.382 -62.203 1.397 0.843 
F66_L3 -12.287 -74.506 1.508 -11.114 -56.576 1.270 0.843 
0   Appendices 
182  Stephen Fienberg – PhD Thesis 
F117_L3 -12.145 -63.370 1.282 -10.805 -48.052 1.079 0.841 
F62_L0 -12.812 -69.646 1.409 -10.908 -52.808 1.186 0.841 
F66-1_L0 -11.191 -55.630 1.126 -10.899 -42.170 0.947 0.841 
F183_L1 -12.221 -61.971 1.254 -10.834 -46.859 1.052 0.839 
F8_L0 -11.247 -58.571 1.185 -10.016 -44.213 0.993 0.838 
F127_L0 -11.517 -67.793 1.372 -10.622 -51.113 1.148 0.837 
F182_L0 -11.737 -56.743 1.148 -10.745 -42.672 0.958 0.834 
F86_L2 -12.148 -58.543 1.185 -9.631 -43.966 0.987 0.833 
F38_L0 -11.549 -72.452 1.466 -10.257 -54.039 1.213 0.828 
F178_L1 -12.697 -69.086 1.398 -12.398 -51.309 1.152 0.824 
F183_L2 -12.454 -74.173 1.501 -11.361 -55.048 1.236 0.823 
F185_L3 -12.676 -61.324 1.241 -10.820 -45.452 1.021 0.822 
F53_L1 -11.664 -65.130 1.318 -10.653 -48.252 1.083 0.822 
F20_L0 -9.805 -85.077 1.722 -10.321 -62.929 1.413 0.821 
F50_L2 -12.041 -70.861 1.434 -10.574 -52.367 1.176 0.820 
F133_L1 -11.656 -78.755 1.594 -11.684 -58.099 1.305 0.819 
F136_L0 -12.060 -71.719 1.451 -11.673 -52.847 1.187 0.818 
F178_L3 -12.937 -64.323 1.302 -10.514 -47.386 1.064 0.817 
F66_L0 -11.202 -60.761 1.230 -10.684 -44.722 1.004 0.817 
F33_L1 -11.519 -59.050 1.195 -12.054 -43.434 0.975 0.816 
F80_L0 -10.031 -85.336 1.727 -10.193 -62.734 1.409 0.816 
F26_L0 -11.900 -69.023 1.397 -10.931 -50.643 1.137 0.814 
F54_L1 -11.855 -82.488 1.669 -10.737 -60.234 1.353 0.810 
F94_L0 -11.269 -70.105 1.419 -11.521 -51.072 1.147 0.808 
F23_L2 -13.522 -66.516 1.346 -12.618 -48.362 1.086 0.807 
F35_L1 -11.570 -67.883 1.374 -12.264 -49.326 1.108 0.806 
F193_L2 -12.308 -49.544 1.003 -12.522 -35.957 0.807 0.805 
F179_L0 -12.116 -62.340 1.262 -10.301 -45.159 1.014 0.804 
F88_L2 -11.345 -67.235 1.361 -10.818 -48.654 1.093 0.803 
F188_L2 -11.982 -53.856 1.090 -9.839 -38.912 0.874 0.802 
F20_L1 -11.390 -90.979 1.841 -10.280 -65.681 1.475 0.801 
F85-1_L0 -12.933 -74.926 1.516 -11.323 -54.082 1.214 0.801 
F36_L3 -13.147 -75.254 1.523 -11.696 -54.305 1.219 0.801 
F62-1_L1 -11.019 -65.078 1.317 -10.716 -46.914 1.053 0.800 
F43_L0 -11.645 -56.140 1.136 -10.160 -40.468 0.909 0.800 
F134_L2 -12.442 -85.001 1.720 -11.355 -61.180 1.374 0.799 
F106_L0 -11.976 -81.665 1.653 -10.299 -58.736 1.319 0.798 
F4_L3 -11.856 -60.669 1.228 -10.631 -43.595 0.979 0.797 
F131_L2 -12.968 -81.459 1.649 -10.814 -58.457 1.313 0.796 
F124_L0 -11.968 -65.772 1.331 -10.288 -46.986 1.055 0.793 
F71_L3 -13.052 -87.995 1.781 -11.570 -62.823 1.411 0.792 
F64_L1 -10.929 -68.221 1.381 -9.919 -48.642 1.092 0.791 
F89_L0 -11.511 -73.515 1.488 -10.565 -52.400 1.177 0.791 
F33_L4 -11.015 -74.790 1.514 -10.924 -52.985 1.190 0.786 
0   Appendices 
183  Stephen Fienberg – PhD Thesis 
F59_L1 -12.776 -77.390 1.566 -11.452 -54.821 1.231 0.786 
F194_L0 -11.360 -44.142 0.893 -10.904 -31.237 0.701 0.785 
F34_L0 -12.094 -65.987 1.335 -11.571 -46.692 1.048 0.785 
F132_L1 -12.039 -74.660 1.511 -11.481 -52.810 1.186 0.785 
F43_L3 -13.494 -76.741 1.553 -11.597 -54.262 1.218 0.785 
F8_L1 -11.807 -54.069 1.094 -10.878 -38.203 0.858 0.784 
F16_L0 -11.304 -66.505 1.346 -10.381 -46.696 1.049 0.779 
F110_L0 -12.837 -71.850 1.454 -11.997 -50.442 1.133 0.779 
F46_L0 -11.935 -59.742 1.209 -10.831 -41.934 0.942 0.779 
F181_L0 -11.728 -61.871 1.252 -10.224 -43.396 0.974 0.778 
F23_L0 -11.974 -61.130 1.237 -10.663 -42.856 0.962 0.778 
F24_L0 -11.338 -75.214 1.522 -11.980 -52.711 1.184 0.778 
F192_L2 -12.220 -67.948 1.375 -11.311 -47.616 1.069 0.778 
F62_L1 -13.246 -77.146 1.561 -10.672 -54.018 1.213 0.777 
F193_L0 -11.290 -62.434 1.264 -9.943 -43.694 0.981 0.777 
F74_L1 -11.687 -81.613 1.652 -10.098 -56.931 1.278 0.774 
F74_L3 -12.747 -100.95 2.043 -12.303 -70.366 1.580 0.773 
F3_L1 -12.190 -63.436 1.284 -11.495 -44.165 0.992 0.772 
F194_L2 -12.242 -59.384 1.202 -11.460 -41.343 0.928 0.772 
F95_L1 -12.539 -77.817 1.575 -11.512 -54.149 1.216 0.772 
F43_L1 (Enalaprilat) -12.778 -66.597 1.348 -11.132 -46.326 1.040 0.772 
F164_L0 -11.973 -81.025 1.640 -10.869 -56.289 1.264 0.771 
F59_L0 -11.568 -64.950 1.314 -9.875 -45.119 1.013 0.771 
F192_L0 -11.468 -56.715 1.148 -10.267 -39.355 0.884 0.770 
F114_L0 -12.650 -50.848 1.029 -10.344 -35.219 0.791 0.769 
F140_L0 -12.522 -71.702 1.451 -10.781 -49.572 1.113 0.767 
F81_L0 -11.371 -78.490 1.588 -10.448 -54.242 1.218 0.767 
F4_L1 -11.518 -61.816 1.251 -9.589 -42.630 0.957 0.765 
F186_L2 -12.733 -68.773 1.392 -11.669 -47.394 1.064 0.765 
F90_L0 -11.391 -72.061 1.458 -10.081 -49.642 1.115 0.764 
F48_L1 -11.402 -89.356 1.808 -11.396 -61.548 1.382 0.764 
F175_L0 -11.450 -87.636 1.774 -10.775 -60.315 1.354 0.764 
F120_L0 -11.634 -65.699 1.330 -10.271 -45.211 1.015 0.764 
F112_L0 -10.836 -79.414 1.607 -10.950 -54.558 1.225 0.762 
F63_L3 -11.591 -80.048 1.620 -10.666 -54.908 1.233 0.761 
F184_L2 -12.398 -71.855 1.454 -10.520 -49.257 1.106 0.761 
F55_L0 -11.871 -68.763 1.392 -10.179 -47.110 1.058 0.760 
F75_L4 -12.068 -88.471 1.790 -11.083 -60.567 1.360 0.760 
F82_L0 -11.276 -77.308 1.565 -10.418 -52.908 1.188 0.759 
F130_L2 -12.731 -84.288 1.706 -10.759 -57.673 1.295 0.759 
F25_L1 -12.149 -74.149 1.501 -10.920 -50.649 1.137 0.758 
F44_L1 -13.141 -60.745 1.229 -10.561 -41.439 0.930 0.757 
F53_L0 -11.817 -71.309 1.443 -10.732 -48.567 1.091 0.756 
F73_L3 -12.431 -88.193 1.785 -10.843 -60.058 1.349 0.756 
0   Appendices 
184  Stephen Fienberg – PhD Thesis 
F42_L0 -9.788 -67.829 1.373 -9.878 -46.120 1.036 0.754 
F132_L2 -12.377 -83.852 1.697 -10.731 -56.942 1.279 0.753 
F185_L2 -13.517 -74.007 1.498 -11.578 -50.227 1.128 0.753 
F11_L0 -11.479 -63.886 1.293 -10.128 -43.337 0.973 0.753 
F35_L2 -12.387 -83.684 1.694 -12.361 -56.701 1.273 0.752 
F56_L1 -12.013 -78.283 1.584 -10.270 -52.944 1.189 0.750 
F195_L2 -10.543 -53.987 1.093 -11.643 -36.473 0.819 0.750 
F48_L0 -11.354 -71.424 1.445 -10.198 -48.176 1.082 0.748 
F9_L1 -11.513 -77.475 1.568 -10.848 -52.229 1.173 0.748 
F70_L2 -11.842 -73.493 1.487 -10.547 -49.517 1.112 0.748 
F169_L0 -10.514 -82.034 1.660 -10.863 -55.259 1.241 0.747 
F72_L0 -11.373 -81.270 1.645 -10.901 -54.618 1.226 0.746 
F47_L2 -12.210 -79.614 1.611 -10.356 -53.499 1.201 0.746 
F145_L0 -12.042 -81.471 1.649 -10.748 -54.721 1.229 0.745 
F56_L2 -11.856 -83.647 1.693 -10.549 -56.109 1.260 0.744 
F24_L1 -12.251 -89.772 1.817 -11.264 -60.210 1.352 0.744 
F46_L2 -13.280 -61.534 1.245 -11.217 -41.227 0.926 0.743 
F154_L0 -12.647 -109.47 2.215 -12.487 -73.343 1.647 0.743 
F131_L1 -12.363 -70.908 1.435 -10.874 -47.480 1.066 0.743 
F69_L0 -11.119 -65.952 1.335 -9.904 -44.161 0.992 0.743 
F40_L0 -11.373 -74.987 1.518 -10.347 -50.043 1.124 0.740 
F182_L2 -12.739 -80.431 1.628 -10.400 -53.577 1.203 0.739 
F117_L0 -11.195 -58.191 1.178 -10.198 -38.700 0.869 0.738 
F92_L0 -11.081 -75.746 1.533 -10.930 -50.212 1.127 0.736 
F191_L0 -11.581 -57.282 1.159 -10.683 -37.936 0.852 0.735 
F113_L1 -11.634 -54.621 1.105 -10.542 -36.169 0.812 0.735 
F80_L1 -11.102 -72.570 1.469 -10.878 -47.999 1.078 0.734 
F4_L0 -10.647 -50.168 1.015 -10.322 -33.159 0.745 0.733 
F50_L0 -11.387 -72.673 1.471 -10.836 -48.024 1.078 0.733 
F179_L2 -13.509 -82.820 1.676 -11.553 -54.614 1.226 0.732 
F71_L0 -11.523 -74.978 1.517 -9.962 -49.365 1.108 0.731 
F79_L0 -9.613 -69.320 1.403 -10.072 -45.632 1.025 0.730 
F185_L0 -11.325 -66.029 1.336 -10.686 -43.440 0.975 0.730 
F38_L2 -13.119 -86.453 1.750 -12.451 -56.863 1.277 0.730 
F5_L1 -11.254 -46.068 0.932 -11.246 -30.281 0.680 0.729 
F21_L2 -13.355 -78.439 1.587 -11.550 -51.517 1.157 0.729 
F70_L3 -12.573 -89.131 1.804 -10.698 -58.498 1.314 0.728 
F138_L0 -10.792 -86.542 1.751 -11.589 -56.687 1.273 0.727 
F132_L0 -11.631 -74.575 1.509 -10.755 -48.762 1.095 0.725 
F54_L0 -11.291 -86.771 1.756 -10.147 -56.685 1.273 0.725 
F27_L0 -11.749 -74.357 1.505 -10.427 -48.567 1.091 0.725 
F71_L2 -11.446 -82.439 1.668 -10.449 -53.737 1.207 0.723 
F37_L1 -13.197 -80.098 1.621 -11.119 -52.199 1.172 0.723 
F75_L0 -9.657 -82.973 1.679 -10.197 -54.028 1.213 0.722 
0   Appendices 
185  Stephen Fienberg – PhD Thesis 
F43_L2 -11.674 -68.262 1.381 -11.410 -44.443 0.998 0.722 
F25_L0 -11.896 -82.278 1.665 -10.958 -53.564 1.203 0.722 
F33_L0 -11.457 -62.310 1.261 -10.302 -40.564 0.911 0.722 
F71_L1 -11.588 -68.101 1.378 -9.875 -44.278 0.994 0.721 
F65-1_L0 -11.381 -61.693 1.249 -10.090 -40.040 0.899 0.720 
F41_L0 -9.648 -67.060 1.357 -9.925 -43.491 0.977 0.720 
F193_L1 -12.052 -60.884 1.232 -10.837 -39.479 0.886 0.719 
F180_L3 -12.609 -75.288 1.524 -10.658 -48.630 1.092 0.717 
F72_L1 -11.298 -76.697 1.552 -10.032 -49.453 1.110 0.715 
F96_L0 -12.465 -76.540 1.549 -10.851 -49.268 1.106 0.714 
F51_L1 -11.341 -74.564 1.509 -10.450 -47.950 1.077 0.714 
F74_L0 -11.396 -64.275 1.301 -10.104 -41.195 0.925 0.711 
F159_L0 -12.762 -71.059 1.438 -10.670 -45.526 1.022 0.711 
F51_L0 -7.788 -60.468 1.224 -10.550 -38.715 0.869 0.710 
F77_L0 -11.164 -61.115 1.237 -11.812 -39.128 0.879 0.710 
F91_L0 -11.216 -68.043 1.377 -9.855 -43.514 0.977 0.710 
F49_L2 -11.607 -77.828 1.575 -10.500 -49.761 1.117 0.709 
F97_L0 -13.308 -86.298 1.746 -10.023 -55.175 1.239 0.709 
F176_L0 -11.003 -85.102 1.722 -11.759 -54.399 1.221 0.709 
F190_L0 -11.718 -55.487 1.123 -9.775 -35.293 0.792 0.706 
F33_L3 -12.482 -66.997 1.356 -12.354 -42.515 0.955 0.704 
F66_L1 -11.348 -84.950 1.719 -11.772 -53.892 1.210 0.704 
F147_L0 -12.862 -90.802 1.838 -11.667 -57.564 1.293 0.703 
F34_L4 -12.810 -73.484 1.487 -12.079 -46.568 1.046 0.703 
F3_L0 -12.292 -48.903 0.990 -10.334 -30.957 0.695 0.702 
F2_L0 -12.197 -57.404 1.162 -13.098 -36.332 0.816 0.702 
F179_L3 -12.785 -83.859 1.697 -11.530 -52.949 1.189 0.701 
F81_L1 -11.459 -86.042 1.741 -10.693 -54.318 1.220 0.700 
F137_L0 -11.125 -96.786 1.959 -11.082 -60.855 1.366 0.698 
F184_L0 -11.519 -66.903 1.354 -10.396 -41.980 0.943 0.696 
F1_L4 -11.777 -62.080 1.256 -10.750 -38.946 0.874 0.696 
F88-1_L0 -11.683 -58.868 1.191 -10.546 -36.806 0.826 0.694 
F57_L2 -11.642 -78.733 1.593 -10.601 -49.099 1.102 0.692 
F26_L1 -12.245 -55.746 1.128 -10.899 -34.761 0.781 0.692 
F197_L0 -11.345 -66.489 1.346 -10.507 -41.373 0.929 0.690 
F95_L2 -12.433 -83.970 1.699 -11.794 -52.237 1.173 0.690 
F29_L1 -11.756 -77.792 1.574 -11.149 -48.303 1.085 0.689 
F105_L0 -11.654 -89.163 1.804 -10.477 -55.076 1.237 0.685 
F173_L0 -12.432 -89.294 1.807 -10.629 -55.061 1.236 0.684 
F95_L0 -11.353 -84.572 1.712 -10.477 -52.081 1.169 0.683 
F69_L3 -11.649 -65.039 1.316 -9.999 -39.921 0.896 0.681 
F7_L1 -11.703 -65.410 1.324 -11.418 -40.138 0.901 0.681 
F9_L0 -11.300 -62.136 1.257 -10.151 -38.122 0.856 0.681 
F178_L2 -13.537 -70.408 1.425 -11.564 -43.165 0.969 0.680 
0   Appendices 
186  Stephen Fienberg – PhD Thesis 
F61_L2 -13.056 -71.380 1.445 -10.412 -43.732 0.982 0.680 
F133_L2 -12.421 -79.276 1.604 -10.754 -48.125 1.081 0.674 
F113_L0 -11.527 -69.859 1.414 -10.313 -42.394 0.952 0.673 
F197_L1 -12.040 -54.996 1.113 -10.998 -33.365 0.749 0.673 
F165_L0 -11.714 -70.238 1.421 -10.822 -42.496 0.954 0.671 
F14_L0 -11.335 -70.026 1.417 -10.183 -42.125 0.946 0.667 
F39_L0 -11.404 -71.950 1.456 -10.016 -43.075 0.967 0.664 
F6_L0 -11.369 -51.692 1.046 -10.956 -30.916 0.694 0.664 
F156_L0 -12.746 -75.621 1.530 -11.563 -45.153 1.014 0.662 
F186_L0 -11.373 -68.059 1.377 -12.199 -40.454 0.908 0.660 
F135_L0 -11.384 -75.524 1.528 -10.691 -44.498 0.999 0.654 
F177_L3 -11.750 -85.933 1.739 -12.023 -50.380 1.131 0.650 
F73_L1 -11.698 -85.848 1.737 -9.886 -50.195 1.127 0.649 
F29_L0 -11.696 -69.100 1.398 -11.162 -40.191 0.902 0.645 
F187_L3 -12.193 -54.061 1.094 -10.735 -31.417 0.705 0.645 
F182_L3 -11.897 -66.970 1.355 -11.386 -38.812 0.871 0.643 
F45_L1 -12.197 -66.992 1.356 -11.719 -38.755 0.870 0.642 
F184_L3 -12.790 -62.135 1.257 -10.800 -35.797 0.804 0.639 
F103_L0 -11.443 -85.989 1.740 -11.090 -49.461 1.111 0.638 
F135_L1 -11.631 -76.521 1.549 -10.763 -43.925 0.986 0.637 
F49_L0 -11.204 -73.373 1.485 -10.213 -41.873 0.940 0.633 
F35_L4 -12.355 -85.025 1.721 -13.304 -48.056 1.079 0.627 
F41_L1 -11.499 -87.129 1.763 -10.454 -49.211 1.105 0.627 
F52_L1 -12.093 -80.820 1.636 -11.216 -45.036 1.011 0.618 
F47_L0 -11.392 -67.876 1.374 -10.532 -37.816 0.849 0.618 
F48_L2 -11.816 -88.539 1.792 -10.486 -49.029 1.101 0.614 
F61_L1 -12.605 -65.186 1.319 -10.817 -35.958 0.807 0.612 
F70_L1 -11.401 -85.499 1.730 -10.374 -47.136 1.058 0.612 
F82_L1 -11.802 -89.059 1.802 -10.550 -49.060 1.102 0.611 
F27_L1 -12.755 -61.783 1.250 -10.676 -33.989 0.763 0.610 
F74_L2 -12.513 -92.595 1.874 -10.735 -50.862 1.142 0.609 
F36_L0 -12.173 -85.337 1.727 -11.267 -46.746 1.050 0.608 
F1_L0 -11.311 -52.840 1.069 -9.791 -28.927 0.650 0.607 
F39_L1 -11.628 -70.030 1.417 -10.945 -38.204 0.858 0.605 
F168_L0 -12.490 -103.56 2.096 -12.429 -56.322 1.265 0.603 
F133_L0 -11.074 -84.576 1.712 -11.889 -45.990 1.033 0.603 
F64_L2 -11.730 -79.199 1.603 -11.145 -42.966 0.965 0.602 
F131_L0 -11.450 -87.652 1.774 -10.613 -47.538 1.067 0.602 
F144_L0 -10.678 -104.25 2.110 -11.055 -56.146 1.261 0.598 
F6_L1 -11.623 -65.134 1.318 -10.249 -35.075 0.788 0.598 
F20_L2 -11.635 -95.018 1.923 -10.695 -51.151 1.149 0.597 
F122_L0 -9.678 -71.580 1.449 -9.974 -38.496 0.864 0.597 
F1_L3 -11.562 -67.901 1.374 -10.495 -36.415 0.818 0.595 
F64_L3 -11.855 -78.093 1.580 -12.192 -41.839 0.939 0.594 
0   Appendices 
187  Stephen Fienberg – PhD Thesis 
F57_L0 -11.449 -77.057 1.559 -10.832 -41.163 0.924 0.593 
F68_L0 -11.498 -52.088 1.054 -12.067 -27.730 0.623 0.591 
F12_L0 -11.324 -62.542 1.266 -10.061 -33.241 0.746 0.590 
F44_L2 -13.684 -69.527 1.407 -11.154 -36.787 0.826 0.587 
F134_L0 -12.797 -78.840 1.596 -11.060 -41.532 0.933 0.584 
F158_L0 -12.658 -87.836 1.778 -10.772 -46.032 1.034 0.581 
F129_L0 -10.403 -61.485 1.244 -10.565 -32.085 0.720 0.579 
F121_L0 -11.851 -88.787 1.797 -11.135 -45.985 1.033 0.575 
F73_L0 -11.767 -88.030 1.782 -10.236 -45.211 1.015 0.570 
F1_L2 -11.477 -52.024 1.053 -10.077 -26.658 0.599 0.569 
F60_L2 -11.682 -88.334 1.788 -11.558 -44.899 1.008 0.564 
F63_L4 -11.781 -71.910 1.455 -11.972 -36.221 0.813 0.559 
F5_L0 -11.166 -61.519 1.245 -9.843 -30.828 0.692 0.556 
F52_L0 -11.892 -69.193 1.400 -9.916 -34.400 0.772 0.552 
F166_L0 -12.715 -87.956 1.780 -12.013 -43.064 0.967 0.543 
F10_L0 -11.143 -83.032 1.680 -10.167 -40.117 0.901 0.536 
F67_L0 -11.843 -63.411 1.283 -12.143 -29.844 0.670 0.522 
F78_L0 -11.735 -83.300 1.686 -10.635 -39.094 0.878 0.521 
F36_L1 -12.641 -83.442 1.689 -11.404 -38.970 0.875 0.518 
F187_L2 -11.891 -70.177 1.420 -11.146 -32.641 0.733 0.516 
F11_L1 -11.942 -65.624 1.328 -10.332 -30.483 0.684 0.515 
F87_L1 -11.790 -64.766 1.311 -10.827 -29.587 0.664 0.507 
F7_L0 -11.480 -65.231 1.320 -10.344 -27.839 0.625 0.474 
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